;indicatorAnalyzingName;missingDatasPercent;ig
0;Population;1.7777777777777715;0.7557524771959168
1;Ambient air pollution  attributable DALYs per 100'000 children under 5 years;0.0;
2;Household air pollution attributable deaths-Both sexes;20.0;1.3573688916374342
3;Household air pollution attributable deaths-Female;20.0;1.3573688916374342
4;Household air pollution attributable deaths-Male;20.0;1.3573688916374342
5;Household air pollution attributable deaths;20.0;-25263.52340193822
6;Household air pollution attributable deaths in children under 5 years-Both sexes;20.0;0.30952416776766434
7;Household air pollution attributable deaths in children under 5 years-Male;20.0;0.30952416776766434
8;Household air pollution attributable deaths in children under 5 years-Female;20.0;0.30952416776766434
9;Household air pollution attributable deaths in children under 5 years;20.0;-25263.52340193822
10;Household air pollution attributable deaths per 100'000 capita;0.0;
11;Household air pollution  attributable deaths per 100'000 children under 5 years;0.0;
12;Household air pollution attributable DALYs-Female;20.0;1.5087612010462434
13;Household air pollution attributable DALYs-Both sexes;20.0;1.5087612010462434
14;Household air pollution attributable DALYs-Male;20.0;1.3573688916374342
15;Household air pollution attributable DALYs;20.0;-25263.52340193822
16;Household air pollution attributable DALYs in children under 5 years-Both sexes;20.0;0.30952416776766434
17;Household air pollution attributable DALYs in children under 5 years-Female;20.0;0.30952416776766434
18;Household air pollution attributable DALYs in children under 5 years-Male;20.0;0.30952416776766434
19;Household air pollution attributable DALYs in children under 5 years;20.0;-25263.52340193822
20;Household air pollution attributable DALYs (per 100 000 population)-Both sexes;20.0;1.5087612010462434
21;Household air pollution attributable DALYs (per 100 000 population)-Female;20.0;1.5087612010462434
22;Household air pollution attributable DALYs (per 100 000 population)-Male;20.0;1.3573688916374342
23;Household air pollution attributable DALYs (per 100 000 population);20.0;-25263.52340193822
24;Household air pollution  attributable DALYs per 100'000 children under 5 years;0.0;
25;Household air pollution attributable DALYs (per 100 000, age-standardized)-Male;20.0;1.3573688916374342
26;Household air pollution attributable DALYs (per 100 000, age-standardized)-Female;20.0;1.5087612010462434
27;Household air pollution attributable DALYs (per 100 000, age-standardized)-Both sexes;20.0;1.5087612010462434
28;Household air pollution attributable DALYs (per 100 000, age-standardized);20.0;-25263.52340193822
29;Ambient air pollution attributable deaths in children under 5 years-Male;18.66666666666667;0.34427392031870685
30;Ambient air pollution attributable deaths in children under 5 years-Both sexes;18.66666666666667;0.34427392031870685
31;Ambient air pollution attributable deaths in children under 5 years-Female;18.66666666666667;0.34427392031870685
32;Ambient air pollution attributable deaths in children under 5 years;18.66666666666667;-25222.59910103469
33;Ambient air pollution attributable deaths-Male;18.66666666666667;1.519959808875119
34;Ambient air pollution attributable deaths-Female;18.66666666666667;1.519959808875119
35;Ambient air pollution attributable deaths-Both sexes;18.66666666666667;1.519959808875119
36;Ambient air pollution attributable deaths;18.66666666666667;-25222.59910103469
37;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;18.66666666666667;1.51967189727364
38;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Female;18.66666666666667;1.519959808875119
39;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Male;18.66666666666667;1.519959808875119
40;Ambient air pollution attributable death rate (per 100 000 population, age-standardized);18.66666666666667;-25222.59910103469
41;Ambient air pollution attributable DALYs;13.777777777777771;-22592.175766746797
42;DALYs attributable to ambient air pollution (age-standardized);13.777777777777771;-25063.872727433587
43;Ambient air pollution attributable YLLs-Both sexes;18.66666666666667;1.519959808875119
44;Ambient air pollution attributable YLLs-Female;18.66666666666667;1.519959808875119
45;Ambient air pollution attributable YLLs-Male;18.66666666666667;1.519959808875119
46;Ambient air pollution attributable YLLs;18.66666666666667;-25222.59910103469
47;Ambient air pollution attributable death rate (per 100 000 population)-Male;18.66666666666667;1.519959808875119
48;Ambient air pollution attributable death rate (per 100 000 population)-Female;18.66666666666667;1.51967189727364
49;Ambient air pollution attributable death rate (per 100 000 population)-Both sexes;18.66666666666667;1.519959808875119
50;Ambient air pollution attributable death rate (per 100 000 population);18.66666666666667;-25222.59910103469
51;Ambient air pollution attributable deaths (per 100 000 population, age-standardized);18.222222222222214;-25199.36682290182
52;Household air pollution attributable death rate (per 100 000 population)-Male;20.0;1.3573688916374342
53;Household air pollution attributable death rate (per 100 000 population)-Female;20.0;1.3573688916374342
54;Household air pollution attributable death rate (per 100 000 population)-Both sexes;20.0;1.3573688916374342
55;Household air pollution attributable death rate (per 100 000 population);20.0;-25263.52340193822
56;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;20.0;1.3573688916374342
57;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Female;20.0;1.3570800803122012
58;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Male;20.0;1.3573688916374342
59;Household air pollution attributable death rate (per 100 000 population, age-standardized);20.0;-25263.52340193822
60;Ambient air pollution  attributable deaths per 100'000 children under 5 years;0.0;
61;Ambient air pollution attributable DALYs;13.777777777777771;-22592.175766746797
62;Ambient air pollution attributable DALYs  in children under 5 years-Female;18.66666666666667;0.34427392031870685
63;Ambient air pollution attributable DALYs  in children under 5 years-Male;18.66666666666667;0.34427392031870685
64;Ambient air pollution attributable DALYs  in children under 5 years-Both sexes;18.66666666666667;0.34427392031870685
65;Ambient air pollution attributable DALYs  in children under 5 years;18.66666666666667;-25222.59910103469
66;Ambient air pollution attributable DALYs  (per 100 000 population)-Female;13.777777777777771;1.5084724245901446
67;Ambient air pollution attributable DALYs  (per 100 000 population)-Both sexes;13.777777777777771;1.5084724245901446
68;Ambient air pollution attributable DALYs  (per 100 000 population)-Male;13.777777777777771;1.519959808875119
69;Ambient air pollution attributable DALYs  (per 100 000 population);13.777777777777771;-25062.749882223197
70;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Both sexes;13.777777777777771;1.5084724245901446
71;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Male;13.777777777777771;1.519959808875119
72;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Female;13.777777777777771;1.5084724245901446
73;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized);13.777777777777771;-25062.749882223197
74;Functioning national AMR surveillance plan;0.0;
75;Establishment of National Coordination Centre (NCC);0.0;
76;Nomination of National Focal Point (NFP);0.0;
77;Establishment of national reference laboratory (NRL);0.0;
78;EQA provided to the national reference laboratory (NRL);0.0;
79;EQA provided for bacterial identification and AST;0.0;
80;EQA provided to local laboratories participating in GLASS;0.0;
81;GLASS pathogens testing covered by EQA;0.0;
82;Types of AST standards followed by countries;0.0;
83;Number of national surveillance sites in each country providing data to GLASS: hospital category;0.0;
84;Number of National surveillance sites in each country providing data to GLASS: outpatient facility category;0.0;
85;Number of local clinical laboratories in each country performing AST to support national AMR surveillance sites;0.0;
86;Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%-15-19 years-nan;49.77777777777778;0
87;Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%-20-49 years-nan;49.77777777777778;0
88;Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%;49.77777777777778;-23024.347371020456
89;Antenatal care coverage - at least one visit (in the five years preceding the survey) (%)-15-19 years-nan;67.55555555555556;0
90;Antenatal care coverage - at least one visit (in the five years preceding the survey) (%)-20-49 years-nan;67.55555555555556;0
91;Antenatal care coverage - at least one visit (in the five years preceding the survey) (%);67.55555555555556;-25037.423992562086
92;Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%)-15-19 years-nan;50.666666666666664;0
93;Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%)-20-49 years-nan;50.666666666666664;0
94;Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%);50.666666666666664;-23458.526258295085
95;Antenatal care coverage - at least four visits (in the five years preceding the survey) (%)-15-19 years-nan;65.77777777777777;0
96;Antenatal care coverage - at least four visits (in the five years preceding the survey) (%)-20-49 years-nan;65.77777777777777;0
97;Antenatal care coverage - at least four visits (in the five years preceding the survey) (%);65.77777777777777;-24986.02616127805
98;Adolescent fertility rate (per 1000 women aged 15-19 years)-nan;59.11111111111111;0
99;Adolescent fertility rate (per 1000 women aged 15-19 years)-None;59.11111111111111;0.37408689154333175
100;Adolescent fertility rate (per 1000 women aged 15-19 years)-Primary;59.11111111111111;0.4743754648478662
101;Adolescent fertility rate (per 1000 women aged 15-19 years)-Secondary or higher;59.11111111111111;0.5008828022484622
102;Adolescent fertility rate (per 1000 women aged 15-19 years);59.11111111111111;-24196.561478447373
103;Prevalence of met need of assistive products (%)-0-4 years-nan;90.22222222222223;0
104;Prevalence of met need of assistive products (%)-18-29 years-nan;90.22222222222223;0
105;Prevalence of met need of assistive products (%)-30-39  years-nan;90.22222222222223;0
106;Prevalence of met need of assistive products (%)-40-49  years-nan;90.22222222222223;0
107;Prevalence of met need of assistive products (%)-50-59  years-nan;90.22222222222223;0
108;Prevalence of met need of assistive products (%)-60-69  years-nan;90.22222222222223;0
109;Prevalence of met need of assistive products (%)-70-79 years-nan;90.22222222222223;0
110;Prevalence of met need of assistive products (%)-80+ years-nan;90.22222222222223;0
111;Prevalence of met need of assistive products (%)-5-17 years-nan;90.22222222222223;0
112;Prevalence of met need of assistive products (%)-All age groups (total)-nan;90.22222222222223;0
113;Prevalence of met need of assistive products (%);90.22222222222223;-27792.92000414784
114;Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate);15.555555555555557;-1193.560505391283
115;Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate);15.555555555555557;-1193.6340866156208
116;Mean systolic blood pressure (crude estimate);20.0;-7722.671720124383
117;Mean systolic blood pressure (age-standardized estimate);15.555555555555557;-1194.036595425473
118;Process evaluation was employed to assess implementation;0.0;
119;Formative research was conducted;0.0;
120;Outcome evaluation was employed to assess effectiveness;0.0;
121;Campaign was part of a comprehensive tobacco control programme;0.0;
122;Campaign was pre-tested;0.0;
123;Campaign utilized media planning;0.0;
124;At least one national mass media campaign ran during the survey period;0.0;
125;Earned media/public relations were used to promote the campaign;0.0;
126;Campaign aired on television and/or radio;0.0;
127;Children aged < 5 years with pneumonia symptoms taken to a health facility (%);53.333333333333336;-24023.77353309984
128;Congenital syphilis number of reported cases;0.0;
129;Cataract surgical coverage of adults aged 50 and over (%)-Female;84.88888888888889;0.06293812346785188
130;Cataract surgical coverage of adults aged 50 and over (%)-Both sexes;84.88888888888889;0.06342774975115528
131;Cataract surgical coverage of adults aged 50 and over (%)-Male;84.88888888888889;0.06109603543072062
132;Cataract surgical coverage of adults aged 50 and over (%);84.88888888888889;-27312.84149043112
133;Effective cataract surgical coverage of adults aged 50 and over (%)-Male;86.66666666666667;0.05430301759272016
134;Effective cataract surgical coverage of adults aged 50 and over (%)-Both sexes;86.66666666666667;0.05585902415380861
135;Effective cataract surgical coverage of adults aged 50 and over (%)-Female;86.66666666666667;0.05528227015932696
136;Effective cataract surgical coverage of adults aged 50 and over (%);86.66666666666667;-27371.25600139184
137;Climate change attributable deaths;0.0;
138;Climate change attributable DALYs ('000);0.0;
139;Climate change attributable deaths per 100'000 capita;0.0;
140;Climate change attributable DALYs per 100'000 capita;0.0;
141;Climate change attributable deaths ('000) in children under 5 years;0.0;
142;Climate change  attributable deaths per 100'000 children under 5 years;0.0;
143;Climate change attributable DALYs ('000) in children under 5 years;0.0;
144;Climate change  attributable DALYs per 100'000 children under 5 years;0.0;
145;Composite coverage index (%)-nan;56.888888888888886;0
146;Composite coverage index (%)-None;56.888888888888886;0.787828303387152
147;Composite coverage index (%)-Primary;56.888888888888886;0.8114098303215096
148;Composite coverage index (%)-Secondary or higher;56.888888888888886;0.8337613529790122
149;Composite coverage index (%);56.888888888888886;-24067.788409440196
150;Composite coverage index (%)-nan;56.888888888888886;0
151;Composite coverage index (%)-None;56.888888888888886;0.787828303387152
152;Composite coverage index (%)-Primary;56.888888888888886;0.8114098303215096
153;Composite coverage index (%)-Secondary or higher;56.888888888888886;0.8337613529790122
154;Composite coverage index (%);56.888888888888886;-24067.788409440196
155;Poverty headcount ratio at $1.25 a day (PPP) (% of population);53.333333333333336;-26295.608125982213
156;Human development index rank;17.777777777777786;-22708.793924001573
157;Gender inequality index rank;30.666666666666657;-23585.141250846274
158;Number of reported cases of cholera;68.44444444444444;-24684.46070454654
159;Number of reported deaths from cholera;0.0;
160;Cholera case fatality rate;68.44444444444444;-24766.138189430083
161;Contraceptive prevalence - modern and traditional methods (%)-15-19 years-nan;49.77777777777778;0
162;Contraceptive prevalence - modern and traditional methods (%)-20-49 years-nan;49.77777777777778;0
163;Contraceptive prevalence - modern and traditional methods (%);49.77777777777778;-23015.631076763086
164;Births by caesarean section (in the two or three years preceding the survey) (%)-15-19 years-nan;50.22222222222222;0
165;Births by caesarean section (in the two or three years preceding the survey) (%)-20-49 years-nan;50.22222222222222;0
166;Births by caesarean section (in the two or three years preceding the survey) (%);50.22222222222222;-23543.24229203942
167;Births by caesarean section (in the five years preceding the survey) (%)-15-19 years-nan;65.77777777777777;0
168;Births by caesarean section (in the five years preceding the survey) (%)-20-49 years-nan;65.77777777777777;0
169;Births by caesarean section (in the five years preceding the survey) (%);65.77777777777777;-25014.904865315908
170;Total density per 100 000 population: Hospitals;39.11111111111111;-25835.749345036624
171;Total density per 100 000 population: Health posts;50.666666666666664;-24652.653815597136
172;Total density per 100 000 population: Health centres;50.22222222222222;-24677.307610066502
173;Total density per 100 000 population: District/rural hospitals;44.44444444444444;-24336.16825346964
174;Total density per 100 000 population: Provincial hospitals;43.111111111111114;-24254.560414740095
175;Total density per 100 000 population: Specialized hospitals;43.111111111111114;-24241.55632943338
176;Availability of national standards or recommended lists of medical devices;28.888888888888886;-25525.203961274063
177;Existence of dementia training for legal professionals;0.0;
178;Types of lists recommending health technology for high burden diseases;29.33333333333333;-25537.95937000554
179;Total density per million population: Magnetic Resonance Imaging;40.888888888888886;-24093.326721045156
180;Total density per million population: Computed tomography units;39.55555555555556;-24022.93629792888
181;Total density per million population: Positron Emission tomography;47.55555555555555;-24546.88373583032
182;Total density per million population: Gamma camera or Nuclear medicine;47.111111111111114;-24509.669299914574
183;Total density per million population: Linear Accelerator;24.0;-23204.77327415616
184;Type of nomenclature system;28.0;-25503.484263813418
185;Use of nomenclature system;87.11111111111111;-27400.02862894691
186;Health technology (medical device) national policy;25.77777777777777;-25431.178173254288
187;Unit in the Ministry of Health responsible for the management of medical devices;26.22222222222223;-25443.448028280538
188;Procurement of medical devices carried out at the national level;27.555555555555557;-25482.619521387107
189;Availability of national list of approved medical devices for procurement or reimbursement;26.22222222222223;-25443.448028280538
190;National guidelines, policies or recommendations on the procurement of medical devices;27.555555555555557;-25488.25569662347
191;Availability of technical specifications of medical devices to support procurement or donations;28.444444444444457;-25511.586660119163
192;Total density per million population: Telecobalt Unit;24.0;-23256.97095826702
193;Total density per million population: Radiotherapy units;23.111111111111114;-23111.429118770837
194;Total density per million females aged from 50 to 69 years old: Mammography units;44.888888888888886;-24337.90285221922
195;Enforcing bans on tobacco advertising, promotion and sponsorship;13.333333333333329;-11526.797882281846
196;Compliance of ban on advertising on national TV and radio;42.22222222222223;-25950.336126805603
197;Ban on advertising: National TV and radio;0.0;
198;Compliance of ban on promotional discounts;63.55555555555556;-26630.56271384295
199;Ban on promotional discounts;0.0;
200;Ban on non-tobacco goods AND services identified with tobacco brand names;0.0;
201;Compliance of ban on non-tobacco goods AND services identified with tobacco brand names;68.44444444444444;-26786.463310739167
202;Ban on brand name of non-tobacco products used for tobacco product;0.0;
203;Compliance of ban on brand name of non-tobacco products used for tobacco product;77.77777777777777;-27090.10654715521
204;Ban on appearance of tobacco brands in TV and/or films (product placement);0.0;
205;Compliance of ban on appearance of tobacco brands in TV and/or films (product placement);58.666666666666664;-26483.05571407379
206;Compliance of ban on appearance of tobacco products in TV and/or films;87.11111111111111;-27385.750897437632
207;Appearance of tobacco products in TV and/or films;0.0;
208;Ban on appearance of tobacco products in TV and/or films;0.0;
209;Requirement to present prescribed anti-tobacco ads before, during or after the broadcasting or showing of any visual entertainment media product that depicts tobacco products, use or images;0.0;
210;Compliance of ban on sponsored events;67.55555555555556;-26767.940531206037
211;Sponsored events;0.0;
212;Complete ban on sponsorship;0.0;
213;Ban on any form of contribution (financial or other support) to any event, activity or individual;0.0;
214;Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals;0.0;
215;Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities;0.0;
216;Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility activities of the tobacco companies;0.0;
217;Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth;0.0;
218;Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images;0.0;
219;Ban on advertising: International TV and radio (broadcast from abroad, including satellite);0.0;
220;Complete ban on tobacco vending machines;0.0;
221;Subnational bans on tobacco advertising, promotion and sponsorship;0.0;
222;Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place;0.0;
223;Ban on internet sales of tobacco products;0.0;
224;Ban on display of tobacco products at points of sale;0.0;
225;Law requires fines for violations of direct advertising bans;0.0;
226;Law requires fines for violations of indirect advertising bans;0.0;
227;Compliance of ban on advertising on local magazines and newspapers;46.22222222222222;-26075.726284491247
228;Ban on advertising: Local magazines and newspapers;0.0;
229;Existence of dementia training for community workers;0.0;
230;Ban on advertising: International magazines and newspapers;0.0;
231;Ban on advertising: Billboards and outdoor advertising;0.0;
232;Compliance of ban on advertising on billboards and outdoor advertising;48.0;-26129.202237982903
233;Compliance of ban on advertising at point of sale;72.44444444444444;-26924.81435829261
234;Ban on advertising: Point of sale;0.0;
235;Ban on display of tobacco products at points of sale;0.0;
236;Ban on advertising: Internet;0.0;
237;Compliance of ban on free distribution of tobacco products in the mail or through other means;56.888888888888886;-26418.584527126608
238;Ban on free distribution of tobacco products in the mail or through other means;0.0;
239;Compliance with bans on direct advertising;33.33333333333334;-22181.774490185984
240;Compliance with bans on promotion and sponsorship;39.11111111111111;-22697.258422894054
241;Electric field (kV/m);0.0;
242;Electric field (kV/m);0.0;
243;Electric field (V/m);0.0;
244;Magnetic flux density (microT);0.0;
245;Power density (W/m^2);0.0;
246;Power frequency (Hz);0.0;
247;Specific absorption rate (SAR) (W/kg);0.0;
248;Existence of standards;0.0;
249;Legislative status;0.0;
250;Availability of estimates on large  health expenditures as a share of total expenditure or income;42.666666666666664;-21919.72732488591
251;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (millions);0.0;
252;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (%);0.0;
253;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, reported data) (%);30.222222222222214;-17920.077285927673
254;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (millions);0.0;
255;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (%);0.0;
256;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, reported data) (%);30.666666666666657;-17933.15215478663
257;Total population  pushed below the $1.90 a day  poverty line by household  health expenditures (millions);0.0;
258;Total population  pushed below the $1.90 a day  poverty line by household  health expenditures (%);0.0;
259;Total population  pushed below the $3.10 a day  poverty line by household  health expenditures (millions);0.0;
260;Total population  pushed below the $3.10 a day  poverty line by household  health expenditures (%);0.0;
261;Population  pushed below the $1.90 a day  poverty line by household  health expenditures (%);34.66666666666667;-18541.543763130725
262;Population  pushed below the $3.10 a day  poverty line by household  health expenditures (%);35.111111111111114;-18565.57470193769
263;Increase in poverty gap due to household  health expenditures, expressed as a proportion of the $1.90 a-day poverty line (%);35.111111111111114;-18599.864196328213
264;Increase in poverty gap due to household  health expenditures, expressed as a proportion of the 3.10 a-day poverty line (%);35.55555555555556;-18623.930987472733
265;Availability of estimates on impoverishment due to out-of-pocket health expenditures;42.666666666666664;-21919.71270087626
266;Demand for family planning satisfied - modern and traditional methods (%)-15-19 years-nan;52.88888888888889;0
267;Demand for family planning satisfied - modern and traditional methods (%)-20-49 years-nan;52.88888888888889;0
268;Demand for family planning satisfied - modern and traditional methods (%);52.88888888888889;-23403.32267069561
269;Demand for family planning satisfied - modern methods (%)-15-19 years-nan;60.888888888888886;0
270;Demand for family planning satisfied - modern methods (%)-20-49 years-nan;60.888888888888886;0
271;Demand for family planning satisfied - modern methods (%);60.888888888888886;-25204.854078262844
272;Age-standardized DALYs (per 100,000);23.555555555555557;-22989.346816091853
273;National regulator approval of anti-dementia medication;0.0;
274;Availability of generic anti-dementia medication;0.0;
275;Availability of at least one anti-dementia medication approved for on-label use reimbursement;0.0;
276;Availability of atleast one adult hygiene products for people with dementia;0.0;
277;Availability of atleast one housing adjustment for people with dementia;0.0;
278;Availability of  atleast one assistive technology for people with dementia;0.0;
279;Existence of dementia national nongovernmental organization;0.0;
280;Dementia nongovernmental organization equipped with office;0.0;
281;Dementia nongovernmental organization office branches (Sub-national);0.0;
282;Dementia nongovernmental organization office branches (Local);0.0;
283;Dementia nongovernmental organization office branches (National only);0.0;
284;Dementia nongovernmental organization staff primarily salaried/volunteer;0.0;
285;Policy;0.0;
286;Provision of governmental funding to dementia nongovernmental organization for activities/services;0.0;
287;Dementia nongovernmental organization's involvement in policy development;0.0;
288;Existence of dementia carer support services;0.0;
289;Implementation level [national/subnational] of dementia carer support services;0.0;
290;Existence of dedicated resources for dementia carer support services;0.0;
291;Existence of implementation plan for dementia carer support services;0.0;
292;Existence of psycho-social supports for dementia carers;0.0;
293;Existence of respite care for dementia carers;0.0;
294;Existence of information on legal rights for dementia carers;0.0;
295;Existence of financial benefits/social protection for dementia carers;0.0;
296;Accessibility of dementia carer training and education [Capital/capital and main cities/capital, main cities, rural areas];0.0;
297;Majority provider of dementia carer training and education (NGO);0.0;
298;Majority provider of dementia carer training and education (Private sector);0.0;
299;Majority provider of dementia carer training and education (Public sector);0.0;
300;Accessibility of psycho-social supports for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
301;Majority provider of psycho-social supports for dementia carers (NGO);0.0;
302;Majority provider of psycho-social supports for dementia carers (Private sector);0.0;
303;Majority provider of psycho-social supports for dementia carers (Public sector);0.0;
304;Accessibility of respite care for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
305;Majority provider of respite care for dementia carers (NGO);0.0;
306;Majority provider of respite care for dementia carers (Private sector);0.0;
307;Majority provider of respite care for dementia carers (Public sector);0.0;
308;Accessibility of information on legal rights for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
309;Majority provider of information on legal rights for dementia carers (NGO);0.0;
310;Majority provider of information on legal rights for dementia carers (Private sector);0.0;
311;Majority provider of information  on legal rights for dementia carers (Public sector);0.0;
312;Accessibility of financial benefits/social protection for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
313;Majority provider of information on financial benefits/social protection for dementia carers (NGO);0.0;
314;Majority provider of information on financial benefits/social protection for dementia carers (Private sector);0.0;
315;Majority provider of information  on financial benefits/social protection for dementia carers (Public sector);0.0;
316;Estimated number of dementia carers receiving training and education;0.0;
317;Estimated number of dementia carers receiving psycho-social supports;0.0;
318;Estimated number of dementia carers receiving respite care;0.0;
319;Estimated number of dementia carers receiving information on legal rights;0.0;
320;Estimated number of dementia carers receiving financial benefits/social protection;0.0;
321;Existence of at least one functioning dementia awareness campaign;0.0;
322;Implementation level [national/subnational] of dementia awareness campaign;0.0;
323;Existence of at least one functioning risk reduction campaign;0.0;
324;Implementation level [national/subnational] of dementia risk reduction campaign;0.0;
325;Availability of dementia-friendly initiatives that improve accessibility;0.0;
326;Existence of dementia-friendly initiative to improve accessibility of public spaces;0.0;
327;Existence of dementia-friendly initiative to improve accessibility of public transportation;0.0;
328;Existence of dementia-friendly initiative for assistance with home modification;0.0;
329;Existence of dementia-friendly initiative with assistive technology for loss of capacity;0.0;
330;Existence of dementia-friendly initiative supporting community places for older people;0.0;
331;Existence of dementia-friendly initiative supporting social opportunities;0.0;
332;Inclusion of dementia training and education for non-health workers;0.0;
333;Existence of dementia training for volunteers;0.0;
334;Existence of dementia training for police and fire services;0.0;
335;Existence of dementia training for first responders;0.0;
336;Existence of dementia training for school children;0.0;
337;Existence of dementia training for financial service staff;0.0;
338;Existence of dementia training for retail and hospitality staff;0.0;
339;Routine monitoring of people with dementia;0.0;
340;Data sources used to routinely monitor people with dementia (Clinical records);0.0;
341;Data sources used to routinely monitor people with dementia (Household surveys);0.0;
342;Data sources used to routinely monitor people with dementia (Administrative data);0.0;
343;Data sources used to routinely monitor people with dementia (Facility survey or records);0.0;
344;Data sources used to routinely monitor people with dementia (Other);0.0;
345;Electronic availability of data sources used to routinely monitor people with dementia;0.0;
346;Data used to routinely monitor people with dementia can be disaggregated;0.0;
347;Availability of routine hospital admissions records for people with dementia for monitoring purposes;0.0;
348;Availability of routine outpatient visit records for people with dementia for monitoring purposes;0.0;
349;Availability of routine outpatient intervention and treatment records for people with dementia for monitoring purposes;0.0;
350;Availability of routine pharmaceutical records for people with dementia for monitoring purposes;0.0;
351;Availability of routine antipsychotic prescription records for people with dementia for monitoring purposes;0.0;
352;Availability and status of dementia reporting in the past two years;0.0;
353;Existence of a current dementia research plan/programme;0.0;
354;Implementation level [national/subnational] of dementia research plan/programme;0.0;
355;Dementia integrated into other national research plan/programme;0.0;
356;Identification of other research plans in which dementia is integrated (Mental health);0.0;
357;Identification of other research plans in which dementia is integrated (Ageing);0.0;
358;Identification of other research plans in which dementia is integrated (Neuro or neurodegenerative disease);0.0;
359;Identification of other research plans in which dementia is integrated (NCD);0.0;
360;Implementation level [national/subnational] of research plan in which dementia is integrated;0.0;
361;Availability of funding for dementia-specific research plan/programme;0.0;
362;Total expenditure on dementia research (local currency, self-report);0.0;
363;Total expenditure on dementia basic research (local currency, self-report);0.0;
364;Total expenditure on dementia clinical/translational research (local currency, self-report);0.0;
365;Total expenditure on dementia implementation research (local currency, self-report);0.0;
366;Number of people with dementia involved in research routinely monitored;0.0;
367;Availability of investigational pharmaceutical trials for dementia;0.0;
368;Number of investigational pharmaceutical trials for dementia;0.0;
369;Inclusion of dementia in ministry portfolio;0.0;
370;Inclusion of dementia in a branch of government [health, ageing, social services, mental health, noncommunicable disease];0.0;
371;Existence of dementia representative in ministry;0.0;
372;Total number of published dementia research output;90.66666666666667;-27502.5739442423
373;Existence of dementia national plan;0.0;
374;Availability of funding for dementia national plan;0.0;
375;Targets for monitoring implementation of dementia national plan;0.0;
376;Dementia integrated into other national plan;0.0;
377;Identification of other plans in which dementia is integrated (Ageing);0.0;
378;Identification of other plans in which dementia is integrated (Disability);0.0;
379;Identification of other plans in which dementia is integrated (Mental health);0.0;
380;Identification of other plans in which dementia is integrated (NCD);0.0;
381;Identification of other plans in which dementia is integrated (Other);0.0;
382;Existence of dementia sub-national plan(s);0.0;
383;Percentage of sub-national regions covered by dementia plan;0.0;
384;Inclusion of human rights as a guiding principle of the dementia plan;0.0;
385;Inclusion of equity as a guiding principle of the dementia plan;0.0;
386;Inclusion of empowerment as a guiding principle of the dementia plan;0.0;
387;Inclusion of multisectoral collaboration as a guiding principles of the dementia plan;0.0;
388;Priorities;0.0;
389;Inclusion of universal health coverage as a guiding principle of the dementia plan;0.0;
390;Inclusion of dementia-friendly communities as a specific action of the dementia plan;0.0;
391;Inclusion of dementia risk reduction as a specific action of the dementia plan;0.0;
392;Inclusion of dementia diagnosis, care and support as a specific action of the dementia plan;0.0;
393;Inclusion of dementia workforce training as a specific action of the dementia plan;0.0;
394;Inclusion of support for dementia carers and families as a specific action of the dementia plan;0.0;
395;Inclusion of improved information system as a specific action of the dementia plan;0.0;
396;Inclusion of research and innovation as a specific action of the dementia plan;0.0;
397;Estimated population-based prevalence of depression;18.66666666666667;-25198.352895140484
398;Existence of dementia legislation;0.0;
399;Implementation level [national/subnational] of dementia legislation;0.0;
400;Existence of other laws that apply to the rights of people with dementia;0.0;
401;Existence of legislation for supported decision making for people with dementia;0.0;
402;Existence of legislation to file appeals protecting the rights of people with dementia;0.0;
403;Existence of legislation to promote community-based services for people with dementia;0.0;
404;Existence of legislation to promote monitoring of human rights conditions of people with dementia in facilities where they reside;0.0;
405;Existence of legislation to end coercieve practices for people with dementia;0.0;
406;Existence of legislation for advanced care directives for people with dementia;0.0;
407;Existence of legislation to end discrimination against people with dementia;0.0;
408;Existence of legislation to end discrimination against carers of people with dementia;0.0;
409;Existence of dementia standards/ guidelines/ protocols;0.0;
410;Implementation level of dementia standards/ guidelines/ protocols (National);0.0;
411;Implementation level of dementia standards/ guidelines/ protocols (Sub-national);0.0;
412;Existence of approved government dementia standards/ guidelines/ protocols;0.0;
413;Existence of standards/ guidelines/ protocols for prevention and risk reduction of dementia;0.0;
414;Existence of standards/ guidelines/ protocols for diagnosis of dementia;0.0;
415;Existence of standards/ guidelines/ protocols for management of dementia;0.0;
416;Existence of standards/ guidelines/ protocols for other post-diagnostic supports of people with dementia;0.0;
417;Existence of standards/ guidelines/ protocols for treatment and support of carers and families of people with dementia;0.0;
418;Existence of standards/ guidelines/ protocols for advance care directives, power of attorney or guardianship for people with dementia;0.0;
419;Existence of standards/ guidelines/ protocols for palliative and end-of-life care for people with dementia;0.0;
420;Existence of standards/ guidelines/ protocols of care in nursing & residential care facilities for people with dementia;0.0;
421;Existence of standards/ guidelines/ protocols of care in hospital for people with dementia;0.0;
422;Availability of mechanisms to coordinate dementia care across sectors;0.0;
423;Identification of different sectors in dementia care coordination  (Health);0.0;
424;Identification of different sectors in dementia care coordination (Social);0.0;
425;Identification of different sectors in dementia care coordination (Education);0.0;
426;Identification of different sectors in dementia care coordination (Employment);0.0;
427;Identification of different sectors in dementia care coordination (Justice);0.0;
428;Identification of different sectors in dementia care coordination (Housing);0.0;
429;Identification of different sectors in dementia care coordination (Civil society);0.0;
430;Identification of different sectors in dementia care coordination (Private sector);0.0;
431;Identification of different sectors in dementia care coordination (Other);0.0;
432;Implementation level [national/subnational] of dementia care coordination;0.0;
433;Presence of formal agreement/joint plan for dementia care coordination;0.0;
434;Availability of dementia care coordination standards/ guidelines/ protocols;0.0;
435;Number of neurologists (per 100,000);0.0;
436;Number of geriatricians or psychogeriatricians (per 100,000);0.0;
437;Inclusion of basic dementia competencies in training of physicians;0.0;
438;Inclusion of basic dementia competencies in training of specialists;0.0;
439;Inclusion of basic dementia competencies in training of nurses;0.0;
440;Inclusion of basic dementia competencies in training of pharmaceutical personnel;0.0;
441;Inclusion of basic dementia competencies in training of social workers;0.0;
442;Inclusion of basic dementia competencies in training of personal support workers;0.0;
443;Availability of dementia diagnostic rate;0.0;
444;Existence of community-based health or social care services for dementia;0.0;
445;Availability of diagnostic services in community for dementia;0.0;
446;Availability of behaviour and psychological management in community for dementia;0.0;
447;Availability of psychosocial and rehabilitation services in community for dementia;0.0;
448;Availability of activities of daily living support services in community for dementia;0.0;
449;Availability of palliative and end-of-life care services in community for dementia;0.0;
450;Availability of social and financial protection for dementia;0.0;
451;Accessibility of diagnostic services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
452;Accessibility of behaviour and psychological management in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
453;Accessibility of psychosocial and rehabilitation services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
454;Accessibility of activities of daily living support services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
455;Accessibility of palliative and end-of-life care services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
456;Accessibility of social and financial protection for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
457;Majority provider of diagnostic services in community for dementia [public, private];0.0;
458;Majority provider of behaviour and psychological management in community for dementia [public, private];0.0;
459;Majority provider of psychosocial and rehabilitation services in community for dementia [public, private];0.0;
460;Majority provider of activities of daily living support services in community for dementia [public, private];0.0;
461;Majority provider of palliative and end-of-life care services in community for dementia [public, private];0.0;
462;Majority provider of social and financial protection for dementia [public, private];0.0;
463;Estimated number of people receiving behaviour and psychological management services in community for dementia;0.0;
464;Estimated number of people receiving psychosocial and rehabilitation services in community for dementia;0.0;
465;Estimated number of people receiving activities of daily living support services in community for dementia;0.0;
466;Estimated number of people receiving palliative and end-of-life care services in community for dementia;0.0;
467;Estimated number of people with dementia receiving social and financial protection for dementia;0.0;
468;Dementia care facilities [hospitals];0.0;
469;Care facilities [long-term care];0.0;
470;Care facilities [hospice centres];0.0;
471;Adult day centres;0.0;
472;Outpatient health centres;0.0;
473;Outpatient social centres;0.0;
474;Dementia-specific hospital beds (per 10,000 population);86.66666666666667;-27375.090884157496
475;Geriatric-specific hospital beds (per 10,000 population);87.55555555555556;-27411.214058455575
476;Total dementia hospital admissions (per 100,000);89.77777777777777;-27486.152252627686
477;Estimated percentage of hospitals following national dementia standards;0.0;
478;Density of residential long-term care facilities (per 100,000 population);82.66666666666666;-27254.195253651036
479;Residential long-term care beds (per 10 000 population);86.22222222222223;-27367.190881933555
480;Dementia-specific residential long-term care beds (per 10,000 population);92.88888888888889;-27577.520750455766
481;Estimated number of people with dementia living in residential long-term care;0.0;
482;Estimated percentage of residential long-term care facilities following national dementia standards;0.0;
483;Density of hospice centres (per 100,000 population);87.55555555555556;-27407.862121299622
484;Hospice centre beds (per 10 000 population);92.0;-27547.612891036704
485;Dementia-specific hospice care beds (per 10,000 population);95.11111111111111;-27652.387665905746
486;Density of adult day centres (per 100,000 population);85.77777777777777;-27355.14606506391
487;Adult day centre places (per 10,000 population);91.55555555555556;-27538.67432761802
488;Dementia-specific adult day centre places (per 10,000 population);93.33333333333333;-27592.905519782762
489;Density of outpatient health centres (per 100,000 population);85.77777777777777;-27349.462420818294
490;Estimated number of people with dementia receiving services at outpatient health centre;0.0;
491;Density of outpatient social centres (per 100,000 population);91.55555555555556;-27533.4514522898
492;Estimated number of people with dementia receiving services at outpatient social centre;0.0;
493;Disability-adjusted life years (DALYs);0.0;
494;Disability-adjusted life years (DALYs) (per 100 000 population);0.0;
495;Years of healthy life lost due to disability (YLDs);0.0;
496;Years of healthy life lost due to disability (YLDs) (per 100 000 population);0.0;
497;Years of life lost from mortality (YLLs);0.0;
498;Years of life lost from mortality (YLLs) (per 100 000 population);0.0;
499;Current health expenditure (CHE) per capita in PPP int$;14.666666666666657;-12.282262309938316
500;Current health expenditure (CHE) per capita in US$;14.666666666666657;-12.31287891638099
501;Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%);14.666666666666657;-13.724089614491886
502;External health expenditure (EXT) per capita in PPP int$;19.111111111111114;-462.3826124783518
503;External health expenditure (EXT) per capita in US$;19.111111111111114;-462.66739414559885
504;External health expenditure (EXT) as percentage of current health expenditure (CHE) (%);19.111111111111114;-462.77728647301376
505;Domestic general government health expenditure (GGHE-D) per capita in PPP int$;14.666666666666657;-12.314837421514229
506;Domestic general government health expenditure (GGHE-D) per capita in US$;14.666666666666657;-12.378684579597186
507;Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%);14.666666666666657;-12.552459132652183
508;Domestic general government health expenditure (GGHE-D) as percentage of gross domestic product (GDP) (%);14.666666666666657;-13.940952514264398
509;Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%);14.666666666666657;-13.330005727086158
510;Out-of-pocket expenditure (OOP) per capita in PPP int$;14.666666666666657;-12.32778590013296
511;Out-of-pocket expenditure (OOP) per capita in US$;14.666666666666657;-12.397832386117786
512;Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%);14.666666666666657;-12.600295195679257
513;Domestic private health expenditure (PVT-D) per capita in PPP int$;14.666666666666657;-12.3147903830347
514;Domestic private health expenditure (PVT-D) per capita in US$;14.666666666666657;-12.37487703717895
515;Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%);14.666666666666657;-12.586628847627436
516;National universal health coverage strategy;0.0;
517;strategy refers to the use of ICT to support UHC;0.0;
518;National eHealth strategy;0.0;
519;National eHealth strategy refers to objectives of UHC;0.0;
520;National  health information system (HIS) policy or strategy;0.0;
521;Public funding for eHealth;0.0;
522;Private funding for eHealth;0.0;
523;Donor/ non-public development funding for eHealth;0.0;
524;Public-private partnerships for eHealth;0.0;
525;Strategy implementation funding available for eHealth;0.0;
526;Proportion of public funding;0.0;
527;Proportion of private funding;0.0;
528;Proportion of donor/non public development funding;0.0;
529;Proportion ofpublic private partnerships funding;0.0;
530;Government-supported health internet sites provide information in multiple languages;0.0;
531;Tertiary institutions provide students of health sciences with training on eHealth;0.0;
532;Institutions offer in-service training to health professionals on ICT for health;0.0;
533;mHealth programmes are sponsored by government;0.0;
534;Regulating mobile devices and software;0.0;
535;Promoting standards and interoperability;0.0;
536;Providing guidance on privacy and security;0.0;
537;Providing oversight and enforcement of data ownership;0.0;
538;Promoting the development and adoption of mHealth;0.0;
539;Regulatory oversight of mobile apps for quality, safety and reliability;0.0;
540;Providing incentives and guidance for innovation research and evaluation of health;0.0;
541;Government-sponsored mHealth programmes are being evaluated;0.0;
542;Capacity;0.0;
543;Infrastructure;0.0;
544;Funding;0.0;
545;Effectiveness;0.0;
546;Cost-effectiveness;0.0;
547;Demand;0.0;
548;Legal;0.0;
549;Country has telehealth policy or strategy;0.0;
550;Strategy includes objectives as to how telehealth contributes to UHC;0.0;
551;Evaluation of any government-sponsored telehealth programmes;0.0;
552;eLearning is used in pre-service education to teach health sciences students;0.0;
553;Reducing cost of delivering content;0.0;
554;Improving access to content and experts;0.0;
555;Enabling access to education where learning facilities are limited;0.0;
556;Pre-service eLearning programmes have been evaluated;0.0;
557;eLearning used for in-service training of health professionals;0.0;
558;Reducing cost of delivering content;0.0;
559;Improving access to content and experts;0.0;
560;Enabling access to education where learning facilities are limited;0.0;
561;eLearning courses accredited by continuing medical education or professional licensing bodies;0.0;
562;eLearning programmes for in-service training of health professionals have been evaluated;0.0;
563;Lack of capacity;0.0;
564;Lack of infrastructure;0.0;
565;Lack of funding;0.0;
566;Not possible to gain a health sciences degree entirely through eLearning;0.0;
567;Lack of evidence that eLearning is effective;0.0;
568;Lack of evidence over cost-effectiveness;0.0;
569;Lack of demand for eLearning programmes;0.0;
570;Lack of suitable courses available;0.0;
571;Insitutional educational policy does not include eLearning as an approach to teaching health sciences;0.0;
572;Competing educational priorities;0.0;
573;Country has national EHR;0.0;
574;Country has specific legislation governing the use of national EHR system;0.0;
575;Lack of capacity;0.0;
576;Lack of infrastructure;0.0;
577;Lack of funding;0.0;
578;lack of evidence showing effectiveness of EHR;0.0;
579;Lack of evidence showing cost-effectiveness or EHR;0.0;
580;Lack of demand by health professionals and patients;0.0;
581;Lack of legislation or regulations covering use of EHR;0.0;
582;National strategy does not promote the adoption of EHR;0.0;
583;Lack of national or international standards for interoperability of EHR;0.0;
584;Competing health system priorities;0.0;
585;To define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth;0.0;
586;To address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria;0.0;
587;To protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format;0.0;
588;To protect the privacy of individuals' health-related  data held in electronic format as an EHR;0.0;
589;Which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR;0.0;
590;Which governs the sharing of digital data between health professionals  in health services in other countries through the use of an EHR;0.0;
591;Which allows for the sharing of personal and health data between research entities;0.0;
592;Which allows individuals electronic access to their own health-related data when held in an EHR;0.0;
593;Which allows individuals to demand that their own data be corrected  when held in an EHR if it is known to be inaccurate;0.0;
594;Which allows individuals to demand the deletion of health-related data from their EHR;0.0;
595;Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice;0.0;
596;Country has national policy or strategy on the use of social media by government organizations;0.0;
597;Policy or strategy makes specific reference tothe use of social media in the health domain;0.0;
598;Country has  national policy or strategy regulating the use of big data in the health sector;0.0;
599;Country has national policy or strategy regulating the use of big data by private companies;0.0;
600;Effective standards and best practices for data capture not fully established;0.0;
601;Insufficient incentives for data sharing;0.0;
602;Capacity building required for new skills;0.0;
603;Privacy and security laws need to be in place;0.0;
604;Research into new analytical methods needs occur to meet the challenges of working with big data;0.0;
605;Lack of integration between various health services;0.0;
606;Estimated number of people (all ages) living with HIV;39.55555555555556;-2304.531222046123
607;Number of deaths due to HIV/AIDS;41.77777777777778;-2719.722472644517
608;Testing and counselling facilities, reported number;48.0;-26110.87692567754
609;Testing and counselling facilities, estimated number per 100 000 adult population;51.55555555555556;-26224.780968464795
610;Reported number of people receiving antiretroviral therapy;32.888888888888886;-1260.4820110650007
611;Reported number of children receiving antiretroviral therapy;55.55555555555556;-5997.820153241245
612;Reported number of children receiving antiretroviral therapy, month and year of report;36.88888888888889;-25752.78476754259
613;Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission;37.33333333333333;-11201.37513812772
614;Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission;58.666666666666664;-15955.482350030088
615;Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods;59.55555555555556;-7294.268015844522
616;Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines;56.0;-26363.192363859547
617;Estimated number of children needing antiretroviral therapy based on WHO methods;58.666666666666664;-6993.303399949799
618;Estimated antiretroviral therapy coverage among children;55.111111111111114;-6612.758833712942
619;Testing and counselling facilities, reporting period;0.0;
620;Number of new HIV infections;41.77777777777778;-2776.194397914333
621;Estimated antiretroviral therapy coverage among people living with HIV (%);40.44444444444445;-2505.7352968637306
622;Biomedical engineers density (per 10 000 population);63.55555555555556;-24981.576848858032
623;Number of licensed qualified surgeons actively working;30.666666666666657;-25575.97580143798
624;Number of licensed qualified obstetricians actively working;28.0;-25489.819105091836
625;Number of licensed qualified anaesthesiologists actively working;28.888888888888886;-25547.27089088218
626;Number of biomedical engineers;38.22222222222222;-25828.17257233612
627;Biomedical technicians density (per 10 000 population);90.22222222222223;-27486.06060826432
628;Number of biomedical technicians;86.66666666666667;-27367.08844683832
629;Countries that have passed legislation on Universal Health Coverage (UHC);0.0;
630;Medical doctors (per 10,000);13.777777777777771;-5262.910743517868
631;Medical doctors (number);12.8888888888889;-5250.347692771235
632;Generalist medical practitioners (number);36.44444444444444;-15610.36123525022
633;Specialist medical practitioners (number);36.44444444444444;-15776.25332269581
634;Medical doctors not further defined (number);16.0;-9863.720233704631
635;Nursing and midwifery personnel (per 10,000);13.777777777777771;-4979.15363131256
636;Nursing and midwifery personnel  (number);12.444444444444443;-4966.939918766771
637;Nursing personnel (number);12.444444444444443;-4966.947430467196
638;Midwifery personnel (number);22.222222222222214;-10309.412634511817
639;Dentists (per 10,000);14.666666666666657;-7181.415989309798
640;Dentists (number);13.777777777777771;-7166.6447917088435
641;Dental Assistants and Therapists (number);40.44444444444445;-23754.598800127933
642;Dental Prosthetic Technicians (number);42.666666666666664;-24047.997840683787
643;Pharmacists  (per 10,000);16.888888888888886;-8564.752506958646
644;Pharmacists  (number);16.0;-8548.507732644175
645;Pharmaceutical Technicians and Assistants  (number);50.22222222222222;-23562.53903882098
646;Environmental and Occupational Health and Hygiene Professionals  (number);50.22222222222222;-23772.684129951565
647;Environmental and Occupational Health Inspectors and Associates  (number);67.11111111111111;-25803.07756365651
648;Medical and Pathology Laboratory scientists  (number);53.77777777777778;-24069.098103651697
649;Medical and Pathology Laboratory Technicians  (number);49.33333333333333;-23122.874946778247
650;Physiotherapists (number);32.888888888888886;-19574.5371927694
651;Physiotherapy Technicians and Assistants  (number);69.33333333333334;-25633.58387600342
652;Traditional and Complementary Medicine Professionals  (number);76.44444444444444;-26199.90404187424
653;Community Health Workers (number);59.11111111111111;-24651.247836809187
654;Handwashing with soap after using the toilet (%);96.0;-27676.320926504417
655;Handwashing with soap after cleaning child's stool (%);0.0;
656;Legislation;13.333333333333329;-13601.864030800256
657;Coordination;13.333333333333329;-13601.55985874755
658;Surveillance;13.333333333333329;-13601.537174276677
659;Response;13.333333333333329;-13601.388988156607
660;Preparedness;13.333333333333329;-13601.3294161887
661;Risk communication;13.333333333333329;-13601.699352779788
662;Human resources;13.333333333333329;-13601.69964502598
663;Laboratory;13.333333333333329;-13601.344126236605
664;Points of entry;13.333333333333329;-13601.139350715086
665;Zoonosis;13.333333333333329;-13601.722790692822
666;Food safety;13.333333333333329;-13601.546578601774
667;Chemical;13.333333333333329;-13601.477967923776
668;Radionuclear;13.333333333333329;-13601.48218879773
669;Infant mortality rate (deaths per 1000 live births);59.11111111111111;-24195.263693651563
670;Mean BMI (kg/m²) (age-standardized estimate);15.555555555555557;-707.7075018842442
671;Percentage of sites for which carbamate resistance was reported;76.44444444444444;-24417.499705587838
672;Carbamate resistance reported for at least one site;0.0;
673;Number of insecticide classes to which resistance was reported;62.666666666666664;-21287.236401940325
674;Percentage of sites for which organochlorine resistance was reported;70.22222222222223;-22968.139607332712
675;Organochlorine resistance reported for at least one site;0.0;
676;Percentage of sites for which organophosphate resistance was reported;72.88888888888889;-24244.91349028518
677;Organophosphate resistance reported for at least one site;0.0;
678;Percentage of sites for which pyrethroid resistance was reported;64.44444444444444;-21897.69754569808
679;Pyrethroid resistance reported for at least one site;0.0;
680;Children aged < 5 years sleeping under insecticide-treated nets (%)-None-nan;77.33333333333334;0
681;Children aged < 5 years sleeping under insecticide-treated nets (%)-Primary-nan;77.33333333333334;0
682;Children aged < 5 years sleeping under insecticide-treated nets (%)-Secondary or higher-nan;77.33333333333334;0
683;Children aged < 5 years sleeping under insecticide-treated nets (%);77.33333333333334;-25702.339467940034
684;Pregnant women sleeping under insecticide-treated nets (%)-15-19 years-nan;78.66666666666666;0
685;Pregnant women sleeping under insecticide-treated nets (%)-20-49 years-nan;78.66666666666666;0
686;Pregnant women sleeping under insecticide-treated nets (%);78.66666666666666;-25994.731123224927
687;Percentage of individuals using the Internet;16.444444444444443;-25151.95631606003
688;Mobile-cellular telephone subscriptions per 100 inhabitants;23.555555555555557;-25363.205180661404
689;ICT Development Index (IDI);31.111111111111114;-23496.208111105883
690;ICT Development Index (IDI) rank;31.111111111111114;-23496.26214103996
691;Percentage of the children under 15 years with blood lead levels above 5ug/dl;0.0;
692;Lead attributable DALYs per 100'000 children under 5 years;0.0;
693;Percentage of the children under 15 years with blood lead levels above 10ug/dl;0.0;
694;Percentage of the adults (15+ years) with blood lead levels above 5ug/dl;0.0;
695;Percentage of the adults (15+ years) with blood lead levels above 10ug/dl;0.0;
696;Lead attributable deaths;0.0;
697;Lead attributable DALYs ('000);0.0;
698;Lead attributable deaths per 100'000 capita;0.0;
699;Lead attributable DALYs per 100'000 capita;0.0;
700;Lead attributable DALYs ('000) in children under 5 years;0.0;
701;Legally-binding controls on lead paint;0.0;
702;nMx - age-specific death rate between ages x and x+n-<1 year-Both sexes;18.66666666666667;1.7615617559386383
703;nMx - age-specific death rate between ages x and x+n-<1 year-Male;18.66666666666667;1.7341147729850102
704;nMx - age-specific death rate between ages x and x+n-<1 year-Female;18.66666666666667;1.7286887946370246
705;nMx - age-specific death rate between ages x and x+n-1-4 years-Both sexes;18.66666666666667;1.5157202760405966
706;nMx - age-specific death rate between ages x and x+n-1-4 years-Male;18.66666666666667;1.496433558176025
707;nMx - age-specific death rate between ages x and x+n-1-4 years-Female;18.66666666666667;1.474695017275554
708;nMx - age-specific death rate between ages x and x+n-5-9 years-Both sexes;18.66666666666667;1.375716523485142
709;nMx - age-specific death rate between ages x and x+n-5-9 years-Male;18.66666666666667;1.3572965558697216
710;nMx - age-specific death rate between ages x and x+n-5-9 years-Female;18.66666666666667;1.330805994797272
711;nMx - age-specific death rate between ages x and x+n-10-14 years-Both sexes;18.66666666666667;1.3229619743580994
712;nMx - age-specific death rate between ages x and x+n-10-14 years-Male;18.66666666666667;1.3269173466887043
713;nMx - age-specific death rate between ages x and x+n-10-14 years-Female;18.66666666666667;1.2643603643396908
714;nMx - age-specific death rate between ages x and x+n-15-19  years-Both sexes;18.66666666666667;1.4078247651999423
715;nMx - age-specific death rate between ages x and x+n-15-19  years-Male;18.66666666666667;1.414994496653593
716;nMx - age-specific death rate between ages x and x+n-15-19  years-Female;18.66666666666667;1.3295025926313029
717;nMx - age-specific death rate between ages x and x+n-20-24 years-Both sexes;18.66666666666667;1.4777756378043616
718;nMx - age-specific death rate between ages x and x+n-20-24 years-Male;18.66666666666667;1.488148003428491
719;nMx - age-specific death rate between ages x and x+n-20-24 years-Female;18.66666666666667;1.4038237018810058
720;nMx - age-specific death rate between ages x and x+n-25-29 years-Both sexes;18.66666666666667;1.527024336854626
721;nMx - age-specific death rate between ages x and x+n-25-29 years-Male;18.66666666666667;1.5223299519648137
722;nMx - age-specific death rate between ages x and x+n-25-29 years-Female;18.66666666666667;1.455831687357355
723;nMx - age-specific death rate between ages x and x+n-30-34 years-Both sexes;18.66666666666667;1.5688564430773813
724;nMx - age-specific death rate between ages x and x+n-30-34 years-Male;18.66666666666667;1.562482193931622
725;nMx - age-specific death rate between ages x and x+n-30-34 years-Female;18.66666666666667;1.4906405965032263
726;nMx - age-specific death rate between ages x and x+n-35-39 years-Both sexes;18.66666666666667;1.605677643239222
727;nMx - age-specific death rate between ages x and x+n-35-39 years-Male;18.66666666666667;1.6063608753621894
728;nMx - age-specific death rate between ages x and x+n-35-39 years-Female;18.66666666666667;1.5363058810465677
729;nMx - age-specific death rate between ages x and x+n-40-44 years-Both sexes;18.66666666666667;1.646573930877583
730;nMx - age-specific death rate between ages x and x+n-40-44 years-Male;18.66666666666667;1.632076753298036
731;nMx - age-specific death rate between ages x and x+n-40-44 years-Female;18.66666666666667;1.5774832546426518
732;nMx - age-specific death rate between ages x and x+n-45-49 years-Both sexes;18.66666666666667;1.6694546705537832
733;nMx - age-specific death rate between ages x and x+n-45-49 years-Male;18.66666666666667;1.6601736168707504
734;nMx - age-specific death rate between ages x and x+n-45-49 years-Female;18.66666666666667;1.616864710847258
735;nMx - age-specific death rate between ages x and x+n-50-54 years-Both sexes;18.66666666666667;1.7013602333179074
736;nMx - age-specific death rate between ages x and x+n-50-54 years-Male;18.66666666666667;1.6872826608670257
737;nMx - age-specific death rate between ages x and x+n-50-54 years-Female;18.66666666666667;1.6577547748391384
738;nMx - age-specific death rate between ages x and x+n-55-59 years-Both sexes;18.66666666666667;1.7224472754416889
739;nMx - age-specific death rate between ages x and x+n-55-59 years-Male;18.66666666666667;1.7066433196482524
740;nMx - age-specific death rate between ages x and x+n-55-59 years-Female;18.66666666666667;1.6782219031297956
741;nMx - age-specific death rate between ages x and x+n-60-64 years-Both sexes;18.66666666666667;1.7436259423449085
742;nMx - age-specific death rate between ages x and x+n-60-64 years-Male;18.66666666666667;1.7223776406814935
743;nMx - age-specific death rate between ages x and x+n-60-64 years-Female;18.66666666666667;1.6972895311870948
744;nMx - age-specific death rate between ages x and x+n-65-69 years-Both sexes;18.66666666666667;1.7570795380721442
745;nMx - age-specific death rate between ages x and x+n-65-69 years-Male;18.66666666666667;1.7235781871499878
746;nMx - age-specific death rate between ages x and x+n-65-69 years-Female;18.66666666666667;1.714865940257468
747;nMx - age-specific death rate between ages x and x+n-70-74 years-Both sexes;18.66666666666667;1.759786276480237
748;nMx - age-specific death rate between ages x and x+n-70-74 years-Male;18.66666666666667;1.7359321626796334
749;nMx - age-specific death rate between ages x and x+n-70-74 years-Female;18.66666666666667;1.7301106350074056
750;nMx - age-specific death rate between ages x and x+n-75-79 years-Both sexes;18.66666666666667;1.7725296804241122
751;nMx - age-specific death rate between ages x and x+n-75-79 years-Male;18.66666666666667;1.7416665626406838
752;nMx - age-specific death rate between ages x and x+n-75-79 years-Female;18.66666666666667;1.7365559551536451
753;nMx - age-specific death rate between ages x and x+n-80-84 years-Both sexes;18.66666666666667;1.773816035265484
754;nMx - age-specific death rate between ages x and x+n-80-84 years-Male;18.66666666666667;1.7499763109610775
755;nMx - age-specific death rate between ages x and x+n-80-84 years-Female;18.66666666666667;1.7398021344665304
756;nMx - age-specific death rate between ages x and x+n-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
757;nMx - age-specific death rate between ages x and x+n-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
758;nMx - age-specific death rate between ages x and x+n-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
759;nMx - age-specific death rate between ages x and x+n-100+ years-Both sexes;18.66666666666667;0.03323680602100332
760;nMx - age-specific death rate between ages x and x+n-85+ years-Male;18.66666666666667;1.7471326302203174
761;nMx - age-specific death rate between ages x and x+n-85+ years-Female;18.66666666666667;1.7464217100351274
762;nMx - age-specific death rate between ages x and x+n-85+ years-Both sexes;18.66666666666667;1.750465937244381
763;nMx - age-specific death rate between ages x and x+n;18.66666666666667;-15892.427893433749
764;nqx - probability of dying between ages x and x+n-10-14 years-Male;18.66666666666667;1.5870128869485844
765;nqx - probability of dying between ages x and x+n-10-14 years-Both sexes;18.66666666666667;1.5920718006926178
766;nqx - probability of dying between ages x and x+n-10-14 years-Female;18.66666666666667;1.5365358693486337
767;nqx - probability of dying between ages x and x+n-<1 year-Both sexes;18.66666666666667;1.7631631585150762
768;nqx - probability of dying between ages x and x+n-<1 year-Male;18.66666666666667;1.7318478462387317
769;nqx - probability of dying between ages x and x+n-<1 year-Female;18.66666666666667;1.7248658613296577
770;nqx - probability of dying between ages x and x+n-1-4 years-Both sexes;18.66666666666667;1.6749461403938462
771;nqx - probability of dying between ages x and x+n-1-4 years-Male;18.66666666666667;1.6481579674140336
772;nqx - probability of dying between ages x and x+n-1-4 years-Female;18.66666666666667;1.632923126481149
773;nqx - probability of dying between ages x and x+n-5-9 years-Both sexes;18.66666666666667;1.6180757657028702
774;nqx - probability of dying between ages x and x+n-5-9 years-Male;18.66666666666667;1.5942488180586931
775;nqx - probability of dying between ages x and x+n-5-9 years-Female;18.66666666666667;1.571906978771282
776;nqx - probability of dying between ages x and x+n-15-19  years-Both sexes;18.66666666666667;1.6585984575461223
777;nqx - probability of dying between ages x and x+n-15-19  years-Male;18.66666666666667;1.6440298480175057
778;nqx - probability of dying between ages x and x+n-15-19  years-Female;18.66666666666667;1.5993152329562967
779;nqx - probability of dying between ages x and x+n-20-24 years-Both sexes;18.66666666666667;1.6928664516079852
780;nqx - probability of dying between ages x and x+n-20-24 years-Male;18.66666666666667;1.6764199043243107
781;nqx - probability of dying between ages x and x+n-20-24 years-Female;18.66666666666667;1.6342805102321112
782;nqx - probability of dying between ages x and x+n-25-29 years-Both sexes;18.66666666666667;1.7143131759619035
783;nqx - probability of dying between ages x and x+n-25-29 years-Male;18.66666666666667;1.6941081394483684
784;nqx - probability of dying between ages x and x+n-25-29 years-Female;18.66666666666667;1.6529612833653449
785;nqx - probability of dying between ages x and x+n-30-34 years-Both sexes;18.66666666666667;1.7319948163604417
786;nqx - probability of dying between ages x and x+n-30-34 years-Male;18.66666666666667;1.7056170286021164
787;nqx - probability of dying between ages x and x+n-30-34 years-Female;18.66666666666667;1.673511436009398
788;nqx - probability of dying between ages x and x+n-35-39 years-Both sexes;18.66666666666667;1.7422925972191692
789;nqx - probability of dying between ages x and x+n-35-39 years-Male;18.66666666666667;1.7166432407204422
790;nqx - probability of dying between ages x and x+n-35-39 years-Female;18.66666666666667;1.6995965471650258
791;nqx - probability of dying between ages x and x+n-40-44 years-Both sexes;18.66666666666667;1.7530795026949262
792;nqx - probability of dying between ages x and x+n-40-44 years-Male;18.66666666666667;1.729131382440798
793;nqx - probability of dying between ages x and x+n-40-44 years-Female;18.66666666666667;1.7078662062537688
794;nqx - probability of dying between ages x and x+n-45-49 years-Both sexes;18.66666666666667;1.764228446190117
795;nqx - probability of dying between ages x and x+n-45-49 years-Male;18.66666666666667;1.7366901213443535
796;nqx - probability of dying between ages x and x+n-45-49 years-Female;18.66666666666667;1.7227801392536186
797;nqx - probability of dying between ages x and x+n-50-54 years-Both sexes;18.66666666666667;1.7706201722403616
798;nqx - probability of dying between ages x and x+n-50-54 years-Male;18.66666666666667;1.7413111025480887
799;nqx - probability of dying between ages x and x+n-50-54 years-Female;18.66666666666667;1.7328201495574564
800;nqx - probability of dying between ages x and x+n-55-59 years-Both sexes;18.66666666666667;1.7737289968245022
801;nqx - probability of dying between ages x and x+n-55-59 years-Male;18.66666666666667;1.7481990104981024
802;nqx - probability of dying between ages x and x+n-55-59 years-Female;18.66666666666667;1.738957048090632
803;nqx - probability of dying between ages x and x+n-60-64 years-Both sexes;18.66666666666667;1.7794105310913864
804;nqx - probability of dying between ages x and x+n-60-64 years-Male;18.66666666666667;1.750821397336976
805;nqx - probability of dying between ages x and x+n-60-64 years-Female;18.66666666666667;1.7439334893869622
806;nqx - probability of dying between ages x and x+n-65-69 years-Both sexes;18.66666666666667;1.7826063941165087
807;nqx - probability of dying between ages x and x+n-65-69 years-Male;18.66666666666667;1.751532317522166
808;nqx - probability of dying between ages x and x+n-65-69 years-Female;18.66666666666667;1.7483331766888108
809;nqx - probability of dying between ages x and x+n-70-74 years-Both sexes;18.66666666666667;1.7817621736077989
810;nqx - probability of dying between ages x and x+n-70-74 years-Male;18.66666666666667;1.7543759982629261
811;nqx - probability of dying between ages x and x+n-70-74 years-Female;18.66666666666667;1.753665078077736
812;nqx - probability of dying between ages x and x+n-75-79 years-Both sexes;18.66666666666667;1.7850920653582705
813;nqx - probability of dying between ages x and x+n-75-79 years-Male;18.66666666666667;1.752954157892546
814;nqx - probability of dying between ages x and x+n-75-79 years-Female;18.66666666666667;1.752243237707356
815;nqx - probability of dying between ages x and x+n-80-84 years-Both sexes;18.66666666666667;1.78438187357491
816;nqx - probability of dying between ages x and x+n-80-84 years-Male;18.66666666666667;1.7554423785407112
817;nqx - probability of dying between ages x and x+n-80-84 years-Female;18.66666666666667;1.752954157892546
818;nqx - probability of dying between ages x and x+n-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
819;nqx - probability of dying between ages x and x+n-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
820;nqx - probability of dying between ages x and x+n-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
821;nqx - probability of dying between ages x and x+n-100+ years-Both sexes;18.66666666666667;0.022217543150563124
822;nqx - probability of dying between ages x and x+n-85+ years-Male;18.66666666666667;0.24677763318952906
823;nqx - probability of dying between ages x and x+n-85+ years-Female;18.66666666666667;0.24677763318952906
824;nqx - probability of dying between ages x and x+n-85+ years-Both sexes;18.66666666666667;0.24677763318952906
825;nqx - probability of dying between ages x and x+n;18.66666666666667;-15892.427893433749
826;lx - number of people left alive at age x-65-69 years-Both sexes;18.66666666666667;1.7897083119501138
827;lx - number of people left alive at age x-65-69 years-Male;18.66666666666667;1.7589969794666613
828;lx - number of people left alive at age x-65-69 years-Female;18.66666666666667;1.7589969794666613
829;lx - number of people left alive at age x-70-74 years-Both sexes;18.66666666666667;1.7897083119501138
830;lx - number of people left alive at age x-70-74 years-Male;18.66666666666667;1.7589969794666613
831;lx - number of people left alive at age x-70-74 years-Female;18.66666666666667;1.7589969794666613
832;lx - number of people left alive at age x-75-79 years-Both sexes;18.66666666666667;1.7897083119501138
833;lx - number of people left alive at age x-75-79 years-Male;18.66666666666667;1.7589969794666613
834;lx - number of people left alive at age x-75-79 years-Female;18.66666666666667;1.7589969794666613
835;lx - number of people left alive at age x-80-84 years-Both sexes;18.66666666666667;1.7897083119501138
836;lx - number of people left alive at age x-80-84 years-Male;18.66666666666667;1.7589969794666613
837;lx - number of people left alive at age x-80-84 years-Female;18.66666666666667;1.7589969794666613
838;lx - number of people left alive at age x-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
839;lx - number of people left alive at age x-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
840;lx - number of people left alive at age x-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
841;lx - number of people left alive at age x-100+ years-Both sexes;18.66666666666667;0.033592266113598335
842;lx - number of people left alive at age x-<1 year-Both sexes;18.66666666666667;0.2494436456153739
843;lx - number of people left alive at age x-<1 year-Male;18.66666666666667;0.24677763318952906
844;lx - number of people left alive at age x-<1 year-Female;18.66666666666667;0.24677763318952906
845;lx - number of people left alive at age x-1-4 years-Both sexes;18.66666666666667;1.7897083119501138
846;lx - number of people left alive at age x-1-4 years-Male;18.66666666666667;1.7589969794666613
847;lx - number of people left alive at age x-1-4 years-Female;18.66666666666667;1.7589969794666613
848;lx - number of people left alive at age x-5-9 years-Both sexes;18.66666666666667;1.7897083119501138
849;lx - number of people left alive at age x-5-9 years-Male;18.66666666666667;1.7589969794666613
850;lx - number of people left alive at age x-5-9 years-Female;18.66666666666667;1.7589969794666613
851;lx - number of people left alive at age x-10-14 years-Both sexes;18.66666666666667;1.7897083119501138
852;lx - number of people left alive at age x-10-14 years-Male;18.66666666666667;1.7589969794666613
853;lx - number of people left alive at age x-10-14 years-Female;18.66666666666667;1.7589969794666613
854;lx - number of people left alive at age x-15-19  years-Both sexes;18.66666666666667;1.7897083119501138
855;lx - number of people left alive at age x-15-19  years-Male;18.66666666666667;1.7589969794666613
856;lx - number of people left alive at age x-15-19  years-Female;18.66666666666667;1.7589969794666613
857;lx - number of people left alive at age x-20-24 years-Both sexes;18.66666666666667;1.7897083119501138
858;lx - number of people left alive at age x-20-24 years-Male;18.66666666666667;1.7589969794666613
859;lx - number of people left alive at age x-20-24 years-Female;18.66666666666667;1.7589969794666613
860;lx - number of people left alive at age x-25-29 years-Both sexes;18.66666666666667;1.7897083119501138
861;lx - number of people left alive at age x-25-29 years-Male;18.66666666666667;1.7589969794666613
862;lx - number of people left alive at age x-25-29 years-Female;18.66666666666667;1.7589969794666613
863;lx - number of people left alive at age x-30-34 years-Both sexes;18.66666666666667;1.7897083119501138
864;lx - number of people left alive at age x-30-34 years-Male;18.66666666666667;1.7589969794666613
865;lx - number of people left alive at age x-30-34 years-Female;18.66666666666667;1.7589969794666613
866;lx - number of people left alive at age x-35-39 years-Both sexes;18.66666666666667;1.7897083119501138
867;lx - number of people left alive at age x-35-39 years-Male;18.66666666666667;1.7589969794666613
868;lx - number of people left alive at age x-35-39 years-Female;18.66666666666667;1.7589969794666613
869;lx - number of people left alive at age x-40-44 years-Both sexes;18.66666666666667;1.7897083119501138
870;lx - number of people left alive at age x-40-44 years-Male;18.66666666666667;1.7589969794666613
871;lx - number of people left alive at age x-40-44 years-Female;18.66666666666667;1.7589969794666613
872;lx - number of people left alive at age x-45-49 years-Both sexes;18.66666666666667;1.7897083119501138
873;lx - number of people left alive at age x-45-49 years-Male;18.66666666666667;1.7589969794666613
874;lx - number of people left alive at age x-45-49 years-Female;18.66666666666667;1.7589969794666613
875;lx - number of people left alive at age x-50-54 years-Both sexes;18.66666666666667;1.7897083119501138
876;lx - number of people left alive at age x-50-54 years-Male;18.66666666666667;1.7589969794666613
877;lx - number of people left alive at age x-50-54 years-Female;18.66666666666667;1.7589969794666613
878;lx - number of people left alive at age x-55-59 years-Both sexes;18.66666666666667;1.7897083119501138
879;lx - number of people left alive at age x-55-59 years-Male;18.66666666666667;1.7589969794666613
880;lx - number of people left alive at age x-55-59 years-Female;18.66666666666667;1.7589969794666613
881;lx - number of people left alive at age x-60-64 years-Both sexes;18.66666666666667;1.7897083119501138
882;lx - number of people left alive at age x-60-64 years-Male;18.66666666666667;1.7589969794666613
883;lx - number of people left alive at age x-60-64 years-Female;18.66666666666667;1.7589969794666613
884;lx - number of people left alive at age x-85+ years-Male;18.66666666666667;1.7589969794666613
885;lx - number of people left alive at age x-85+ years-Female;18.66666666666667;1.7589969794666613
886;lx - number of people left alive at age x-85+ years-Both sexes;18.66666666666667;1.7589969794666613
887;lx - number of people left alive at age x;18.66666666666667;-15892.427893433749
888;ndx - number of people dying between ages x and x+n-<1 year-Both sexes;18.66666666666667;1.7897083119501138
889;ndx - number of people dying between ages x and x+n-<1 year-Male;18.66666666666667;1.7589969794666613
890;ndx - number of people dying between ages x and x+n-<1 year-Female;18.66666666666667;1.7589969794666613
891;ndx - number of people dying between ages x and x+n-50-54 years-Both sexes;18.66666666666667;1.7897083119501138
892;ndx - number of people dying between ages x and x+n-50-54 years-Male;18.66666666666667;1.7589969794666613
893;ndx - number of people dying between ages x and x+n-50-54 years-Female;18.66666666666667;1.7589969794666613
894;ndx - number of people dying between ages x and x+n-55-59 years-Both sexes;18.66666666666667;1.7897083119501138
895;ndx - number of people dying between ages x and x+n-55-59 years-Male;18.66666666666667;1.7589969794666613
896;ndx - number of people dying between ages x and x+n-55-59 years-Female;18.66666666666667;1.7589969794666613
897;ndx - number of people dying between ages x and x+n-60-64 years-Both sexes;18.66666666666667;1.7897083119501138
898;ndx - number of people dying between ages x and x+n-60-64 years-Male;18.66666666666667;1.7589969794666613
899;ndx - number of people dying between ages x and x+n-60-64 years-Female;18.66666666666667;1.7589969794666613
900;ndx - number of people dying between ages x and x+n-65-69 years-Both sexes;18.66666666666667;1.7897083119501138
901;ndx - number of people dying between ages x and x+n-65-69 years-Male;18.66666666666667;1.7589969794666613
902;ndx - number of people dying between ages x and x+n-65-69 years-Female;18.66666666666667;1.7589969794666613
903;ndx - number of people dying between ages x and x+n-70-74 years-Both sexes;18.66666666666667;1.7897083119501138
904;ndx - number of people dying between ages x and x+n-70-74 years-Male;18.66666666666667;1.7589969794666613
905;ndx - number of people dying between ages x and x+n-70-74 years-Female;18.66666666666667;1.7589969794666613
906;ndx - number of people dying between ages x and x+n-75-79 years-Both sexes;18.66666666666667;1.7897083119501138
907;ndx - number of people dying between ages x and x+n-75-79 years-Male;18.66666666666667;1.7589969794666613
908;ndx - number of people dying between ages x and x+n-75-79 years-Female;18.66666666666667;1.7589969794666613
909;ndx - number of people dying between ages x and x+n-80-84 years-Both sexes;18.66666666666667;1.7897083119501138
910;ndx - number of people dying between ages x and x+n-80-84 years-Male;18.66666666666667;1.7589969794666613
911;ndx - number of people dying between ages x and x+n-80-84 years-Female;18.66666666666667;1.7589969794666613
912;ndx - number of people dying between ages x and x+n-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
913;ndx - number of people dying between ages x and x+n-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
914;ndx - number of people dying between ages x and x+n-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
915;ndx - number of people dying between ages x and x+n-100+ years-Both sexes;18.66666666666667;0.033592266113598335
916;ndx - number of people dying between ages x and x+n-1-4 years-Both sexes;18.66666666666667;1.7897083119501138
917;ndx - number of people dying between ages x and x+n-1-4 years-Male;18.66666666666667;1.7589969794666613
918;ndx - number of people dying between ages x and x+n-1-4 years-Female;18.66666666666667;1.7589969794666613
919;ndx - number of people dying between ages x and x+n-5-9 years-Both sexes;18.66666666666667;1.7897083119501138
920;ndx - number of people dying between ages x and x+n-5-9 years-Male;18.66666666666667;1.7589969794666613
921;ndx - number of people dying between ages x and x+n-5-9 years-Female;18.66666666666667;1.7589969794666613
922;ndx - number of people dying between ages x and x+n-10-14 years-Both sexes;18.66666666666667;1.7897083119501138
923;ndx - number of people dying between ages x and x+n-10-14 years-Male;18.66666666666667;1.7589969794666613
924;ndx - number of people dying between ages x and x+n-10-14 years-Female;18.66666666666667;1.7589969794666613
925;ndx - number of people dying between ages x and x+n-15-19  years-Both sexes;18.66666666666667;1.7897083119501138
926;ndx - number of people dying between ages x and x+n-15-19  years-Male;18.66666666666667;1.7589969794666613
927;ndx - number of people dying between ages x and x+n-15-19  years-Female;18.66666666666667;1.7589969794666613
928;ndx - number of people dying between ages x and x+n-20-24 years-Both sexes;18.66666666666667;1.7897083119501138
929;ndx - number of people dying between ages x and x+n-20-24 years-Male;18.66666666666667;1.7589969794666613
930;ndx - number of people dying between ages x and x+n-20-24 years-Female;18.66666666666667;1.7589969794666613
931;ndx - number of people dying between ages x and x+n-25-29 years-Both sexes;18.66666666666667;1.7897083119501138
932;ndx - number of people dying between ages x and x+n-25-29 years-Male;18.66666666666667;1.7589969794666613
933;ndx - number of people dying between ages x and x+n-25-29 years-Female;18.66666666666667;1.7589969794666613
934;ndx - number of people dying between ages x and x+n-30-34 years-Both sexes;18.66666666666667;1.7897083119501138
935;ndx - number of people dying between ages x and x+n-30-34 years-Male;18.66666666666667;1.7589969794666613
936;ndx - number of people dying between ages x and x+n-30-34 years-Female;18.66666666666667;1.7589969794666613
937;ndx - number of people dying between ages x and x+n-35-39 years-Both sexes;18.66666666666667;1.7897083119501138
938;ndx - number of people dying between ages x and x+n-35-39 years-Male;18.66666666666667;1.7589969794666613
939;ndx - number of people dying between ages x and x+n-35-39 years-Female;18.66666666666667;1.7589969794666613
940;ndx - number of people dying between ages x and x+n-40-44 years-Both sexes;18.66666666666667;1.7897083119501138
941;ndx - number of people dying between ages x and x+n-40-44 years-Male;18.66666666666667;1.7589969794666613
942;ndx - number of people dying between ages x and x+n-40-44 years-Female;18.66666666666667;1.7589969794666613
943;ndx - number of people dying between ages x and x+n-45-49 years-Both sexes;18.66666666666667;1.7897083119501138
944;ndx - number of people dying between ages x and x+n-45-49 years-Male;18.66666666666667;1.7589969794666613
945;ndx - number of people dying between ages x and x+n-45-49 years-Female;18.66666666666667;1.7589969794666613
946;ndx - number of people dying between ages x and x+n-85+ years-Male;18.66666666666667;1.7589969794666613
947;ndx - number of people dying between ages x and x+n-85+ years-Female;18.66666666666667;1.7589969794666613
948;ndx - number of people dying between ages x and x+n-85+ years-Both sexes;18.66666666666667;1.7589969794666613
949;ndx - number of people dying between ages x and x+n;18.66666666666667;-15893.326923076438
950;nLx - person-years lived between ages x and x+n-<1 year-Both sexes;18.66666666666667;1.7897083119501138
951;nLx - person-years lived between ages x and x+n-<1 year-Male;18.66666666666667;1.7589969794666613
952;nLx - person-years lived between ages x and x+n-<1 year-Female;18.66666666666667;1.7589969794666613
953;nLx - person-years lived between ages x and x+n-25-29 years-Both sexes;18.66666666666667;1.7897083119501138
954;nLx - person-years lived between ages x and x+n-25-29 years-Male;18.66666666666667;1.7589969794666613
955;nLx - person-years lived between ages x and x+n-25-29 years-Female;18.66666666666667;1.7589969794666613
956;nLx - person-years lived between ages x and x+n-30-34 years-Both sexes;18.66666666666667;1.7897083119501138
957;nLx - person-years lived between ages x and x+n-30-34 years-Male;18.66666666666667;1.7589969794666613
958;nLx - person-years lived between ages x and x+n-30-34 years-Female;18.66666666666667;1.7589969794666613
959;nLx - person-years lived between ages x and x+n-35-39 years-Both sexes;18.66666666666667;1.7897083119501138
960;nLx - person-years lived between ages x and x+n-35-39 years-Male;18.66666666666667;1.7589969794666613
961;nLx - person-years lived between ages x and x+n-35-39 years-Female;18.66666666666667;1.7589969794666613
962;nLx - person-years lived between ages x and x+n-40-44 years-Both sexes;18.66666666666667;1.7897083119501138
963;nLx - person-years lived between ages x and x+n-40-44 years-Male;18.66666666666667;1.7589969794666613
964;nLx - person-years lived between ages x and x+n-40-44 years-Female;18.66666666666667;1.7589969794666613
965;nLx - person-years lived between ages x and x+n-45-49 years-Both sexes;18.66666666666667;1.7897083119501138
966;nLx - person-years lived between ages x and x+n-45-49 years-Male;18.66666666666667;1.7589969794666613
967;nLx - person-years lived between ages x and x+n-45-49 years-Female;18.66666666666667;1.7589969794666613
968;nLx - person-years lived between ages x and x+n-50-54 years-Both sexes;18.66666666666667;1.7897083119501138
969;nLx - person-years lived between ages x and x+n-50-54 years-Male;18.66666666666667;1.7589969794666613
970;nLx - person-years lived between ages x and x+n-50-54 years-Female;18.66666666666667;1.7589969794666613
971;nLx - person-years lived between ages x and x+n-55-59 years-Both sexes;18.66666666666667;1.7897083119501138
972;nLx - person-years lived between ages x and x+n-55-59 years-Male;18.66666666666667;1.7589969794666613
973;nLx - person-years lived between ages x and x+n-55-59 years-Female;18.66666666666667;1.7589969794666613
974;nLx - person-years lived between ages x and x+n-60-64 years-Both sexes;18.66666666666667;1.7897083119501138
975;nLx - person-years lived between ages x and x+n-60-64 years-Male;18.66666666666667;1.7589969794666613
976;nLx - person-years lived between ages x and x+n-60-64 years-Female;18.66666666666667;1.7589969794666613
977;nLx - person-years lived between ages x and x+n-65-69 years-Both sexes;18.66666666666667;1.7897083119501138
978;nLx - person-years lived between ages x and x+n-65-69 years-Male;18.66666666666667;1.7589969794666613
979;nLx - person-years lived between ages x and x+n-65-69 years-Female;18.66666666666667;1.7589969794666613
980;nLx - person-years lived between ages x and x+n-70-74 years-Both sexes;18.66666666666667;1.7897083119501138
981;nLx - person-years lived between ages x and x+n-70-74 years-Male;18.66666666666667;1.7589969794666613
982;nLx - person-years lived between ages x and x+n-70-74 years-Female;18.66666666666667;1.7589969794666613
983;nLx - person-years lived between ages x and x+n-75-79 years-Both sexes;18.66666666666667;1.7897083119501138
984;nLx - person-years lived between ages x and x+n-75-79 years-Male;18.66666666666667;1.7589969794666613
985;nLx - person-years lived between ages x and x+n-75-79 years-Female;18.66666666666667;1.7589969794666613
986;nLx - person-years lived between ages x and x+n-80-84 years-Both sexes;18.66666666666667;1.7897083119501138
987;nLx - person-years lived between ages x and x+n-80-84 years-Male;18.66666666666667;1.7589969794666613
988;nLx - person-years lived between ages x and x+n-80-84 years-Female;18.66666666666667;1.7589969794666613
989;nLx - person-years lived between ages x and x+n-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
990;nLx - person-years lived between ages x and x+n-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
991;nLx - person-years lived between ages x and x+n-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
992;nLx - person-years lived between ages x and x+n-100+ years-Both sexes;18.66666666666667;0.033592266113598335
993;nLx - person-years lived between ages x and x+n-1-4 years-Both sexes;18.66666666666667;1.7897083119501138
994;nLx - person-years lived between ages x and x+n-1-4 years-Male;18.66666666666667;1.7589969794666613
995;nLx - person-years lived between ages x and x+n-1-4 years-Female;18.66666666666667;1.7589969794666613
996;nLx - person-years lived between ages x and x+n-5-9 years-Both sexes;18.66666666666667;1.7897083119501138
997;nLx - person-years lived between ages x and x+n-5-9 years-Male;18.66666666666667;1.7589969794666613
998;nLx - person-years lived between ages x and x+n-5-9 years-Female;18.66666666666667;1.7589969794666613
999;nLx - person-years lived between ages x and x+n-10-14 years-Both sexes;18.66666666666667;1.7897083119501138
1000;nLx - person-years lived between ages x and x+n-10-14 years-Male;18.66666666666667;1.7589969794666613
1001;nLx - person-years lived between ages x and x+n-10-14 years-Female;18.66666666666667;1.7589969794666613
1002;nLx - person-years lived between ages x and x+n-15-19  years-Both sexes;18.66666666666667;1.7897083119501138
1003;nLx - person-years lived between ages x and x+n-15-19  years-Male;18.66666666666667;1.7589969794666613
1004;nLx - person-years lived between ages x and x+n-15-19  years-Female;18.66666666666667;1.7589969794666613
1005;nLx - person-years lived between ages x and x+n-20-24 years-Both sexes;18.66666666666667;1.7897083119501138
1006;nLx - person-years lived between ages x and x+n-20-24 years-Male;18.66666666666667;1.7589969794666613
1007;nLx - person-years lived between ages x and x+n-20-24 years-Female;18.66666666666667;1.7589969794666613
1008;nLx - person-years lived between ages x and x+n-85+ years-Male;18.66666666666667;1.7589969794666613
1009;nLx - person-years lived between ages x and x+n-85+ years-Female;18.66666666666667;1.7589969794666613
1010;nLx - person-years lived between ages x and x+n-85+ years-Both sexes;18.66666666666667;1.7589969794666613
1011;nLx - person-years lived between ages x and x+n;18.66666666666667;-15892.427893433749
1012;Tx - person-years lived above age x-10-14 years-Both sexes;18.66666666666667;1.7897083119501138
1013;Tx - person-years lived above age x-10-14 years-Male;18.66666666666667;1.7589969794666613
1014;Tx - person-years lived above age x-10-14 years-Female;18.66666666666667;1.7589969794666613
1015;Tx - person-years lived above age x-<1 year-Both sexes;18.66666666666667;1.7897083119501138
1016;Tx - person-years lived above age x-<1 year-Male;18.66666666666667;1.7589969794666613
1017;Tx - person-years lived above age x-<1 year-Female;18.66666666666667;1.7589969794666613
1018;Tx - person-years lived above age x-1-4 years-Both sexes;18.66666666666667;1.7897083119501138
1019;Tx - person-years lived above age x-1-4 years-Male;18.66666666666667;1.7589969794666613
1020;Tx - person-years lived above age x-1-4 years-Female;18.66666666666667;1.7589969794666613
1021;Tx - person-years lived above age x-5-9 years-Both sexes;18.66666666666667;1.7897083119501138
1022;Tx - person-years lived above age x-5-9 years-Male;18.66666666666667;1.7589969794666613
1023;Tx - person-years lived above age x-5-9 years-Female;18.66666666666667;1.7589969794666613
1024;Tx - person-years lived above age x-15-19  years-Both sexes;18.66666666666667;1.7897083119501138
1025;Tx - person-years lived above age x-15-19  years-Male;18.66666666666667;1.7589969794666613
1026;Tx - person-years lived above age x-15-19  years-Female;18.66666666666667;1.7589969794666613
1027;Tx - person-years lived above age x-20-24 years-Both sexes;18.66666666666667;1.7897083119501138
1028;Tx - person-years lived above age x-20-24 years-Male;18.66666666666667;1.7589969794666613
1029;Tx - person-years lived above age x-20-24 years-Female;18.66666666666667;1.7589969794666613
1030;Tx - person-years lived above age x-25-29 years-Both sexes;18.66666666666667;1.7897083119501138
1031;Tx - person-years lived above age x-25-29 years-Male;18.66666666666667;1.7589969794666613
1032;Tx - person-years lived above age x-25-29 years-Female;18.66666666666667;1.7589969794666613
1033;Tx - person-years lived above age x-30-34 years-Both sexes;18.66666666666667;1.7897083119501138
1034;Tx - person-years lived above age x-30-34 years-Male;18.66666666666667;1.7589969794666613
1035;Tx - person-years lived above age x-30-34 years-Female;18.66666666666667;1.7589969794666613
1036;Tx - person-years lived above age x-35-39 years-Both sexes;18.66666666666667;1.7897083119501138
1037;Tx - person-years lived above age x-35-39 years-Male;18.66666666666667;1.7589969794666613
1038;Tx - person-years lived above age x-35-39 years-Female;18.66666666666667;1.7589969794666613
1039;Tx - person-years lived above age x-40-44 years-Both sexes;18.66666666666667;1.7897083119501138
1040;Tx - person-years lived above age x-40-44 years-Male;18.66666666666667;1.7589969794666613
1041;Tx - person-years lived above age x-40-44 years-Female;18.66666666666667;1.7589969794666613
1042;Tx - person-years lived above age x-45-49 years-Both sexes;18.66666666666667;1.7897083119501138
1043;Tx - person-years lived above age x-45-49 years-Male;18.66666666666667;1.7589969794666613
1044;Tx - person-years lived above age x-45-49 years-Female;18.66666666666667;1.7589969794666613
1045;Tx - person-years lived above age x-50-54 years-Both sexes;18.66666666666667;1.7897083119501138
1046;Tx - person-years lived above age x-50-54 years-Male;18.66666666666667;1.7589969794666613
1047;Tx - person-years lived above age x-50-54 years-Female;18.66666666666667;1.7589969794666613
1048;Tx - person-years lived above age x-55-59 years-Both sexes;18.66666666666667;1.7897083119501138
1049;Tx - person-years lived above age x-55-59 years-Male;18.66666666666667;1.7589969794666613
1050;Tx - person-years lived above age x-55-59 years-Female;18.66666666666667;1.7589969794666613
1051;Tx - person-years lived above age x-60-64 years-Both sexes;18.66666666666667;1.7897083119501138
1052;Tx - person-years lived above age x-60-64 years-Male;18.66666666666667;1.7589969794666613
1053;Tx - person-years lived above age x-60-64 years-Female;18.66666666666667;1.7589969794666613
1054;Tx - person-years lived above age x-65-69 years-Both sexes;18.66666666666667;1.7897083119501138
1055;Tx - person-years lived above age x-65-69 years-Male;18.66666666666667;1.7589969794666613
1056;Tx - person-years lived above age x-65-69 years-Female;18.66666666666667;1.7589969794666613
1057;Tx - person-years lived above age x-70-74 years-Both sexes;18.66666666666667;1.7897083119501138
1058;Tx - person-years lived above age x-70-74 years-Male;18.66666666666667;1.7589969794666613
1059;Tx - person-years lived above age x-70-74 years-Female;18.66666666666667;1.7589969794666613
1060;Tx - person-years lived above age x-75-79 years-Both sexes;18.66666666666667;1.7897083119501138
1061;Tx - person-years lived above age x-75-79 years-Male;18.66666666666667;1.7589969794666613
1062;Tx - person-years lived above age x-75-79 years-Female;18.66666666666667;1.7589969794666613
1063;Tx - person-years lived above age x-80-84 years-Both sexes;18.66666666666667;1.7897083119501138
1064;Tx - person-years lived above age x-80-84 years-Male;18.66666666666667;1.7589969794666613
1065;Tx - person-years lived above age x-80-84 years-Female;18.66666666666667;1.7589969794666613
1066;Tx - person-years lived above age x-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
1067;Tx - person-years lived above age x-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
1068;Tx - person-years lived above age x-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
1069;Tx - person-years lived above age x-100+ years-Both sexes;18.66666666666667;0.033592266113598335
1070;Tx - person-years lived above age x-85+ years-Male;18.66666666666667;1.7589969794666613
1071;Tx - person-years lived above age x-85+ years-Female;18.66666666666667;1.7589969794666613
1072;Tx - person-years lived above age x-85+ years-Both sexes;18.66666666666667;1.7589969794666613
1073;Tx - person-years lived above age x;18.66666666666667;-15892.427893433749
1074;ex - expectation of life at age x-100+ years-Both sexes;18.66666666666667;0.033592266113598335
1075;ex - expectation of life at age x-<1 year-Both sexes;18.66666666666667;1.7897083119501138
1076;ex - expectation of life at age x-<1 year-Male;18.66666666666667;1.7586415193740663
1077;ex - expectation of life at age x-<1 year-Female;18.66666666666667;1.7586415193740663
1078;ex - expectation of life at age x-1-4 years-Both sexes;18.66666666666667;1.7897083119501138
1079;ex - expectation of life at age x-1-4 years-Male;18.66666666666667;1.7589969794666613
1080;ex - expectation of life at age x-1-4 years-Female;18.66666666666667;1.7589969794666613
1081;ex - expectation of life at age x-5-9 years-Both sexes;18.66666666666667;1.7897083119501138
1082;ex - expectation of life at age x-5-9 years-Male;18.66666666666667;1.7589969794666613
1083;ex - expectation of life at age x-5-9 years-Female;18.66666666666667;1.7589969794666613
1084;ex - expectation of life at age x-10-14 years-Both sexes;18.66666666666667;1.7897083119501138
1085;ex - expectation of life at age x-10-14 years-Male;18.66666666666667;1.7589969794666613
1086;ex - expectation of life at age x-10-14 years-Female;18.66666666666667;1.7589969794666613
1087;ex - expectation of life at age x-15-19  years-Both sexes;18.66666666666667;1.7897083119501138
1088;ex - expectation of life at age x-15-19  years-Male;18.66666666666667;1.7586415193740663
1089;ex - expectation of life at age x-15-19  years-Female;18.66666666666667;1.7589969794666613
1090;ex - expectation of life at age x-20-24 years-Both sexes;18.66666666666667;1.7897083119501138
1091;ex - expectation of life at age x-20-24 years-Male;18.66666666666667;1.7589969794666613
1092;ex - expectation of life at age x-20-24 years-Female;18.66666666666667;1.7589969794666613
1093;ex - expectation of life at age x-25-29 years-Both sexes;18.66666666666667;1.7897083119501138
1094;ex - expectation of life at age x-25-29 years-Male;18.66666666666667;1.7589969794666613
1095;ex - expectation of life at age x-25-29 years-Female;18.66666666666667;1.7589969794666613
1096;ex - expectation of life at age x-30-34 years-Both sexes;18.66666666666667;1.7897083119501138
1097;ex - expectation of life at age x-30-34 years-Male;18.66666666666667;1.7589969794666613
1098;ex - expectation of life at age x-30-34 years-Female;18.66666666666667;1.7589969794666613
1099;ex - expectation of life at age x-35-39 years-Both sexes;18.66666666666667;1.7897083119501138
1100;ex - expectation of life at age x-35-39 years-Male;18.66666666666667;1.7589969794666613
1101;ex - expectation of life at age x-35-39 years-Female;18.66666666666667;1.7589969794666613
1102;ex - expectation of life at age x-40-44 years-Both sexes;18.66666666666667;1.7893532160584336
1103;ex - expectation of life at age x-40-44 years-Male;18.66666666666667;1.7589969794666613
1104;ex - expectation of life at age x-40-44 years-Female;18.66666666666667;1.7589969794666613
1105;ex - expectation of life at age x-45-49 years-Both sexes;18.66666666666667;1.7893532160584336
1106;ex - expectation of life at age x-45-49 years-Male;18.66666666666667;1.7589969794666613
1107;ex - expectation of life at age x-45-49 years-Female;18.66666666666667;1.7589969794666613
1108;ex - expectation of life at age x-50-54 years-Both sexes;18.66666666666667;1.7897083119501138
1109;ex - expectation of life at age x-50-54 years-Male;18.66666666666667;1.7589969794666613
1110;ex - expectation of life at age x-50-54 years-Female;18.66666666666667;1.7589969794666613
1111;ex - expectation of life at age x-55-59 years-Both sexes;18.66666666666667;1.7889981201667533
1112;ex - expectation of life at age x-55-59 years-Male;18.66666666666667;1.7589969794666613
1113;ex - expectation of life at age x-55-59 years-Female;18.66666666666667;1.7586415193740663
1114;ex - expectation of life at age x-60-64 years-Both sexes;18.66666666666667;1.7893532160584336
1115;ex - expectation of life at age x-60-64 years-Male;18.66666666666667;1.7589969794666613
1116;ex - expectation of life at age x-60-64 years-Female;18.66666666666667;1.7589969794666613
1117;ex - expectation of life at age x-65-69 years-Both sexes;18.66666666666667;1.7893532160584336
1118;ex - expectation of life at age x-65-69 years-Male;18.66666666666667;1.7589969794666613
1119;ex - expectation of life at age x-65-69 years-Female;18.66666666666667;1.7589969794666613
1120;ex - expectation of life at age x-70-74 years-Both sexes;18.66666666666667;1.7893532160584336
1121;ex - expectation of life at age x-70-74 years-Male;18.66666666666667;1.7589969794666613
1122;ex - expectation of life at age x-70-74 years-Female;18.66666666666667;1.7582860592814713
1123;ex - expectation of life at age x-75-79 years-Both sexes;18.66666666666667;1.7897083119501138
1124;ex - expectation of life at age x-75-79 years-Male;18.66666666666667;1.7589969794666613
1125;ex - expectation of life at age x-75-79 years-Female;18.66666666666667;1.7586415193740663
1126;ex - expectation of life at age x-80-84 years-Both sexes;18.66666666666667;1.7893532160584336
1127;ex - expectation of life at age x-80-84 years-Male;18.66666666666667;1.7582860592814713
1128;ex - expectation of life at age x-80-84 years-Female;18.66666666666667;1.7586415193740663
1129;ex - expectation of life at age x-85-89 years-Both sexes;18.66666666666667;0.033592266113598335
1130;ex - expectation of life at age x-90-94 years-Both sexes;18.66666666666667;0.033592266113598335
1131;ex - expectation of life at age x-95-99 years-Both sexes;18.66666666666667;0.033592266113598335
1132;ex - expectation of life at age x-85+ years-Male;18.66666666666667;1.7586415193740663
1133;ex - expectation of life at age x-85+ years-Female;18.66666666666667;1.7579305991888763
1134;ex - expectation of life at age x-85+ years-Both sexes;18.66666666666667;1.7586415193740663
1135;ex - expectation of life at age x;18.66666666666667;-15892.427893433749
1136;Adult indicator 1 rate;0.0;
1137;Youth indicator 1 rate;0.0;
1138;Adult indicator 1 definition;0.0;
1139;Youth indicator 1 definition;0.0;
1140;Adult indicator 2 rate;0.0;
1141;Youth indicator 2 rate;0.0;
1142;Adult indicator 2 definition;0.0;
1143;Youth indicator 2 definition;0.0;
1144;Estimate of current cigarette smoking prevalence (%)-Both sexes;27.111111111111114;1.566047009453582
1145;Estimate of current cigarette smoking prevalence (%)-Male;27.111111111111114;1.6345561628611929
1146;Estimate of current cigarette smoking prevalence (%)-Female;27.111111111111114;1.4420491661528452
1147;Estimate of current cigarette smoking prevalence (%);27.111111111111114;-15296.026593278704
1148;Estimate of current tobacco use prevalence (%)-Both sexes;27.111111111111114;1.6006598959463076
1149;Estimate of current tobacco use prevalence (%)-Male;27.111111111111114;1.6547680187718568
1150;Estimate of current tobacco use prevalence (%)-Female;27.111111111111114;1.538640355697873
1151;Estimate of current tobacco use prevalence (%);27.111111111111114;-15296.010018462335
1152;Monitoring tobacco use and prevention policies;13.333333333333329;-11526.69666660996
1153;Adult survey age range - smokeless;0.0;
1154;Youth survey age range - smokeless;0.0;
1155;Adult smokeless tobacco use indicator definition;0.0;
1156;Youth smokeless tobacco use indicator definition;0.0;
1157;Adult smokeless tobacco use indicator rate;0.0;
1158;Youth smokeless tobacco use indicator rate;0.0;
1159;Name of survey of adults - smokeless;0.0;
1160;Name of survey of youth - smokeless;0.0;
1161;Representativeness of survey of adults - smokeless;0.0;
1162;Representativeness of survey of youth - smokeless;0.0;
1163;Name of survey of adults;0.0;
1164;Name of survey of youth;0.0;
1165;Adult survey age range;0.0;
1166;Youth survey age range;0.0;
1167;Representativeness of survey of adults;0.0;
1168;Representativeness of youth survey;0.0;
1169;Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%);20.444444444444443;-3366.8164859899016
1170;Adolescent birth rate (per 1000 women aged 15-19 years);14.222222222222229;-1678.93020148751
1171;Median availability of selected generic medicines (%) - Public;84.0;-27276.155469354107
1172;Median consumer price ratio of selected generic medicines - Public;91.11111111111111;-27509.639487045963
1173;Children aged <5 years with fever who received treatment with any antimalarial (%);75.11111111111111;-26969.340447096718
1174;Prevalence of condom use by adults during higher-risk sex (15-49) (%)-Male;82.66666666666666;0.07242757861604332
1175;Prevalence of condom use by adults during higher-risk sex (15-49) (%)-Female;82.66666666666666;0.07238646252869163
1176;Prevalence of condom use by adults during higher-risk sex (15-49) (%);82.66666666666666;-27227.22747831407
1177;Deaths due to tuberculosis among HIV-negative people (per 100 000 population);14.222222222222229;0.19885899410528474
1178;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%)-Male;80.44444444444444;0.0741556552840743
1179;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%)-Female;80.44444444444444;0.08285649914640114
1180;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%);80.44444444444444;-27152.000148885814
1181;Births attended by skilled health personnel (%);16.888888888888886;-6163.965312451088
1182;Births attended by skilled health personnel, among girls aged 15-19 (%);63.55555555555556;-26579.322042157462
1183;Maternal mortality ratio (per 100 000 live births);18.66666666666667;-569.9637154482311
1184;Prevalence of HIV among adults aged 15 to 49 (%);40.0;-2390.2294879475103
1185;Smear-positive tuberculosis case-detection rate (%);15.555555555555557;-22765.930587467607
1186;Smear-positive tuberculosis treatment-success rate (%);15.555555555555557;-5872.3320898529055
1187;Maternal mortality ratio (per 100 000 live births) - Country reported estimates;99.55555555555556;-27793.259715089294
1188;Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%);56.0;-26364.535379216788
1189;Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines;53.77777777777778;-26299.400395814304
1190;Number of suspected meningitis deaths reported;91.55555555555556;-26554.572138284337
1191;Number of suspected meningitis cases reported;91.55555555555556;-26341.403498468768
1192;Number of meningitis epidemic districts;91.55555555555556;-26584.448868300093
1193;Mental health policy;0.0;
1194;Mental health outpatient facilities (per 100,000);38.22222222222222;-25843.694551994693
1195;Mental health day treatment facilities (per 100,000);67.11111111111111;-26772.25926725289
1196;Age-standardized suicide rates (per 100 000 population);18.66666666666667;-70.62729512598325
1197;Beds for mental health in general hospitals (per 100,000);41.333333333333336;-25936.558329200467
1198;Community residential facilities (per 100,000);71.11111111111111;-26889.252076492015
1199;Beds in community residential facilities (per 100,000);74.22222222222223;-26982.785124220813
1200;Beds in mental hospitals (per 100,000);41.77777777777778;-25961.370418460305
1201;Mental hospitals (per 100,000);41.77777777777778;-25964.546699456336
1202;Mental health units in general hospitals (per 100,000);38.66666666666667;-25854.107566092116
1203;Mental hospital admissions (per 100,000);47.55555555555555;-26110.12885442928
1204;Mental health plan;0.0;
1205;Outpatient visits (per 100,000);60.44444444444444;-26518.067267422346
1206;Mental health units in general hospitals admissions (per 100,000);60.44444444444444;-26523.217999819968
1207;Stand-alone policy or plan for mental health;0.0;
1208;Stand-alone mental health legislation;0.0;
1209;Government expenditures on mental health as a percentage of total government expenditures on health (%);65.33333333333333;-26693.090052612162
1210;Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%);65.33333333333333;-26709.3286030312
1211;Psychiatrists working in mental health sector (per 100,000);35.111111111111114;-25739.568133272875
1212;Nurses working in mental health sector (per 100,000);43.55555555555556;-25996.657360219626
1213;Social workers working in mental health sector (per 100,000);55.55555555555556;-26372.066541396372
1214;Psychologists working in mental health sector (per 100,000);46.666666666666664;-26100.799403173663
1215;Number of deaths;13.777777777777771;-240.89486287471306
1216;Deaths per 1 000 live births;13.777777777777771;-240.89324492646787
1217;Distribution of causes of death among children aged < 5 years (%);13.777777777777771;-254.73910400586297
1218;Deaths per 100 000 population;0.0;
1219;Number of deaths;13.777777777777771;-240.89486287471306
1220;Projection of number of deaths;0.0;
1221;Projection of deaths per 100 000 population;0.0;
1222;Number of maternal deaths;18.66666666666667;-570.5317609515204
1223;Adolescent mortality rate (per 100 000 population);18.66666666666667;-25198.35325060058
1224;Prevalence of underweight among adults, BMI < 18 (age-standardized estimate) (%);15.555555555555557;-707.2754361561659
1225;Prevalence of underweight among adults, BMI < 18 (crude estimate) (%);15.555555555555557;-707.2480547152489
1226;"Prevalence of overweight among adults, BMI &GreaterEqual; 25 (age-standardized estimate) (%)";15.555555555555557;-706.4755267519344
1227;"Prevalence of overweight among adults, BMI &GreaterEqual; 25 (crude estimate) (%)";15.555555555555557;-706.4189779741844
1228;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)";15.555555555555557;-706.6283701047478
1229;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)";15.555555555555557;-706.6527950042691
1230;"Mean BMI (kg/m&#xb2;) (crude estimate)";15.111111111111114;-682.7013294015185
1231;Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%);15.555555555555557;-706.6302207517197
1232;Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%);15.555555555555557;-706.0845328837175
1233;Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%);15.555555555555557;-706.3737504288398
1234;General availability of ACE inhibitors in the public health sector;0.0;
1235;Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol;0.0;
1236;General availability of aspirin (100 mg) in the public health sector;0.0;
1237;General availability of beta blockers in the public health sector;0.0;
1238;General availability of colon cancer screening at the primary health care level;0.0;
1239;General availability of breast cancer screening (by palpation or mammogram) at the primary health care level;0.0;
1240;Existence of national screening program for breast cancer;0.0;
1241;General availability of bronchodilators in the public health sector;0.0;
1242;Existence of operational policy/strategy/action plan for cancer;0.0;
1243;Existence of population-based cancer registry;0.0;
1244;General availability of CC blockers in the public health sector;0.0;
1245;General availability of cervical cytology at the primary health care level;0.0;
1246;Most widely used screening method in national cervical cancer screening program;0.0;
1247;Coverage of national cervical cancer screening program (%);0.0;
1248;Type of national cervical cancer screening program;0.0;
1249;Existence of national screening program for cervical cancer;0.0;
1250;General availability of total cholesterol measurement at the primary health care level;0.0;
1251;General availability of coronary bypass or stenting in the public health system;0.0;
1252;Existence of operational policy/strategy/action plan for chronic respiratory diseases;0.0;
1253;Existence of operational policy/strategy/action plan for cardiovascular diseases;0.0;
1254;Existence of a diabetes registry;0.0;
1255;General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level;0.0;
1256;Existence of operational policy/strategy/action plan for diabetes;0.0;
1257;General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level;0.0;
1258;General availability of dialysis in the public health system;0.0;
1259;Implementation of diet and/or physical activity public awareness program;0.0;
1260;Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs;0.0;
1261;General availability of diabetes testing (by HbA1c) at the primary health care level;0.0;
1262;Existence of national HPV vaccination programme;0.0;
1263;General availability of insulin in the public health sector;0.0;
1264;Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors;0.0;
1265;General availability of metformin in the public health sector;0.0;
1266;Existence of any policies on marketing of foods to children;0.0;
1267;Existence of a national multisectoral commission, agency or mechanism for NCDs;0.0;
1268;Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach;0.0;
1269;Existence of a set of national NCD indicators and has set time-bound national targets for these indicators;0.0;
1270;Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs;0.0;
1271;General availability of nicotine replacement therapy in the public health sector;0.0;
1272;Existence of operational policy/strategy/action plan for oral health;0.0;
1273;General availability of oral morphine in the public health sector;0.0;
1274;Implementation of physical activity public awareness program;0.0;
1275;General availability of palliative care in community or home-based care in the public health system;0.0;
1276;General availability of palliative care in primary health care in the public health system;0.0;
1277;Existence of operational policy/strategy/action plan to reduce physical inactivity;0.0;
1278;General availability of retinal photocoagulation in the public health system;0.0;
1279;Has a STEPS survey or a comprehensive health examination survey every 5 years;0.0;
1280;General availability of renal replacement by transplantation in the public health system;0.0;
1281;Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities;0.0;
1282;Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease;0.0;
1283;Existence of a register of patients who had rheumatic fever and rheumatic heart disease;0.0;
1284;Availability of cardiovascular risk stratification in 50% or more primary health care facilities;0.0;
1285;Existence of any policies to reduce population salt consumption;0.0;
1286;Existence of national policies on saturated fatty acids / trans-fats;0.0;
1287;Existence of tax on sugar-sweetened beverages;0.0;
1288;General availability of statins in the public health sector;0.0;
1289;General availability of steroid inhalers in the public health sector;0.0;
1290;Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities;0.0;
1291;General availability of sulphonylurea(s) in the public health sector;0.0;
1292;Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets;0.0;
1293;Existence of a set of time-bound national targets based on WHO guidance;0.0;
1294;General availability of thiazide diuretics in the public health sector;0.0;
1295;General availability of thrombolytic therapy in the public health system;0.0;
1296;Existence of operational policy/strategy/action plan to decrease tobacco use;0.0;
1297;General availability of urine testing for albumin;0.0;
1298;Total NCD Deaths (in thousands);18.66666666666667;-70.5442531229003
1299;Mean fasting blood glucose (mmol/l) (age-standardized estimate);14.666666666666657;-1710.4762928923612
1300;Mean fasting blood glucose (mmol/l) (crude estimate)-25+ years-Female;20.0;1.182210702889681
1301;Mean fasting blood glucose (mmol/l) (crude estimate)-25+ years-Male;20.0;1.1629073968410877
1302;Mean fasting blood glucose (mmol/l) (crude estimate);20.0;-7723.84631455954
1303;Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate);15.555555555555557;-1822.248755474315
1304;Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate);15.555555555555557;-1822.2554025656436
1305;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Both sexes;28.444444444444457;0.30478286517490805
1306;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Female;28.444444444444457;0.30478286517490805
1307;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Male;28.444444444444457;0.30478286517490805
1308;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%);28.444444444444457;-25519.584669202126
1309;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Both sexes;28.444444444444457;0.30478286517490805
1310;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Female;28.444444444444457;0.30478286517490805
1311;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Male;28.444444444444457;0.30478286517490805
1312;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%);28.444444444444457;-25519.584669202126
1313;Insufficiently active (crude estimate);40.888888888888886;-5544.245008960533
1314;Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths;18.66666666666667;-70.5446085829929
1315;Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease;18.66666666666667;-70.54496404308549
1316;Basis for NHA estimate;61.77777777777778;-26542.08658987257
1317;Neonatal mortality rate (deaths per 1000 live births);59.11111111111111;-24181.319437904236
1318;National agency for tobacco control exists;0.0;
1319;Budget year;28.0;-23946.24018544125
1320;Reported currency;0.0;
1321;Number of full-time equivalent staff in national agency;35.111111111111114;-19787.78071407693
1322;Annual budget for tobacco control in currency reported;45.77777777777777;-19253.161026591944
1323;Government objectives on tobacco control exist;0.0;
1324;Number of new reported cases of Buruli ulcer;91.55555555555556;-24292.344031206067
1325;Dracunculiasis certification status of countries at the beginning of the year;0.0;
1326;Annual incidence of dracunculiasis cases;0.0;
1327;Number of new reported cases of human African trypanosomiasis (T.b. gambiense);90.22222222222223;-22449.25662685214
1328;Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense);96.44444444444444;-26022.955349796277
1329;Status of elimination of trachoma as a public health problem;0.0;
1330;Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem;73.77777777777777;-22727.51750925687
1331;Number of people who received treatment with antibiotics for trachoma;72.0;-20229.502368900772
1332;Status of bejel endemicity;0.0;
1333;Status of endemicity of cutaneous leishmaniasis;0.0;
1334;Number of cases of cutaneous leishmaniasis reported;65.33333333333333;-16184.302755332345
1335;Number of imported cases of cutaneous leishmaniasis reported;57.33333333333333;-22390.743509847252
1336;Status of endemicity of visceral leishmaniasis;0.0;
1337;Number of cases of visceral leishmaniasis reported;66.22222222222223;-16464.122096427855
1338;Number of imported cases of visceral leishmaniasis reported;53.77777777777778;-22140.492707055546
1339;Number of female leprosy new cases;16.0;-15627.05236549026
1340;New leprosy case detection rate per 1 000 000 population;15.555555555555557;-14717.7202295837
1341;Leprosy - Number of cases registered for treatment;16.888888888888886;-15456.645888553861
1342;Leprosy registered prevalence rate per 1 000 000 population;16.888888888888886;-15409.987303290965
1343;Number of new G2D leprosy cases;17.33333333333333;-15841.808149210045
1344;Leprosy - New leprosy cases with G2D rate per 1 000 000 population;17.33333333333333;-15841.537279311586
1345;Leprosy - Number of new leprosy cases among children (less than 15 years of age);16.0;-15659.002778515527
1346;Number of new leprosy cases with G2D among children (less than 15 years of age);20.888888888888886;-20459.9447530622
1347;Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis;86.22222222222223;-24629.825480567208
1348;Status of endemicity of onchocerciasis;0.0;
1349;Reported number of individuals treated for onchocerciasis;84.44444444444444;-22054.746597975132
1350;Status of pinta endemicity;0.0;
1351;Reported number of human rabies deaths;36.0;-17629.997893744185
1352;Number of people operated for trachomatous trichiasis;72.0;-23133.593310814067
1353;Status of endemicity of Taenia solium;0.0;
1354;Number of pigs in the country;18.222222222222214;-25200.28664127389
1355;Practice of backyard pig production;0.0;
1356;Status of yaws endemicity;0.0;
1357;Number of cases of yaws reported;94.66666666666667;-26831.329545107557
1358;Overweight numbers among children under 5 years of age (millions);0.0;
1359;Overweight prevalence among children under 5 years of age (%);31.111111111111114;-948.5294845336037
1360;Proportion of children aged 6-23 months who receive a minimum acceptable diet;71.11111111111111;-26496.91255583905
1361;Children aged <5 years wasted for age (%)-Male;31.111111111111114;0.673933347213155
1362;Children aged <5 years wasted for age (%)-Both sexes;31.111111111111114;0.772753180895843
1363;Children aged <5 years wasted for age (%)-Female;31.111111111111114;0.6585108227280285
1364;Children aged <5 years wasted for age (%);31.111111111111114;-21399.691166396373
1365;Early initiation of breastfeeding (%);42.22222222222223;-22939.30198916425
1366;Exclusive breastfeeding under 6 months (%);48.0;-25084.498958942342
1367;Prevalence of underweight children under 5 years of age   (% weight-for-age <-2 SD) (%);32.44444444444444;-18969.675369982506
1368;Prevalence of wasted children under 5 years of age   (% weight-for-height <-2 SD);32.44444444444444;-18949.373061372327
1369;Prevalence of severely wasted children under 5 years of age   (% weight-for-height <-3 SD)-Both sexes;33.33333333333334;0.8252041064302915
1370;Prevalence of severely wasted children under 5 years of age   (% weight-for-height <-3 SD);33.33333333333334;-19546.468186348095
1371;Severe wasted numbers among children under 5 years of age (millions);0.0;
1372;Severe wasted prevalence among children under 5 years of age (%);0.0;
1373;Stunting numbers among children under 5 years of age (millions);0.0;
1374;Stunting prevalence among children under 5 years of age (%);31.111111111111114;-940.2395071928518
1375;Underweight numbers among children under 5 years of age (millions);0.0;
1376;Underweight prevalence among children under 5 years of age (%);0.0;
1377;Wasted numbers among children under 5 years of age (millions);0.0;
1378;Wasted prevalence among children under 5 years of age (%);0.0;
1379;Treatment for tobacco dependence available in the community;0.0;
1380;Treatment for tobacco dependence available in health clinics or other primary care facilities;0.0;
1381;Treatment for tobacco dependence available in hospitals;0.0;
1382;Treatment for tobacco dependence available in offices of health professionals;0.0;
1383;Treatment for tobacco dependence available in other settings;0.0;
1384;Bupropion - cost covered;0.0;
1385;Bupropion - legally sold;0.0;
1386;Bupropion - place available;0.0;
1387;Offering help to quit tobacco use;13.333333333333329;-11526.730704372489
1388;Treatment for tobacco dependence in the community cost covered;0.0;
1389;Treatment for tobacco dependence in health clinics or other primary care facilities cost covered;0.0;
1390;Treatment for tobacco dependence in hospitals cost covered;0.0;
1391;Treatment for tobacco dependence in offices of health professionals cost covered;0.0;
1392;Treatment for tobacco dependence in other settings cost covered;0.0;
1393;Nicotine replacement therapy on the Essential Medicines List;0.0;
1394;Nicotine replacement therapy - cost covered;0.0;
1395;Nicotine replacement therapy - legally sold;0.0;
1396;Nicotine replacement therapy - place available;0.0;
1397;Access to a toll-free quit line;0.0;
1398;Varenicline - cost covered;0.0;
1399;Varenicline - legally sold;0.0;
1400;Varenicline - place available;0.0;
1401;Occupational risk factors attributable deaths;0.0;
1402;Occupational carcinogens attributable DALYs ('000);0.0;
1403;Occupational carcinogens attributable deaths per 100'000 capita;0.0;
1404;Occupational carcinogens attributable DALYs per 100'000 capita;0.0;
1405;Occupational noise attributable DALYs ('000);0.0;
1406;Occupational noise attributable DALYs per 100'000 capita;0.0;
1407;Occupational ergonomic stressors attributable deaths;0.0;
1408;Occupational ergonomic stressors attributable DALYs ('000);0.0;
1409;Occupational ergonomic stressors attributable deaths per 100'000 capita;0.0;
1410;Occupational ergonomic stressors attributable DALYs per 100'000 capita;0.0;
1411;Occupational injuries attributable deaths;0.0;
1412;Occupational risk factors attributable DALYs ('000);0.0;
1413;Occupational injuries attributable DALYs ('000);0.0;
1414;Occupational injuries attributable deaths per 100'000 capita;0.0;
1415;Occupational injuries attributable DALYs per 100'000 capita;0.0;
1416;Occupational risk factors attributable deaths per 100'000 capita;0.0;
1417;Occupational risk factors attributable DALYs per 100'000 capita;0.0;
1418;Occupational airborne particulates attributable deaths;0.0;
1419;Occupational airborne particulates attributable DALYs ('000);0.0;
1420;Occupational airborne particulates attributable deaths per 100'000 capita;0.0;
1421;Occupational airborne particulates attributable DALYs per 100'000 capita;0.0;
1422;Occupational carcinogens attributable deaths;0.0;
1423;Donor commitments (Million, constant 2009 US$);88.88888888888889;-24442.163337768845
1424;Commitments to recipient countries (Million, constant 2009 US$);47.111111111111114;-11870.284860756678
1425;Donor disbursements (Million, constant 2009 US$);88.88888888888889;-24607.889864514313
1426;Disbursements to recipient countries (Million, constant 2009 US$);47.111111111111114;-11870.288904983883
1427;Children aged < 5 years with diarrhoea receiving oral rehydration salts (%);50.22222222222222;-23160.856593751323
1428;Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%);50.22222222222222;-23184.79976484272
1429;Overweight prevalence in children aged <three years (%);0.0;
1430;Overweight prevalence in children aged <five years (%);54.22222222222222;-23826.766535990773
1431;National smoking ban: NUMBER OF PLACES SMOKE-FREE;13.333333333333329;-11526.511560154979
1432;Protecting people from tobacco smoke;13.333333333333329;-11526.70185058272
1433;Compliance of ban on smoking in HEALTH-CARE FACILITIES;52.88888888888889;-26278.74419242248
1434;National smoking ban in HEALTH-CARE FACILITIES;0.0;
1435;Subnational smoking bans - authority exists;0.0;
1436;National smoking ban: FINES FOR VIOLATIONS;0.0;
1437;National smoking ban: FINES ON THE ESTABLISHMENT;0.0;
1438;National smoking ban: FINES ON THE PATRON;0.0;
1439;National smoking ban: DEDICATED FUNDS FOR ENFORCEMENT;0.0;
1440;National smoking ban: CITIZEN COMPLAINTS AND INVESTIGATIONS;0.0;
1441;Comprehensive bans in place subnationally;0.0;
1442;Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES;52.0;-26252.632423436742
1443;National smoking ban in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES;0.0;
1444;Compliance of ban on smoking in UNIVERSITIES;58.666666666666664;-26465.218525870245
1445;National smoking ban in UNIVERSITIES;0.0;
1446;Compliance of ban on smoking in GOVERNMENT FACILITIES;64.44444444444444;-26656.68990636671
1447;National smoking ban in GOVERNMENT FACILITIES;0.0;
1448;Compliance of ban on smoking in INDOOR OFFICES;75.55555555555556;-27014.28637580507
1449;National smoking ban in INDOOR OFFICES;0.0;
1450;Compliance of ban on smoking in RESTAURANTS;76.44444444444444;-27041.67385818581
1451;National smoking ban in RESTAURANTS;0.0;
1452;Compliance of ban on smoking in PUBS AND BARS;77.77777777777777;-27086.71961744715
1453;National smoking ban in PUBS AND BARS;0.0;
1454;Compliance of ban on smoking in PUBLIC TRANSPORT;64.0;-26636.9948878661
1455;National smoking ban in PUBLIC TRANSPORT;0.0;
1456;National smoking ban in ALL OTHER INDOOR PUBLIC PLACES;0.0;
1457;Compliance with regulations on smoke-free environments (national legislation);34.66666666666667;-22525.62511919416
1458;Pneumoccocal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%);34.66666666666667;-14133.707181753636
1459;Antenatal care attendees who were positive for syphilis (%);34.66666666666667;-15670.39482449003
1460;Men who have sex with men (MSM) with active syphilis (%);52.88888888888889;-23594.15580470759
1461;Sex workers with active syphilis (%);48.88888888888889;-22892.05873095886
1462;Women accessing antenatal care (ANC) services who were tested for syphilis (%);35.55555555555556;-17006.633394744964
1463;Antenatal care attendees positive for syphilis who received treatment (%);0.0;
1464;Postnatal care visit within two days of birth (in the x years preceding the survey) (%);0.0;
1465;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-None-nan;80.0;0
1466;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-Primary-nan;80.0;0
1467;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-Secondary or higher-nan;80.0;0
1468;Postnatal care visit within two days of birth (in the three years preceding the survey) (%);80.0;-27100.31791585502
1469;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-Primary-nan;80.0;0
1470;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-Secondary or higher-nan;80.0;0
1471;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-None-nan;80.0;0
1472;Postnatal care visit within two days of birth (in the five years preceding the survey) (%);80.0;-27100.31791585502
1473;Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%);0.0;
1474;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-Secondary or higher-nan;84.0;0
1475;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-None-nan;84.0;0
1476;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-Primary-nan;84.0;0
1477;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%);84.0;-27232.029334491326
1478;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-Secondary or higher-nan;83.55555555555556;0
1479;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-None-nan;83.55555555555556;0
1480;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-Primary-nan;83.55555555555556;0
1481;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%);83.55555555555556;-27218.037062610205
1482;Polio immunization coverage among one-year-olds (%);51.55555555555556;-23204.66986303012
1483;Average - taxes as a % of cigarette price - ad valorem excise;49.33333333333333;-24887.35504166526
1484;Most sold brand of cigarettes - taxes as a % of price - ad valorem excise;13.333333333333329;-14033.676698031357
1485;Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks);0.0;
1486;Tax administration: Bans or limits on duty free imports by travellers;0.0;
1487;Tax administration: Tax stamps applied on tobacco products;0.0;
1488;Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand;14.666666666666657;-16121.107441646538
1489;Affordability: Price dispersion: share of cheapest brand price in premium brand price (the higher the % the smaller the gap);29.777777777777786;-27807.40911192029
1490;Affordability: Specific tax component automatically adjusted for inflation (or other);0.0;
1491;Cheapest brand of cigarettes - currency reported;0.0;
1492;Most sold brand of cigarettes - currency reported;0.0;
1493;Premium brand of cigarettes - currency reported;0.0;
1494;Tobacco excises increased over the survey period;0.0;
1495;Tax structure: Minimum specific tax applied in ad valorem or mixed excise regime;0.0;
1496;Tax structure: Excise tax proportion of price;19.555555555555557;-27807.40911192029
1497;Tax structure: Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT);0.0;
1498;Tax structure: Greater reliance on specific tax in mixed excise regime;0.0;
1499;Tax structure: Type of excise tax applied;0.0;
1500;Tax structure: Uniform excise tax;0.0;
1501;Raising taxes on tobacco;14.222222222222229;-13550.990689297763
1502;Average - taxes as a % of cigarette price - import duties;49.33333333333333;-24887.495443252108
1503;Most sold brand of cigarettes - taxes as a % of price - import duties;13.333333333333329;-14034.109821985448
1504;Average - taxes as a % of cigarette price - other taxes;49.33333333333333;-24887.50897124463
1505;Most sold brand of cigarettes - taxes as a % of price - other taxes;13.333333333333329;-14034.146387464853
1506;Most sold brand of cigarettes - price in currency reported;13.333333333333329;-13979.877893537794
1507;Premium brand of cigarettes - price in currency reported;25.77777777777777;-27807.40911192029
1508;Premium brand of cigarettes - price in international dollars;28.0;-27807.40911192029
1509;Premium brand of cigarettes - price in US$ at official exchange rates;25.77777777777777;-27807.40911192029
1510;Average - taxes as a % of cigarette price - specific excise;49.33333333333333;-24887.30725831092
1511;Most sold brand of cigarettes - taxes as a % of price - specific excise;13.333333333333329;-14033.585303444304
1512;Average - taxes as a % of cigarette price - total tax;49.33333333333333;-24887.26925614183
1513;Most sold brand of cigarettes - taxes as a % of price - total tax;13.333333333333329;-14023.248783982053
1514;Average - taxes as a % of cigarette price - value added tax;49.33333333333333;-24887.36257482148
1515;Most sold brand of cigarettes - taxes as a % of price - value added tax;13.333333333333329;-14033.71911083928
1516;Existence of any national radon activity;0.0;
1517;Existence of national radon survey(s);0.0;
1518;National radon concentration levels;98.66666666666667;-27764.632952512067
1519;Existence of national radon database;0.0;
1520;Data in national radon database;0.0;
1521;Existence of national radon action plan;0.0;
1522;Existence of national radon regulations;0.0;
1523;Radon in building regulations for new buildings;0.0;
1524;Radon in building regulations for existing buildings i.e. renovation/remodeling/major alteration;0.0;
1525;Radon in national drinking-water regulations;0.0;
1526;Existence of national reference level for dwellings and buildings with high public occupancy;0.0;
1527;Existence of national reference level for buildings with high public occupancy;0.0;
1528;Existence of official protocols for radon measurements;0.0;
1529;Radon concentration measurements for new buildings;0.0;
1530;Radon concentration measurements for existing buildings;0.0;
1531;Authorization/accreditation required for official radon measurement providers;0.0;
1532;Mandatory preventive measures (new buildings);0.0;
1533;Mandatory mitigation measures if legal value is exceeded (existing buildings);0.0;
1534;Financial support provided for mitigation (existing dwellings);0.0;
1535;Authorization/accreditation required for prevention/mitigation service providers;0.0;
1536;Official standards/guidelines for prevention/mitigation;0.0;
1537;Existence of training/education on prevention/mitigation;0.0;
1538;Existence of national radon risk communication strategy;0.0;
1539;Inclusion of radon measurements in property transactions;0.0;
1540;Inclusion of radon in national cancer control strategy;0.0;
1541;Congenital syphilis rate per 100 000 live births;0.0;
1542;Annual tax revenues - currency;0.0;
1543;Annual tax revenues - total excise (specific and ad valorem);34.222222222222214;-27807.40911192029
1544;Annual tax revenues - total revenues;72.44444444444444;-27807.40911192029
1545;Annual tax revenues - import duties and all other taxes (excluding corporate taxes on tobacco companies);64.44444444444444;-27807.40911192029
1546;Annual tax revenues - tobacco products included;0.0;
1547;Annual tax revenues - value added tax (vat) and other sales taxes;65.33333333333333;-27807.40911192029
1548;Annual tax revenues - year;0.0;
1549;Intimate partner violence prevalence among ever partnered women (%);0.0;
1550;Non-partner sexual violence prevalence (%);0.0;
1551;Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%);52.0;-18543.721868648012
1552;Population;1.7777777777777715;0.7557524771959168
1553;Income level;0.0;
1554;Number of registered vehicles;0.0;
1555;Estimated number of road traffic deaths;18.66666666666667;-70.73078158245775
1556;Estimated road traffic death rate (per 100 000 population);18.66666666666667;-70.5489681810631
1557;Existence of a national drink-driving law;0.0;
1558;Definition of drink-driving by BAC;0.0;
1559;Blood Alcohol Concentration (BAC) limit for drivers;0.0;
1560;Attribution of road traffic deaths to alcohol (%);0.0;
1561;Existence of a national seat-belt law;0.0;
1562;Applicability of seat-belt law to all occupants;0.0;
1563;Seat-belt wearing rate (%);0.0;
1564;Existence of a national child-restraint law;0.0;
1565;Existence of national speed limits;0.0;
1566;Maximum speed limits;0.0;
1567;Applicability of national motorcycle helmet law to all occupants;0.0;
1568;Law requires helmet to be fastened;0.0;
1569;Existence of a road safety lead agency;0.0;
1570;Existence of a national road safety strategy;0.0;
1571;Availability of funding for national road safety strategy;0.0;
1572;Existence of a formal pre-hospital care system;0.0;
1573;Existence of a universal access telephone number for pre-hospital care;0.0;
1574;Vehicle standards;0.0;
1575;Distribution of road traffic deaths by type of road user (%);34.66666666666667;-25718.52087669929
1576;Gross national income per capita (Atlas method);21.333333333333343;-25296.70362894618
1577;Point prevalence (%), alcohol use disorders, 15+ years-Female;15.111111111111114;0.3202264381234805
1578;Point prevalence (%), alcohol use disorders, 15+ years-Male;15.111111111111114;0.3584396105249388
1579;Point prevalence (%), alcohol use disorders, 15+ years;15.111111111111114;-25081.81048767581
1580;National survey on substance use among children and adolescents;0.0;
1581;Government unit/official responsible for prevention for substance use;0.0;
1582;Data on substance use disorders disseminated in national annual reports;0.0;
1583;Ministry/office that takes primary responsibility for prevention for substance use;0.0;
1584;Substance use policy at the national level;0.0;
1585;Five years change in international cooperation for prevention for substance use;0.0;
1586;Substance use policy at the national level, level of integration;0.0;
1587;Government unit/official responsible for treatment of substance use disorders;0.0;
1588;Policy documents on the pharmacological treatment of substance use disorders;0.0;
1589;Ministry/office that takes primary responsibility for treatment of substance use disorders;0.0;
1590;Guidelines on the pharmacological treatment of substance use disorders;0.0;
1591;Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders;0.0;
1592;Legislative provision for treatment and rehabilitation of substance use disorders;0.0;
1593;Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders;0.0;
1594;Legislative provision for compulsory treatment;0.0;
1595;Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs;0.0;
1596;Drug courts;0.0;
1597;Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs;0.0;
1598;Programmes diverting clients from the justice system towards treatment;0.0;
1599;Five years change in international cooperation for treatment of substance use disorders;0.0;
1600;Point prevalence (%), drug use disorders, 15+ years-Male;15.111111111111114;0.3219669829295224
1601;Point prevalence (%), drug use disorders, 15+ years-Female;15.111111111111114;0.287479764093284
1602;Point prevalence (%), drug use disorders, 15+ years;15.111111111111114;-25081.837674665432
1603;Confidentiality of health records on substance use disorders  protected by law;0.0;
1604;Confidentiality of people in treatment for substance use disorders;0.0;
1605;Government unit for substance use disorder treatment;0.0;
1606;Voluntary treatment for people with alcohol use disorders in the criminal justice system;0.0;
1607;Budget line for substance use disorder treatment;0.0;
1608;Voluntary treatment for people with drug use disorders in the criminal justice system;0.0;
1609;Financing method for substance use disorder treatment;0.0;
1610;Compulsory treatment for people with alcohol use disorders in the criminal justice system;0.0;
1611;Compulsory treatment for people with drug use disorders in the criminal justice system;0.0;
1612;Five-year change in government resources for prevention for substance use;0.0;
1613;Governement benefits for persons with substance use disorders;0.0;
1614;Five-year change in government resources for treatment of substance use disorders;0.0;
1615;Government benefits for alcohol use disorders, subsidy or disability pension;0.0;
1616;Financing methods for treatment for alcohol use disorders;0.0;
1617;Government benefits for drug use disorders, subsidy or disability pension;0.0;
1618;Financing methods for treatment for drug use disorders;0.0;
1619;Sector for inpatient detoxification of alcohol use disorders;0.0;
1620;Hypothecated taxes to be spent on prevention and treatment for substance use disorders;0.0;
1621;Age-standardized death rates, alcohol and drug use disorders, per 100 000;16.0;-25148.877439902353
1622;Sector for inpatient treatment of alcohol dependence;0.0;
1623;Government benefits for people with alcohol use disorders;0.0;
1624;Sector for outpatient treatment of alcohol dependence;0.0;
1625;Government benefits for people with drug use disorders;0.0;
1626;Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions;0.0;
1627;Main sector for treatment for alcohol use disorders;0.0;
1628;Sector for residential long-term rehabilitation of alcohol use disorders;0.0;
1629;Main sector for treatment for drug use disorders;0.0;
1630;Sector for inpatient detoxification of drug use disorders;0.0;
1631;Treatment programmes for children and adolescents with alcohol use disorders;0.0;
1632;Sector for inpatient treatment of drug dependence;0.0;
1633;Treatment programmes for children and adolescents with drug use disorders;0.0;
1634;Sector for outpatient treatment of drug dependence;0.0;
1635;Specialized treatment facilities for substance use disorders;0.0;
1636;Sector for substitution maintenance therapy of opioid dependence;0.0;
1637;Specialized treatment facilities for alcohol use disorders;0.0;
1638;Sector for residential long-term rehabilitation of drug use disorders;0.0;
1639;Specialized treatment facilities for drug use disorders;0.0;
1640;Treatment system for substance use disorders;0.0;
1641;Self-help groups;0.0;
1642;Treatment setting for substance use disorders, most common;0.0;
1643;Main substance at treatment entry;0.0;
1644;Specialized treatment services for drug use disoders and HIV/AIDS;0.0;
1645;Reported treatment coverage for substance dependence;0.0;
1646;Specialized treatment services for substance use disorders and TB;0.0;
1647;Guidelines on pharmacological treatment for substance use disorders;0.0;
1648;Open access services for substance use disorders;0.0;
1649;Pharmacotherapy with methadone;0.0;
1650;Treatment slots for alcohol and drug use disorders, outpatient, per 10 000;85.33333333333333;-27339.710474887717
1651;Pharmacotherapy with buprenorphine;0.0;
1652;Beds for the treatment of substance use disorders, per 100 000;63.55555555555556;-26646.066449117196
1653;Pharmacotherapy with buprenorphine/naloxone;0.0;
1654;Length of stay for inpatient detoxification, days;75.11111111111111;-27012.687619768887
1655;Access restrictions to maintenance treatment;0.0;
1656;Length of stay for inpatient short-term treatment, days;68.88888888888889;-26803.81359253018
1657;Timeframe for maintenance treatment of opioid dependence;0.0;
1658;Length of stay for inpatient long-term residential treatment, days;74.22222222222223;-26980.797858419606
1659;Registration of medications for alcohol dependence and withdrawal;0.0;
1660;Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance);0.0;
1661;Registration of medications for opioid dependence;0.0;
1662;Age-standardized DALYs, alcohol and drug use disorders, per 100 000;15.555555555555557;-25137.0783796378
1663;Timeframe of opioid agonist treatment;0.0;
1664;Registration of medications for opioid withdrawal;0.0;
1665;Methadone used for the treatment of opioid dependence;0.0;
1666;Registration of naloxone for injection for opioid overdose;0.0;
1667;Methadone used for detoxification or maintenance;0.0;
1668;Availability of naloxone;0.0;
1669;Methadone formulation used for the treatment of opiod dependence;0.0;
1670;Screening and brief intervention for substance use in primary health care;0.0;
1671;Buprenorphine used for the treatment of opioid dependence;0.0;
1672;Screening and brief intervention for substance use in antenatal services;0.0;
1673;Buprenorphine used for detoxification or maintenance;0.0;
1674;Recommendations for screening and brief interventions for substance use in primary health care;0.0;
1675;Buprenorphine/naloxone used for the treatment of opioid dependence;0.0;
1676;Recommendations for screening and brief interventions for substance use in antenatal services;0.0;
1677;Buprenorphine/naloxone used for detoxification or maintenance;0.0;
1678;Groups and agencies involved in prevention programs;0.0;
1679;Methadone provision in clinical and community-based settings;0.0;
1680;Prevention programmes for alcohol;0.0;
1681;Buprenorphine provision in clinical and community-based settings;0.0;
1682;Prevention programmes for specific populations for alcohol;0.0;
1683;Buprenorphine/naloxone provision in clinical and community-based settings;0.0;
1684;Prevention programmes for drugs;0.0;
1685;Supervision requirements for methadone administration;0.0;
1686;Prevention programmes for specific populations for drugs;0.0;
1687;Supervision requirements for buprenorphine administration;0.0;
1688;HIV, Hepatitis counselling and treatment availability in specialized facilities and services;0.0;
1689;Supervision requirements for buprenorphine/naloxone administration;0.0;
1690;Programmes readily available;0.0;
1691;Prescription requirements for methadone;0.0;
1692;Standards of treatment and care for public specialized treatment facilities;0.0;
1693;Prescription requirements for buprenorphine;0.0;
1694;Special treatment programmes for gambling disorder;0.0;
1695;Prescription requirements for buprenorphine/naloxone;0.0;
1696;Treatment programmes for women with alcohol use disorders;0.0;
1697;Commencement of treatment with opioid agonists;0.0;
1698;Treatment programmes for women with drug use disorders;0.0;
1699;Pharmacotherapy used for the management of alcohol withdrawal;0.0;
1700;Special housing services for alcohol use disorders;0.0;
1701;Pharmacotherapy used for the management of benzodiazepine withdrawal;0.0;
1702;Special housing services for drug use disorders;0.0;
1703;Psychoactive substance causing entry into treatment;0.0;
1704;Pharmacotherapy used for the management of cannabis withdrawal;0.0;
1705;Employment services for alcohol use disorders;0.0;
1706;Essential list of medicines;0.0;
1707;Employment services for drug use disorders;0.0;
1708;Essential list of medicines, pharmacotherapy for substance use disorders;0.0;
1709;Open access interventions for alcohol;0.0;
1710;Government unit for substance use disorder prevention;0.0;
1711;Open access interventions for drugs;0.0;
1712;Budget line for substance use disorder prevention;0.0;
1713;Health professionals providing treatment for alcohol and drug use disorders;0.0;
1714;Funding method for substance use disorder prevention;0.0;
1715;Standards of care for professionals providing treatment for alcohol and drug use disorders;0.0;
1716;Prevention activities for substance use disorders, main focus;0.0;
1717;Educational attainment in prevention;0.0;
1718;Programmes for the prevention of substance use disorders for special populations;0.0;
1719;Postgraduate training programme in prevention;0.0;
1720;Screening and brief interventions for substance use and substance use disorders;0.0;
1721;Continuing professional development in prevention;0.0;
1722;Harm reduction programmes for IDUs;0.0;
1723;Educational attainment in treatment;0.0;
1724;Epidemiological data collection system for substance use disorders;0.0;
1725;Health professionals mostly involved in treatment of substance use disorders;0.0;
1726;Postgraduate training programme in treatment;0.0;
1727;Clinical supervision of health care staff;0.0;
1728;Continuing professional development in treatment;0.0;
1729;Standards of care for health professionals;0.0;
1730;Epidemiological data collection for substance use;0.0;
1731;Standards of care for health professionals, maintenance;0.0;
1732;Service delivery data collection for substance use;0.0;
1733;Standards of care for health professionals, human rights;0.0;
1734;Regular reports on epidemiological and service delivery data for substance use;0.0;
1735;NGOs for alcohol use disorders;0.0;
1736;System of monitoring alcohol involvement in forensic pathology;0.0;
1737;NGOs for drug use disorders;0.0;
1738;System of monitoring drugs involvement in forensic pathology;0.0;
1739;Self-help groups for substance use disorders;0.0;
1740;Epidemiological data collection system for substance use among children and adolescents;0.0;
1741;Groups and agencies for the prevention of substance use disorders;0.0;
1742;Epidemiological data collection system for substance use among children and adolescents;0.0;
1743;Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance);0.0;
1744;Treatment programmes for children and adolescents with alcohol use disorders;0.0;
1745;Service delivery data collection system for substance use disorders;0.0;
1746;Treatment programmes for children and adolescents with drug use disorders;0.0;
1747;Alcohol, consumption of pure alcohol by type of beverage (%);99.55555555555556;-27794.02433969697
1748;Alcohol, consumption of pure alcohol by type of beverage (%);99.55555555555556;-27794.02433969697
1749;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-13.950939873125103
1750;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-13.951295333217695
1751;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average;15.555555555555557;-22543.474887041906
1752;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average;15.555555555555557;-22543.474887041906
1753;Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010;0.0;
1754;Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010;0.0;
1755;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Both sexes;15.555555555555557;1.0764365114889127
1756;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Male;15.555555555555557;0.6192947631187025
1757;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Female;15.555555555555557;0.5509159507419596
1758;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-22543.397852704384
1759;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Both sexes;15.555555555555557;1.0764365114889127
1760;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Male;15.555555555555557;0.6192947631187025
1761;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Female;15.555555555555557;0.5509159507419596
1762;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-22543.3971417842
1763;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Female;15.555555555555557;0.9890316318161965
1764;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Male;15.555555555555557;1.0210138616097613
1765;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Both sexes;15.555555555555557;1.0147698135714078
1766;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol;15.555555555555557;-20883.81763537946
1767;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Female;15.555555555555557;0.9890316318161965
1768;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Male;15.555555555555557;1.0210138616097613
1769;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Both sexes;15.555555555555557;1.0147698135714078
1770;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol;15.555555555555557;-20883.81763537946
1771;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-24760.27435562595
1772;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-24760.27435562595
1773;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-20131.044845526343
1774;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-20131.044845526343
1775;Alcohol, abstainers lifetime (%)-Male;58.22222222222222;0.06828495951224234
1776;Alcohol, abstainers lifetime (%)-Female;58.22222222222222;0.07728483026682298
1777;Alcohol, abstainers lifetime (%)-Both sexes;58.22222222222222;0.07311872912296913
1778;Alcohol, abstainers lifetime (%);58.22222222222222;-26454.01265678943
1779;Alcohol, abstainers lifetime (%)-Male;58.22222222222222;0.06828495951224234
1780;Alcohol, abstainers lifetime (%)-Both sexes;58.22222222222222;0.07311872912296913
1781;Alcohol, abstainers lifetime (%)-Female;58.22222222222222;0.07728483026682298
1782;Alcohol, abstainers lifetime (%);58.22222222222222;-26454.01265678943
1783;Abstainers (15-19 years), lifetime (%)-Male;79.11111111111111;0.09176341232599405
1784;Abstainers (15-19 years), lifetime (%)-Both sexes;79.11111111111111;0.09349539309130606
1785;Abstainers (15-19 years), lifetime (%)-Female;79.11111111111111;0.09105249214080402
1786;Abstainers (15-19 years), lifetime (%);79.11111111111111;-27111.97048307321
1787;Alcohol, abstainers past 12 months (%)-Male;15.111111111111114;0.4056058604029502
1788;Alcohol, abstainers past 12 months (%)-Both sexes;15.111111111111114;0.41045727575193425
1789;Alcohol, abstainers past 12 months (%)-Female;15.111111111111114;0.4283852851550911
1790;Alcohol, abstainers past 12 months (%);15.111111111111114;-23943.279305086045
1791;Alcohol, abstainers past 12 months (%)-Female;15.111111111111114;0.4283852851550911
1792;Alcohol, abstainers past 12 months (%)-Male;15.111111111111114;0.4056058604029502
1793;Alcohol, abstainers past 12 months (%)-Both sexes;15.111111111111114;0.41045727575193425
1794;Alcohol, abstainers past 12 months (%);15.111111111111114;-23943.279305086045
1795;Abstainers (15-19 years), past 12 months (%)-Both sexes;93.77777777777777;0.02862259848552995
1796;Abstainers (15-19 years), past 12 months (%)-Male;93.77777777777777;0.02451265650554202
1797;Abstainers (15-19 years), past 12 months (%)-Female;93.77777777777777;0.02451265650554202
1798;Abstainers (15-19 years), past 12 months (%);93.77777777777777;-27596.334623785686
1799;Alcohol, consumers past 12 months (%)-Male;39.55555555555556;0.10723968227944791
1800;Alcohol, consumers past 12 months (%)-Female;39.55555555555556;0.14650855668181606
1801;Alcohol, consumers past 12 months (%)-Both sexes;39.55555555555556;0.11579463323691819
1802;Alcohol, consumers past 12 months (%);39.55555555555556;-25859.958818822466
1803;Alcohol, consumers past 12 months (%)-Male;39.55555555555556;0.10723968227944791
1804;Alcohol, consumers past 12 months (%)-Both sexes;39.55555555555556;0.11579463323691819
1805;Alcohol, consumers past 12 months (%)-Female;39.55555555555556;0.14650855668181606
1806;Alcohol, consumers past 12 months (%);39.55555555555556;-25859.958818822466
1807;Alcohol, former drinkers (%)-Both sexes;47.55555555555555;0.10001183040681383
1808;Alcohol, former drinkers (%)-Female;47.55555555555555;0.06691380636598243
1809;Alcohol, former drinkers (%)-Male;47.55555555555555;0.0862242390023864
1810;Alcohol, former drinkers (%);47.55555555555555;-26123.856022027925
1811;Alcohol, former drinkers (%)-Both sexes;47.55555555555555;0.10001183040681383
1812;Alcohol, former drinkers (%)-Female;47.55555555555555;0.06691380636598243
1813;Alcohol, former drinkers (%)-Male;47.55555555555555;0.0862242390023864
1814;Alcohol, former drinkers (%);47.55555555555555;-26123.856663569495
1815;Alcohol, heavy episodic drinking (population) past 30 days (%)-Female;46.666666666666664;0.09608997976301392
1816;Alcohol, heavy episodic drinking (population) past 30 days (%)-Both sexes;46.666666666666664;0.08949139175811904
1817;Alcohol, heavy episodic drinking (population) past 30 days (%)-Male;46.666666666666664;0.11573693285680609
1818;Alcohol, heavy episodic drinking (population) past 30 days (%);46.666666666666664;-26089.50158933983
1819;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Male;16.0;0.44732285368185476
1820;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Both sexes;16.0;0.4321148021813155
1821;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Female;16.0;0.44661482049404455
1822;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%);16.0;-23490.489514828994
1823;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Male;16.0;0.44732285368185476
1824;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Female;16.0;0.44661482049404455
1825;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Both sexes;16.0;0.4321148021813155
1826;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%);16.0;-23490.4891593689
1827;Alcohol, patterns of drinking score;0.0;
1828;Alcohol, patterns of drinking score;0.0;
1829;Age-standardized DALYs, alcohol use disorders, per 100,000-Both sexes;16.888888888888886;0.34715269589032616
1830;Age-standardized DALYs, alcohol use disorders, per 100,000-Male;16.888888888888886;0.3554472370861639
1831;Age-standardized DALYs, alcohol use disorders, per 100,000-Female;16.888888888888886;0.28624327630866286
1832;Age-standardized DALYs, alcohol use disorders, per 100,000;16.888888888888886;-25138.126900947336
1833;Age-standardized DALYs, breast cancer, per 100,000-Female;15.111111111111114;0.3514175363842176
1834;Age-standardized DALYs, breast cancer, per 100,000-Both sexes;15.111111111111114;0.3414399554490508
1835;Age-standardized DALYs, breast cancer, per 100,000-Male;15.111111111111114;0.008713075462984499
1836;Age-standardized DALYs, breast cancer, per 100,000;15.111111111111114;-25081.81235210399
1837;Age-standardized DALYs, colon and rectum cancers, per 100,000-Both sexes;15.555555555555557;0.3311735397245643
1838;Age-standardized DALYs, colon and rectum cancers, per 100,000-Male;15.555555555555557;0.3341771131708473
1839;Age-standardized DALYs, colon and rectum cancers, per 100,000-Female;15.555555555555557;0.33031691305838784
1840;Age-standardized DALYs, colon and rectum cancers, per 100,000;15.555555555555557;-25096.03071903694
1841;Age-standardized DALYs, diabetes mellitus, per 100,000-Male;15.111111111111114;0.35986145089531885
1842;Age-standardized DALYs, diabetes mellitus, per 100,000-Female;15.111111111111114;0.3565281438712553
1843;Age-standardized DALYs, diabetes mellitus, per 100,000-Both sexes;15.111111111111114;0.3592846969008372
1844;Age-standardized DALYs, diabetes mellitus, per 100,000;15.111111111111114;-25081.803774023287
1845;Age-standardized DALYs, drownings, per 100,000-Both sexes;16.0;0.34419189181645304
1846;Age-standardized DALYs, drownings, per 100,000-Female;16.0;0.29169630711733685
1847;Age-standardized DALYs, drownings, per 100,000-Male;16.0;0.3484672536966844
1848;Age-standardized DALYs, drownings, per 100,000;16.0;-25109.74408663255
1849;Age-standardized DALYs, falls, per 100,000-Female;15.111111111111114;0.33712739585838314
1850;Age-standardized DALYs, falls, per 100,000-Male;15.111111111111114;0.3485961957804804
1851;Age-standardized DALYs, falls, per 100,000-Both sexes;15.111111111111114;0.3451063824286873
1852;Age-standardized DALYs, falls, per 100,000;15.111111111111114;-25081.81128572371
1853;Age-standardized DALYs, fires, per 100,000-Female;16.888888888888886;0.30030033488932784
1854;Age-standardized DALYs, fires, per 100,000-Male;16.888888888888886;0.3316899523965935
1855;Age-standardized DALYs, fires, per 100,000-Both sexes;16.888888888888886;0.3263566633015955
1856;Age-standardized DALYs, fires, per 100,000;16.888888888888886;-25133.75306316731
1857;Age-standardized DALYs, ischaemic heart disease, per 100,000-Male;15.111111111111114;0.3658171447582559
1858;Age-standardized DALYs, ischaemic heart disease, per 100,000-Female;15.111111111111114;0.3643953043878758
1859;Age-standardized DALYs, ischaemic heart disease, per 100,000-Both sexes;15.111111111111114;0.36497205838235747
1860;Age-standardized DALYs, ischaemic heart disease, per 100,000;15.111111111111114;-25081.803063103103
1861;Age-standardized DALYs, liver cancer, per 100,000-Both sexes;15.555555555555557;0.3608310009007676
1862;Age-standardized DALYs, liver cancer, per 100,000-Female;15.555555555555557;0.3600329530043993
1863;Age-standardized DALYs, liver cancer, per 100,000-Male;15.555555555555557;0.361676087276666
1864;Age-standardized DALYs, liver cancer, per 100,000;15.555555555555557;-25095.520427288877
1865;Age-standardized DALYs, liver cirrhosis, per 100,000-Female;15.555555555555557;0.3415024773945454
1866;Age-standardized DALYs, liver cirrhosis, per 100,000-Both sexes;15.555555555555557;0.35209690155584106
1867;Age-standardized DALYs, liver cirrhosis, per 100,000-Male;15.555555555555557;0.35441086678165057
1868;Age-standardized DALYs, liver cirrhosis, per 100,000;15.555555555555557;-25094.610520605616
1869;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Both sexes;15.111111111111114;0.31944897588363474
1870;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Female;15.111111111111114;0.2718084641399914
1871;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Male;15.111111111111114;0.33601346379666897
1872;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000;15.111111111111114;-25081.81950834432
1873;Age-standardized DALYs, oesophagus cancer, per 100,000-Male;20.444444444444443;0.30079768563734355
1874;Age-standardized DALYs, oesophagus cancer, per 100,000-Female;20.444444444444443;0.20996098465489332
1875;Age-standardized DALYs, oesophagus cancer, per 100,000-Both sexes;20.444444444444443;0.2892817231819578
1876;Age-standardized DALYs, oesophagus cancer, per 100,000;20.444444444444443;-25247.988737304204
1877;Age-standardized DALYs, poisoning, per 100,000-Female;23.555555555555557;0.2689379186554266
1878;Age-standardized DALYs, poisoning, per 100,000-Male;23.555555555555557;0.3044333014739804
1879;Age-standardized DALYs, poisoning, per 100,000-Both sexes;23.555555555555557;0.29950539099159545
1880;Age-standardized DALYs, poisoning, per 100,000;23.555555555555557;-25339.997991117307
1881;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Male;15.555555555555557;0.35121396595717513
1882;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Female;15.555555555555557;0.3549027330738328
1883;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Both sexes;15.555555555555557;0.3594091605303875
1884;Age-standardized DALYs, prematurity and low birth rate, per 100,000;15.555555555555557;-25095.198960779595
1885;Age-standardized DALYs, road traffic accidents, per 100,000-Female;15.111111111111114;0.3579499842416354
1886;Age-standardized DALYs, road traffic accidents, per 100,000-Both sexes;15.111111111111114;0.36261800392490073
1887;Age-standardized DALYs, road traffic accidents, per 100,000-Male;15.111111111111114;0.3643953043878758
1888;Age-standardized DALYs, road traffic accidents, per 100,000;15.111111111111114;-25081.805195863657
1889;Age-standardized DALYs, self-inflicted injury, per 100,000-Male;15.555555555555557;0.3545455734600491
1890;Age-standardized DALYs, self-inflicted injury, per 100,000-Both sexes;15.555555555555557;0.3486770073082912
1891;Age-standardized DALYs, self-inflicted injury, per 100,000-Female;15.555555555555557;0.3355622171735906
1892;Age-standardized DALYs, self-inflicted injury, per 100,000;15.555555555555557;-25094.24937413263
1893;Age-standardized DALYs, other unintentional injuries, per 100,000-Both sexes;15.111111111111114;0.3615516236471157
1894;Age-standardized DALYs, other unintentional injuries, per 100,000-Female;15.111111111111114;0.35857377671564716
1895;Age-standardized DALYs, other unintentional injuries, per 100,000-Male;15.111111111111114;0.36297346401749575
1896;Age-standardized DALYs, other unintentional injuries, per 100,000;15.111111111111114;-25081.803774023287
1897;Age-standardized DALYs, violence, per 100,000-Male;15.111111111111114;0.36070653727121726
1898;Age-standardized DALYs, violence, per 100,000-Both sexes;15.111111111111114;0.3574480520451848
1899;Age-standardized DALYs, violence, per 100,000-Female;15.111111111111114;0.33553833595180294
1900;Age-standardized DALYs, violence, per 100,000;15.111111111111114;-25081.804840403565
1901;Age-standardized death rates, alcohol use disorders, per 100,000-Female;17.777777777777786;0.21136641920441424
1902;Age-standardized death rates, alcohol use disorders, per 100,000-Male;17.777777777777786;0.29131304446893846
1903;Age-standardized death rates, alcohol use disorders, per 100,000-Both sexes;17.777777777777786;0.27355190195315426
1904;Age-standardized death rates, alcohol use disorders, per 100,000-nan;17.777777777777786;0
1905;Age-standardized death rates, alcohol use disorders, per 100,000;17.777777777777786;-22668.05695387489
1906;Age-standardized death rates, breast cancer, per 100,000-nan;15.111111111111114;0
1907;Age-standardized death rates, breast cancer, per 100,000-Male;15.111111111111114;0.17540719961022333
1908;Age-standardized death rates, breast cancer, per 100,000-Both sexes;15.111111111111114;0.3341718890639349
1909;Age-standardized death rates, breast cancer, per 100,000-Female;15.111111111111114;0.3435033373880696
1910;Age-standardized death rates, breast cancer, per 100,000;15.111111111111114;-22489.929280380493
1911;Age-standardized death rates, colon and rectum cancers, per 100,000-Both sexes;15.111111111111114;0.3380418608508329
1912;Age-standardized death rates, colon and rectum cancers, per 100,000-Male;15.111111111111114;0.33814398434336024
1913;Age-standardized death rates, colon and rectum cancers, per 100,000-Female;15.111111111111114;0.33307346608796884
1914;Age-standardized death rates, colon and rectum cancers, per 100,000-nan;15.111111111111114;0
1915;Age-standardized death rates, colon and rectum cancers, per 100,000;15.111111111111114;-22502.15260897758
1916;Age-standardized death rates, diabetes mellitus, per 100,000-Both sexes;15.111111111111114;0.3563939776805469
1917;Age-standardized death rates, diabetes mellitus, per 100,000-Female;15.111111111111114;0.35870794290635555
1918;Age-standardized death rates, diabetes mellitus, per 100,000-Male;15.111111111111114;0.35857377671564716
1919;Age-standardized death rates, diabetes mellitus, per 100,000;15.111111111111114;-25081.804840403565
1920;Age-standardized death rates, drownings, per 100,000-Female;15.111111111111114;0.29747876668922846
1921;Age-standardized death rates, drownings, per 100,000-Both sexes;15.111111111111114;0.32171019083838637
1922;Age-standardized death rates, drownings, per 100,000-Male;15.111111111111114;0.3361349852395419
1923;Age-standardized death rates, drownings, per 100,000-nan;15.111111111111114;0
1924;Age-standardized death rates, drownings, per 100,000;15.111111111111114;-22489.934321609355
1925;Age-standardized death rates, falls, per 100,000-Both sexes;16.0;0.3163533659717732
1926;Age-standardized death rates, falls, per 100,000-Female;16.0;0.3070718020172736
1927;Age-standardized death rates, falls, per 100,000-Male;16.0;0.3235836368253233
1928;Age-standardized death rates, falls, per 100,000-nan;16.0;0
1929;Age-standardized death rates, falls, per 100,000;16.0;-22551.842421056488
1930;Age-standardized death rates, fires, per 100,000-Male;17.33333333333333;0.3036715514744044
1931;Age-standardized death rates, fires, per 100,000-Both sexes;17.33333333333333;0.30128893785477384
1932;Age-standardized death rates, fires, per 100,000-Female;17.33333333333333;0.29806735059003575
1933;Age-standardized death rates, fires, per 100,000-nan;17.33333333333333;0
1934;Age-standardized death rates, fires, per 100,000;17.33333333333333;-22614.075612488625
1935;Age-standardized death rates, ischaemic heart disease, per 100,000-Female;15.111111111111114;0.3636843842026858
1936;Age-standardized death rates, ischaemic heart disease, per 100,000-Both sexes;15.111111111111114;0.3636843842026858
1937;Age-standardized death rates, ischaemic heart disease, per 100,000-Male;15.111111111111114;0.36510622457306585
1938;Age-standardized death rates, ischaemic heart disease, per 100,000;15.111111111111114;-25081.803063103103
1939;Age-standardized death rates, liver cancer, per 100,000-Both sexes;15.111111111111114;0.30900658775152756
1940;Age-standardized death rates, liver cancer, per 100,000-Male;15.111111111111114;0.34652822279906914
1941;Age-standardized death rates, liver cancer, per 100,000-Female;15.111111111111114;0.3278499352616624
1942;Age-standardized death rates, liver cancer, per 100,000-nan;15.111111111111114;0
1943;Age-standardized death rates, liver cancer, per 100,000;15.111111111111114;-22516.289716537492
1944;Age-standardized death rates, liver cirrhosis, per 100,000-Male;15.555555555555557;0.34723687735559494
1945;Age-standardized death rates, liver cirrhosis, per 100,000-Female;15.555555555555557;0.23876791363761996
1946;Age-standardized death rates, liver cirrhosis, per 100,000-Both sexes;15.555555555555557;0.32781524910809434
1947;Age-standardized death rates, liver cirrhosis, per 100,000-nan;15.555555555555557;0
1948;Age-standardized death rates, liver cirrhosis, per 100,000;15.555555555555557;-22516.670704327753
1949;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-nan;15.111111111111114;0
1950;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Male;15.111111111111114;0.3344402214453508
1951;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Both sexes;15.111111111111114;0.32119822441806445
1952;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Female;15.111111111111114;0.19743395801848163
1953;Age-standardized death rates, mouth and oropharynx cancer, per 100,000;15.111111111111114;-22515.58201585072
1954;Age-standardized death rates, oesophagus cancer, per 100,000-nan;15.555555555555557;0
1955;Age-standardized death rates, oesophagus cancer, per 100,000-Female;15.555555555555557;0.19826733361982019
1956;Age-standardized death rates, oesophagus cancer, per 100,000-Both sexes;15.555555555555557;0.29298623258411816
1957;Age-standardized death rates, oesophagus cancer, per 100,000-Male;15.555555555555557;0.3326061799416893
1958;Age-standardized death rates, oesophagus cancer, per 100,000;15.555555555555557;-22531.452966240846
1959;Age-standardized death rates, poisoning, per 100,000-nan;18.222222222222214;0
1960;Age-standardized death rates, poisoning, per 100,000-Female;18.222222222222214;0.1900490973883775
1961;Age-standardized death rates, poisoning, per 100,000-Both sexes;18.222222222222214;0.3074677118063658
1962;Age-standardized death rates, poisoning, per 100,000-Male;18.222222222222214;0.3127777607428808
1963;Age-standardized death rates, poisoning, per 100,000;18.222222222222214;-22703.31953832381
1964;Age-standardized death rates, prematurity and low birth rate, per 100,000-Male;17.33333333333333;0.33850437837227076
1965;Age-standardized death rates, prematurity and low birth rate, per 100,000-Both sexes;17.33333333333333;0.3398098016465676
1966;Age-standardized death rates, prematurity and low birth rate, per 100,000-Female;17.33333333333333;0.25071084951138367
1967;Age-standardized death rates, prematurity and low birth rate, per 100,000;17.33333333333333;-25151.47079700913
1968;Age-standardized death rates, road traffic accidents, per 100,000-nan;15.111111111111114;0
1969;Age-standardized death rates, road traffic accidents, per 100,000-Male;15.111111111111114;0.3584396105249388
1970;Age-standardized death rates, road traffic accidents, per 100,000-Both sexes;15.111111111111114;0.3499486575343074
1971;Age-standardized death rates, road traffic accidents, per 100,000-Female;15.111111111111114;0.2505816896635569
1972;Age-standardized death rates, road traffic accidents, per 100,000;15.111111111111114;-22489.919280459413
1973;Age-standardized death rates, self-inflicted injury, per 100,000-nan;16.0;0
1974;Age-standardized death rates, self-inflicted injury, per 100,000-Both sexes;16.0;0.3382745876639772
1975;Age-standardized death rates, self-inflicted injury, per 100,000-Female;16.0;0.23029264945985783
1976;Age-standardized death rates, self-inflicted injury, per 100,000-Male;16.0;0.3441803515261741
1977;Age-standardized death rates, self-inflicted injury, per 100,000;16.0;-22540.837289330557
1978;Age-standardized death rates, other unintentional injuries, per 100,000-Female;15.111111111111114;0.3374828559509746
1979;Age-standardized death rates, other unintentional injuries, per 100,000-Both sexes;15.111111111111114;0.34310083881594267
1980;Age-standardized death rates, other unintentional injuries, per 100,000-Male;15.111111111111114;0.35204132885823025
1981;Age-standardized death rates, other unintentional injuries, per 100,000;15.111111111111114;-25081.806617704027
1982;Age-standardized death rates, violence, per 100,000-nan;15.111111111111114;0
1983;Age-standardized death rates, violence, per 100,000-Female;15.111111111111114;0.2150151917804246
1984;Age-standardized death rates, violence, per 100,000-Male;15.111111111111114;0.3457571060821154
1985;Age-standardized death rates, violence, per 100,000-Both sexes;15.111111111111114;0.33587647733564197
1986;Age-standardized death rates, violence, per 100,000;15.111111111111114;-22489.93030667153
1987;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Male;75.11111111111111;0.4929258104096341
1988;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Both sexes;75.11111111111111;0.4884274551063301
1989;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Female;75.11111111111111;0.4723199248858698
1990;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000;75.11111111111111;-24077.573980078727
1991;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Male;52.44444444444444;0.6739085375368958
1992;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Female;52.44444444444444;0.6834625350542538
1993;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Both sexes;52.44444444444444;0.5996086277923078
1994;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population;52.44444444444444;-22308.05714440555
1995;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Female;52.44444444444444;0.6834625350542538
1996;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Both sexes;52.44444444444444;0.5996086277923078
1997;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Male;52.44444444444444;0.6739085375368958
1998;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population;52.44444444444444;-22308.05714440555
1999;Age-standardized death rates (15+ years), poisoning, per 100,000-Female;70.22222222222223;0.5694272063202703
2000;Age-standardized death rates (15+ years), poisoning, per 100,000-Both sexes;70.22222222222223;0.5973685491552878
2001;Age-standardized death rates (15+ years), poisoning, per 100,000-Male;70.22222222222223;0.609374013840223
2002;Age-standardized death rates (15+ years), poisoning, per 100,000;70.22222222222223;-23116.648015404993
2003;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Female;87.55555555555556;0.0406314754948669
2004;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Male;87.55555555555556;0.04533747853483927
2005;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population;87.55555555555556;-27399.515094298134
2006;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Female;87.55555555555556;0.0406314754948669
2007;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Male;87.55555555555556;0.04533747853483927
2008;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population;87.55555555555556;-27399.515094298134
2009;Age-standardized death rates (15+ years), violence, per 100,000-Male;70.22222222222223;0.621038383922361
2010;Age-standardized death rates (15+ years), violence, per 100,000-Both sexes;70.22222222222223;0.6157936102446149
2011;Age-standardized death rates (15+ years), violence, per 100,000-Female;70.22222222222223;0.5977568642758451
2012;Age-standardized death rates (15+ years), violence, per 100,000;70.22222222222223;-23104.225855617657
2013;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Male;48.88888888888889;0.07239719808251088
2014;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Female;48.88888888888889;0.0788619407144191
2015;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Both sexes;48.88888888888889;0.0891410365982992
2016;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI;48.88888888888889;-26174.868375832044
2017;Random breath testing (RBT) use;0.0;
2018;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Female;48.88888888888889;0.0788619407144191
2019;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Male;48.88888888888889;0.07239719808251088
2020;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Both sexes;48.88888888888889;0.0891410365982992
2021;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI;48.88888888888889;-26174.868375832044
2022;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Female;42.22222222222223;0.11384996319305252
2023;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Male;42.22222222222223;0.10647360102041592
2024;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Both sexes;42.22222222222223;0.06233134725736189
2025;Alcohol use disorders (15+), 12 month prevalence (%) with 95%;42.22222222222223;-25951.991437269608
2026;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Male;42.22222222222223;0.10647360102041592
2027;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Female;42.22222222222223;0.11384996319305252
2028;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Both sexes;42.22222222222223;0.06233134725736189
2029;Alcohol use disorders (15+), 12 month prevalence (%) with 95%;42.22222222222223;-25951.991437269608
2030;Alcoholic psychosis, incidence, per 100,000;84.88888888888889;-24778.635191055666
2031;Alcoholic psychosis, incidence, per 100,000;84.88888888888889;-24778.635191055666
2032;Cautions and arrests for drink-driving, per 100,000 population;83.11111111111111;-25830.41252957628
2033;Cautions and arrests for drink-driving, per 100,000 population;83.11111111111111;-25830.41252957628
2034;Hospital discharges, alcohol-related injuries and poisoning, per 100,000;77.33333333333334;-23506.330980345803
2035;Hospital discharges, alcoholic liver disease, per 100,000;88.44444444444444;-26311.044508826257
2036;Perceived trend in alcohol-related harm and consequences;0.0;
2037;Treatment admissions (inpatient), alcohol dependence, per 100,000;92.44444444444444;-27807.40911192029
2038;Treatment admissions (inpatient), alcoholic psychosis, per 100,000;88.0;-27102.98102093746
2039;Alcohol-related road traffic crashes, per 100,000 population;69.77777777777777;-25673.25175204768
2040;Alcohol-related road traffic crashes, per 100,000 population;69.77777777777777;-25673.25175204768
2041;Alcohol-related road traffic crashes (% of all traffic crashes);77.77777777777777;-25542.6650427037
2042;Alcohol-related road traffic crashes (% of all traffic crashes);77.77777777777777;-25542.6650427037
2043;Alcohol-related injury mortality, per 1,000-Female;65.77777777777777;0.0
2044;Alcohol-related injury mortality, per 1,000-Male;65.77777777777777;0.0
2045;Alcohol-related injury mortality, per 1,000;65.77777777777777;-27807.40911192029
2046;Alcohol-related disease mortality, per 100,000 (15+ years)-Both sexes;89.77777777777777;0.1054439194285468
2047;Alcohol-related disease mortality, per 100,000 (15+ years)-Female;89.77777777777777;0.07013175500944602
2048;Alcohol-related disease mortality, per 100,000 (15+ years)-Male;89.77777777777777;0.06940096802079232
2049;Alcohol-related disease mortality, per 100,000 (15+ years);89.77777777777777;-26741.54078918704
2050;Alcoholic excise tax revenue as a per cent of government revenue;82.66666666666666;-24310.71581161768
2051;Alcoholic excise tax revenue as a per cent of government revenue;82.66666666666666;-24310.71581161768
2052;Annual revenues from alcohol excise tax in millions US$;61.77777777777778;-17736.77455547146
2053;Annual revenues from alcohol excise tax in millions US$;61.77777777777778;-17736.77455547146
2054;Alcohol expenditure as a per cent of total household expenditure;75.55555555555556;-23180.232693202608
2055;Alcohol expenditure as a per cent of total household expenditure;75.55555555555556;-23180.232693202608
2056;Social costs of alcohol use in millions US$;95.11111111111111;-27711.31817698139
2057;Social costs of alcohol use in millions US$;95.11111111111111;-27711.31817698139
2058;Adopted written national policy on alcohol;0.0;
2059;Adopted written national policy on alcohol;0.0;
2060;Alcoholic beverage legally defined;0.0;
2061;Alcohol use is banned;0.0;
2062;Alcohol use is banned;0.0;
2063;National legislation to prevent illegal alcohol;0.0;
2064;National legislation to prevent illegal alcohol;0.0;
2065;Advertising restrictions on national television;0.0;
2066;Advertising restrictions on national television;0.0;
2067;Advertising restrictions on cable television;0.0;
2068;Advertising restrictions on cable television;0.0;
2069;Advertising restrictions on national radio;0.0;
2070;Advertising restrictions on national radio;0.0;
2071;Advertising restrictions on local radio;0.0;
2072;Advertising restrictions on local radio;0.0;
2073;Advertising restrictions in print media;0.0;
2074;Advertising restrictions in print media;0.0;
2075;Advertising restrictions at cinemas;0.0;
2076;Advertising restrictions at cinemas;0.0;
2077;Advertising restrictions on billboards;0.0;
2078;Advertising restrictions on billboards;0.0;
2079;Advertising restrictions at point-of-sale;0.0;
2080;Advertising restrictions at point-of-sale;0.0;
2081;Advertising restrictions on the internet;0.0;
2082;Advertising restrictions on the internet;0.0;
2083;Restrictions on product placement on national television;0.0;
2084;Restrictions on product placement on national television;0.0;
2085;Restrictions on product placement on cable television;0.0;
2086;Restrictions on product placement on cable television;0.0;
2087;Age limits on-premise service;0.0;
2088;Age limits on-premise service;0.0;
2089;Minimum legal drinking age;69.77777777777777;-26838.695299298262
2090;Legal blood alcohol concentration (BAC) limits;0.0;
2091;Random breath testing (RBT) use;0.0;
2092;Prices for alcoholic beverages (average, US$);0.0;
2093;Prices for alcoholic beverages (average, US$);0.0;
2094;Off-premise sales restrictions on days;0.0;
2095;Off-premise sales restrictions on days;0.0;
2096;Off-premise sales restrictions on hours;0.0;
2097;Off-premise sales restrictions on hours;0.0;
2098;Off-premise sales restrictions on places;0.0;
2099;Off-premise sales restrictions on places;0.0;
2100;Off-premise sales restrictions on outlet density;0.0;
2101;Off-premise sales restrictions on outlet density;0.0;
2102;Off-premise sales restrictions at specific events;0.0;
2103;Off-premise sales restrictions at specific events;0.0;
2104;Off-premise sales restrictions at petrol stations;0.0;
2105;Off-premise sales restrictions at petrol stations;0.0;
2106;On-premise sales restrictions on days;0.0;
2107;On-premise sales restrictions on days;0.0;
2108;On-premise sales restrictions on hours;0.0;
2109;On-premise sales restrictions on hours;0.0;
2110;On-premise sales restrictions on places;0.0;
2111;On-premise sales restrictions on places;0.0;
2112;On-premise sales restrictions on outlet density;0.0;
2113;On-premise sales restrictions on outlet density;0.0;
2114;On-premise sales restrictions at specific events;0.0;
2115;On-premise sales restrictions at specific events;0.0;
2116;On-premise sales restrictions to intoxicated persons;0.0;
2117;On-premise sales restrictions to intoxicated persons;0.0;
2118;Restrictions on sponsorship of sporting events;0.0;
2119;Restrictions on sponsorship of sporting events;0.0;
2120;Restrictions on sponsorship of youth events;0.0;
2121;Restrictions on sponsorship of youth events;0.0;
2122;Restrictions on sales promotion from producers (parties, events);0.0;
2123;Restrictions on sales promotion from producers (parties, events);0.0;
2124;Restrictions on sales promotion from retailers (sales below cost);0.0;
2125;Restrictions on sales promotion from retailers (sales below cost);0.0;
2126;Restrictions on sales promotion from owners of pubs and bars (alcohol for free);0.0;
2127;Restrictions on sales promotion from owners of pubs and bars (alcohol for free);0.0;
2128;Government monopoly on production;0.0;
2129;Government monopoly on production;0.0;
2130;Government monopoly on retail sales;0.0;
2131;Government monopoly on retail sales;0.0;
2132;Licence required for production;0.0;
2133;Licence required for production;0.0;
2134;Licence required for retail sales;0.0;
2135;Licence required for retail sales;0.0;
2136;Excise tax as a per cent of the retail price of alcoholic beverages;99.55555555555556;-27793.88102939118
2137;Excise tax as a per cent of the retail price of alcoholic beverages;99.55555555555556;-27793.88102939118
2138;Excise duty (average) per hectolitre in Euros;83.11111111111111;-23305.156145127934
2139;Excise duty (average) per hectolitre in Euros;83.11111111111111;-23305.156366421837
2140;Excise tax as a per cent of the total retail price for 1 litre of pure alcohol;0.0;
2141;Excise tax as a per cent of the total retail price for 1 litre of pure alcohol;0.0;
2142;Duty paid or excise stamp on alcohol container;0.0;
2143;Duty paid or excise stamp on alcohol container;0.0;
2144;Excise tax on alcoholic beverages;0.0;
2145;Excise tax on alcoholic beverages;0.0;
2146;Value-added tax (VAT) on alcohol (%);0.0;
2147;Value-added tax (VAT) on alcohol (%);0.0;
2148;Restrictions on alcohol use in public places;0.0;
2149;Restrictions on alcohol use in public places;0.0;
2150;Health warning labels on alcohol advertising;0.0;
2151;Health warning labels on alcohol advertising;0.0;
2152;Health warning labels on alcohol containers;0.0;
2153;Health warning labels on alcohol containers;0.0;
2154;Awareness activities;0.0;
2155;Awareness activities;0.0;
2156;Information, education, prevention;0.0;
2157;National drinking guidelines;0.0;
2158;Standard drink measures, in grams per unit;92.44444444444444;-27565.637594771335
2159;Standard drink measures, in grams per unit;92.44444444444444;-27565.637594771335
2160;Monitoring;0.0;
2161;Interventions, projects, training;0.0;
2162;Treatment, services;0.0;
2163;Surveys, research;0.0;
2164;Counselling;0.0;
2165;Production in 1000s hectolitres;27.555555555555557;-15456.026749057244
2166;Imports in 1000s hectolitres;35.111111111111114;-14651.7006831506
2167;Sales of beer in 1000s hectolitres;23.111111111111114;-8802.43130782493
2168;Exports of beer (barley) in 1000s hectolitres;57.77777777777778;-17393.782907756213
2169;Perceived trend in production;0.0;
2170;Perceived trend in imports;0.0;
2171;Perceived trend in sales;0.0;
2172;Perceived trend in exports;0.0;
2173;Sales of wine in 1000s hectolitres;66.22222222222223;-20133.976453045292
2174;Sales of spirits in 1000s hectolitres;86.66666666666667;-25385.592715640872
2175;Exports of wine (grape) in 1000s hectolitres;70.22222222222223;-21993.192945990028
2176;Exports of spirits in 1000s hectolitres;67.11111111111111;-22043.226908153814
2177;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2);16.444444444444443;-22.54875672018821
2178;Total (recorded+unrecorded) alcohol per capita (15+) consumption;74.22222222222223;-26969.990824039785
2179;Age-standardized DALYs, cerebrovascular disease, per 100,000-Female;15.111111111111114;0.3631947579193824
2180;Age-standardized DALYs, cerebrovascular disease, per 100,000-Male;15.111111111111114;0.36475076448047083
2181;Age-standardized DALYs, cerebrovascular disease, per 100,000-Both sexes;15.111111111111114;0.36248383773419235
2182;Age-standardized DALYs, cerebrovascular disease, per 100,000;15.111111111111114;-25081.802707643008
2183;Age-standardized death rates, cerebrovascular disease, per 100,000-Both sexes;15.111111111111114;0.36475076448047083
2184;Age-standardized death rates, cerebrovascular disease, per 100,000-Male;15.111111111111114;0.36475076448047083
2185;Age-standardized death rates, cerebrovascular disease, per 100,000-Female;15.111111111111114;0.3617729175490023
2186;Age-standardized death rates, cerebrovascular disease, per 100,000;15.111111111111114;-25081.802352182916
2187;Central coordinating entity for alcohol policy implementation;0.0;
2188;Central coordinating entity for alcohol policy implementation;0.0;
2189;Framework of national alcohol policy;0.0;
2190;Framework of national alcohol policy;0.0;
2191;Level of adoption of national alcohol policy;0.0;
2192;Level of adoption of national alcohol policy;0.0;
2193;Sectors represented in national alcohol policy;0.0;
2194;Sectors represented in national alcohol policy;0.0;
2195;Cautions and arrests for public drunkenness, per 100,000 population;91.55555555555556;-27257.306515887336
2196;Cautions and arrests for public drunkenness, per 100,000 population;91.55555555555556;-27257.306515887336
2197;Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities);76.88888888888889;-22285.621257908042
2198;Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities);76.88888888888889;-22285.621257908042
2199;Adopted written national policy on alcohol, year adopted;0.0;
2200;Adopted written national policy on alcohol, year revised;0.0;
2201;Age limits off-premise sales;0.0;
2202;Age limits off-premise sales;0.0;
2203;Consumer information on alcohol and health at points of sale;0.0;
2204;Educational programmes involving target groups in school curriculum;0.0;
2205;Brief interventions as health promotion/disease prevention;0.0;
2206;Server training on a regular basis;0.0;
2207;Data collection on alcohol-related health indicators;0.0;
2208;System for monitoring alcohol-related harm;0.0;
2209;National treatment policy for alcohol use disorders;0.0;
2210;Persons with alcohol use disorders receiving treatment (%);84.44444444444444;-27316.488120263162
2211;Designation of alcohol tax revenues to health services;0.0;
2212;National surveys on drink-driving;0.0;
2213;Public-funded alcohol research/monitoring programmes;0.0;
2214;Public funds designated for alcohol research/monitoring programmes, in Euros;97.33333333333333;-27722.91794166846
2215;Community-based interventions/projects involving stakeholders;0.0;
2216;Interventions/projects actively involving young people and civil society;0.0;
2217;Training in screening and brief interventions for alcohol problems;0.0;
2218;Counselling to children in families with alcohol problems;0.0;
2219;Counselling to pregnant women with alcohol problems;0.0;
2220;Prevention/counselling at workplaces for those with alcohol problems;0.0;
2221;Advertising restrictions on social media;0.0;
2222;Advertising restrictions on social media;0.0;
2223;Restrictions on product placement in films/movies;0.0;
2224;Restrictions on product placement in films/movies;0.0;
2225;Importance of measures for enhancing compliance with age limits;0.0;
2226;Importance of measures for enhancing compliance with age limits;0.0;
2227;Government support for community action;0.0;
2228;Government support for community action;0.0;
2229;Community-based interventions involving stakeholders;0.0;
2230;Community-based interventions involving stakeholders;0.0;
2231;National guidelines for implementing effective community-based interventions;0.0;
2232;National guidelines for implementing effective community-based interventions;0.0;
2233;National alcohol policy specifically involves young people activities;0.0;
2234;National alcohol policy specifically involves young people activities;0.0;
2235;Penalties for drink driving;0.0;
2236;Penalties for drink driving;0.0;
2237;Sobriety checkpoints;0.0;
2238;Sobriety checkpoints;0.0;
2239;Detection of marketing infringements;0.0;
2240;Detection of marketing infringements;0.0;
2241;Penalties for marketing infringements;0.0;
2242;Price measures;0.0;
2243;Price measures;0.0;
2244;Level of taxation adjusted for inflation;0.0;
2245;Level of taxation adjusted for inflation;0.0;
2246;New types of alcoholic beverages emerging;0.0;
2247;New types of alcoholic beverages emerging;0.0;
2248;Consumer information about calories, additives, etc on containers;0.0;
2249;Consumer information about calories, additives, etc on containers;0.0;
2250;Number of standard alcoholic drinks displayed on containers;0.0;
2251;Number of standard alcoholic drinks displayed on containers;0.0;
2252;Alcohol content displayed on containers;0.0;
2253;Alcohol content displayed on containers;0.0;
2254;Action Plan for implementation of alcohol policy;0.0;
2255;Action Plan for implementation of alcohol policy;0.0;
2256;Alcohol, regional per capita (15+) consumption (in litres of pure alcohol);0.0;
2257;Alcohol, regional per capita (15+) consumption (in litres of pure alcohol);0.0;
2258;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Both sexes;16.0;0.7467913775865878
2259;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Female;16.0;0.40905277418594643
2260;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Male;16.0;0.45618233196860913
2261;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI;16.0;-22593.767440739102
2262;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Both sexes;16.0;0.7467913775865878
2263;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Female;16.0;0.40905277418594643
2264;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Male;16.0;0.45618233196860913
2265;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI;16.0;-22593.76695111282
2266;Alcohol-attributable Years of Life Lost (YLL) score;0.0;
2267;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Male;87.11111111111111;0.04691944090611866
2268;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Female;87.11111111111111;0.02843234689679708
2269;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%);87.11111111111111;-27382.12960097497
2270;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Male;87.11111111111111;0.04691944090611866
2271;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Female;87.11111111111111;0.02843234689679708
2272;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%);87.11111111111111;-27382.12960097497
2273;Alcohol-attributable fractions (15+), road traffic crash deaths (%);0.0;
2274;Alcohol-attributable fractions (15+), road traffic crash deaths (%);0.0;
2275;Alcohol-attributable fractions, all-cause deaths (%)-Female;65.77777777777777;0.08656292924610565
2276;Alcohol-attributable fractions, all-cause deaths (%)-Both sexes;65.77777777777777;0.030977679650665557
2277;Alcohol-attributable fractions, all-cause deaths (%)-Male;65.77777777777777;0.01927663348169073
2278;Alcohol-attributable fractions, all-cause deaths (%);65.77777777777777;-26691.525372331293
2279;Alcohol-attributable fractions, all-cause deaths (%)-Female;65.77777777777777;0.08656292924610565
2280;Alcohol-attributable fractions, all-cause deaths (%)-Both sexes;65.77777777777777;0.030977679650665557
2281;Alcohol-attributable fractions, all-cause deaths (%)-Male;65.77777777777777;0.01927663348169073
2282;Alcohol-attributable fractions, all-cause deaths (%);65.77777777777777;-26691.525372331293
2283;Alcohol, regional prevalence of alcohol dependence (%);0.0;
2284;Alcohol, regional prevalence of alcohol dependence (%);0.0;
2285;Alcohol, regional prevalence of alcohol use disorders (%);0.0;
2286;Alcohol, regional prevalence of alcohol use disorders (%);0.0;
2287;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025;16.888888888888886;-25142.024452614485
2288;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025;16.888888888888886;-25142.024452614485
2289;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI;15.555555555555557;-20156.064998606565
2290;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-20164.194013759527
2291;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-20164.194013759527
2292;15-years old first drink at 13 years or younger, (%)-Male;82.66666666666666;0.3080338739140265
2293;15-years old first drink at 13 years or younger, (%)-Both sexes;82.66666666666666;0.3106334064961356
2294;15-years old first drink at 13 years or younger, (%)-Female;82.66666666666666;0.3109564090030936
2295;15-years old first drink at 13 years or younger, (%);82.66666666666666;-25805.98846314035
2296;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;15.555555555555557;0.5509159507419596
2297;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;15.555555555555557;0.598753419657748
2298;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;15.555555555555557;0.6192947631187025
2299;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-25113.13408820691
2300;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;15.555555555555557;0.5509159507419596
2301;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;15.555555555555557;0.598753419657748
2302;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;15.555555555555557;0.6192947631187025
2303;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-25113.136220967466
2304;Alcohol, average daily intake in grams among drinkers with 95%CI-Both sexes;15.555555555555557;0.4723456642411614
2305;Alcohol, average daily intake in grams among drinkers with 95%CI-Female;15.555555555555557;0.46055177968436745
2306;Alcohol, average daily intake in grams among drinkers with 95%CI-Male;15.555555555555557;0.48928004470621733
2307;Alcohol, average daily intake in grams among drinkers with 95%CI;15.555555555555557;-23134.960239284774
2308;Alcohol, average daily intake in grams among drinkers with 95%CI-Both sexes;15.555555555555557;0.4723456642411614
2309;Alcohol, average daily intake in grams among drinkers with 95%CI-Female;15.555555555555557;0.46055177968436745
2310;Alcohol, average daily intake in grams among drinkers with 95%CI-Male;15.555555555555557;0.48928004470621733
2311;Alcohol, average daily intake in grams among drinkers with 95%CI;15.555555555555557;-23134.96095020496
2312;Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016;17.33333333333333;-25177.928397051764
2313;Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016;17.33333333333333;-25177.928397051764
2314;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Female;45.333333333333336;0.08159375808128289
2315;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Male;45.333333333333336;0.1048229408834569
2316;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Both sexes;45.333333333333336;0.11159501866190347
2317;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI;45.333333333333336;-26050.806298278825
2318;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Both sexes;51.111111111111114;0.08580676523932773
2319;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Female;51.111111111111114;0.07187750395680137
2320;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Male;51.111111111111114;0.09793741216263552
2321;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI;51.111111111111114;-26235.687047839165
2322;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Both sexes;51.111111111111114;0.08580676523932773
2323;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Female;51.111111111111114;0.07187750395680137
2324;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Male;51.111111111111114;0.09793741216263552
2325;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI;51.111111111111114;-26235.687047839165
2326;15-19 years old heavy episodic drinkers (population), % with 95%CI-Both sexes;15.555555555555557;0.8485627585318314
2327;15-19 years old heavy episodic drinkers (population), % with 95%CI-Male;15.555555555555557;0.8652217254784116
2328;15-19 years old heavy episodic drinkers (population), % with 95%CI-Female;15.555555555555557;0.7792685738244263
2329;15-19 years old heavy episodic drinkers (population), % with 95%CI;15.555555555555557;-22579.08895944443
2330;15-19 years old heavy episodic drinkers (population), % with 95%CI-Both sexes;15.555555555555557;0.8485627585318314
2331;15-19 years old heavy episodic drinkers (population), % with 95%CI-Female;15.555555555555557;0.7792685738244263
2332;15-19 years old heavy episodic drinkers (population), % with 95%CI-Male;15.555555555555557;0.8652217254784116
2333;15-19 years old heavy episodic drinkers (population), % with 95%CI;15.555555555555557;-22579.089314904526
2334;15-19 years old heavy episodic drinkers (drinkers only), %-Male;15.555555555555557;0.6823384638396259
2335;15-19 years old heavy episodic drinkers (drinkers only), %-Both sexes;15.555555555555557;0.3431958836020925
2336;15-19 years old heavy episodic drinkers (drinkers only), %-Female;15.555555555555557;0.6574191605254995
2337;15-19 years old heavy episodic drinkers (drinkers only), %;15.555555555555557;-22579.06863878877
2338;15-19 years old abstainers, lifetime (%)-Female;15.555555555555557;0.6546482393608333
2339;15-19 years old abstainers, lifetime (%)-Male;15.555555555555557;0.6480354542568696
2340;15-19 years old abstainers, lifetime (%);15.555555555555557;-25113.131244526165
2341;15-19 years old abstainers, lifetime (%)-Female;15.555555555555557;0.6546482393608333
2342;15-19 years old abstainers, lifetime (%)-Male;15.555555555555557;0.6480354542568696
2343;15-19 years old abstainers, lifetime (%);15.555555555555557;-25113.131244526165
2344;15-19 years old former drinkers (%)-Female;15.555555555555557;0.4412237973442501
2345;15-19 years old former drinkers (%)-Male;15.555555555555557;0.42245947166447184
2346;15-19 years old former drinkers (%);15.555555555555557;-25113.20909843246
2347;15-19 years old former drinkers (%)-Female;15.555555555555557;0.4412237973442501
2348;15-19 years old former drinkers (%)-Male;15.555555555555557;0.42245947166447184
2349;15-19 years old former drinkers (%);15.555555555555557;-25113.213775762204
2350;15-19 years old, current drinkers (%)-Female;15.555555555555557;0.6762131055967284
2351;15-19 years old, current drinkers (%)-Both sexes;15.555555555555557;0.34548055944299794
2352;15-19 years old, current drinkers (%)-Male;15.555555555555557;0.6870465727545376
2353;15-19 years old, current drinkers (%);15.555555555555557;-22579.059615274367
2354;15-19 years old, current drinkers (%)-Both sexes;15.555555555555557;0.34548055944299794
2355;15-19 years old, current drinkers (%)-Female;15.555555555555557;0.6762131055967284
2356;15-19 years old, current drinkers (%)-Male;15.555555555555557;0.6870465727545376
2357;15-19 years old, current drinkers (%);15.555555555555557;-22579.059970734463
2358;15-19 years old total alcohol consumption in litres of pure alcohol-Male;16.0;0.6196663498101902
2359;15-19 years old total alcohol consumption in litres of pure alcohol-Female;16.0;0.5654458681371572
2360;15-19 years old total alcohol consumption in litres of pure alcohol-Both sexes;16.0;0.596171482833622
2361;15-19 years old total alcohol consumption in litres of pure alcohol;16.0;-25126.303159305335
2362;15-19 years old total alcohol consumption in litres of pure alcohol-Both sexes;16.0;0.596171482833622
2363;15-19 years old total alcohol consumption in litres of pure alcohol-Female;16.0;0.5654458681371572
2364;15-19 years old total alcohol consumption in litres of pure alcohol-Male;16.0;0.6196663498101902
2365;15-19 years old total alcohol consumption in litres of pure alcohol;16.0;-25126.30315930533
2366;National guidelines for the prevention and reduction of alcohol-related harm in schools;0.0;
2367;National guidelines for alcohol problem prevention and counselling at workplaces;0.0;
2368;National guidelines for alcohol problem prevention and counselling at workplaces;0.0;
2369;Workplace representatives nationally involved to prevent and address alcohol-related harm;0.0;
2370;Workplace representatives nationally involved to prevent and address alcohol-related harm;0.0;
2371;Server training;0.0;
2372;Server training;0.0;
2373;Legal obligation for schools to include alcohol use prevention;0.0;
2374;Legal obligation for schools to include alcohol use prevention;0.0;
2375;Legal obligation for schools to interact with parents regarding education and well-being;0.0;
2376;Legal obligation for schools to interact with parents regarding education and well-being;0.0;
2377;Legislation on alcohol testing at workplaces;0.0;
2378;Legislation on alcohol testing at workplaces;0.0;
2379;Standard drink defined;0.0;
2380;Standard drink defined;0.0;
2381;National systems for monitoring alcohol consumption and harms;0.0;
2382;National systems for monitoring alcohol consumption and harms;0.0;
2383;Regular reports from national monitoring systems;0.0;
2384;Regular reports from national monitoring systems;0.0;
2385;Comprehensive and regular reporting of alcohol situation;0.0;
2386;Comprehensive and regular reporting of alcohol situation;0.0;
2387;Clinical guidelines for brief interventions;0.0;
2388;Clinical guidelines for brief interventions;0.0;
2389;National surveys on adult alcohol consumption;0.0;
2390;National surveys on adult alcohol consumption;0.0;
2391;National surveys on youth alcohol consumption;0.0;
2392;National surveys on youth alcohol consumption;0.0;
2393;National surveys on heavy espisodic drinking;0.0;
2394;National surveys on heavy espisodic drinking;0.0;
2395;Data collection on Foetal Alcohol Syndome;0.0;
2396;Data collection on Foetal Alcohol Syndome;0.0;
2397;Data collected on harm from alcohol at workplace;0.0;
2398;Data collected on harm from alcohol at workplace;0.0;
2399;Level of enforcement of BAC limits;0.0;
2400;15-years old any alcoholic beverage consumed in past 12 months, (%)-Female;68.44444444444444;0.3349265544450546
2401;15-years old any alcoholic beverage consumed in past 12 months, (%)-Male;68.44444444444444;0.3255973114714372
2402;15-years old any alcoholic beverage consumed in past 12 months, (%)-Both sexes;68.44444444444444;0.46456232941704734
2403;15-years old any alcoholic beverage consumed in past 12 months, (%);68.44444444444444;-25219.687914990194
2404;15-years old any alcoholic beverage consumed in past 12 months, (%)-Male;68.44444444444444;0.3255973114714372
2405;15-years old any alcoholic beverage consumed in past 12 months, (%)-Both sexes;68.44444444444444;0.46456232941704734
2406;15-years old any alcoholic beverage consumed in past 12 months, (%)-Female;68.44444444444444;0.3349265544450546
2407;15-years old any alcoholic beverage consumed in past 12 months, (%);68.44444444444444;-25219.687914990194
2408;15-years old first drink at 13 years or younger, (%)-Both sexes;82.66666666666666;0.3106334064961356
2409;15-years old first drink at 13 years or younger, (%)-Male;82.66666666666666;0.3080338739140265
2410;15-years old first drink at 13 years or younger, (%)-Female;82.66666666666666;0.3109564090030936
2411;15-years old first drink at 13 years or younger, (%);82.66666666666666;-25805.98846314035
2412;15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;74.66666666666666;0.4315155502301513
2413;15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;74.66666666666666;0.3016782811887735
2414;15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;74.66666666666666;0.306460661493972
2415;15-years old any alcoholic beverage consumed in past 30 days, (%);74.66666666666666;-25809.607675013685
2416;15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;74.66666666666666;0.4315155502301513
2417;15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;74.66666666666666;0.306460661493972
2418;15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;74.66666666666666;0.3016782811887735
2419;15-years old any alcoholic beverage consumed in past 30 days, (%);74.66666666666666;-25809.607675013685
2420;15-years old, any alcoholic beverage consumed at least once a week, (%)-Male;82.66666666666666;0.30701246137441807
2421;15-years old, any alcoholic beverage consumed at least once a week, (%)-Female;82.66666666666666;0.2963933705554691
2422;15-years old, any alcoholic beverage consumed at least once a week, (%);82.66666666666666;-25778.225017610093
2423;15-years old, any alcoholic beverage consumed at least once a week, (%)-Male;82.66666666666666;0.30701246137441807
2424;15-years old, any alcoholic beverage consumed at least once a week, (%)-Female;82.66666666666666;0.2963933705554691
2425;15-years old, any alcoholic beverage consumed at least once a week, (%);82.66666666666666;-25778.225017610093
2426;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;75.55555555555556;0.1197255473702441
2427;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;75.55555555555556;0.12054192946781761
2428;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;75.55555555555556;0.12103155575112101
2429;13-15-years old any alcoholic beverage consumed in past 30 days, (%);75.55555555555556;-26882.597678822593
2430;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;75.55555555555556;0.12054192946781761
2431;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;75.55555555555556;0.1197255473702441
2432;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;75.55555555555556;0.12103155575112101
2433;13-15-years old any alcoholic beverage consumed in past 30 days, (%);75.55555555555556;-26882.597678822593
2434;13-15-years old first drink before age 14, (%)-Both sexes;75.11111111111111;0.18873482379755036
2435;13-15-years old first drink before age 14, (%)-Female;75.11111111111111;0.14186491679668478
2436;13-15-years old first drink before age 14, (%)-Male;75.11111111111111;0.16534620020410706
2437;13-15-years old first drink before age 14, (%);75.11111111111111;-26825.948401749978
2438;13-15-years old first drink before age 14, (%)-Female;75.11111111111111;0.14186491679668478
2439;13-15-years old first drink before age 14, (%)-Both sexes;75.11111111111111;0.18873482379755036
2440;13-15-years old first drink before age 14, (%)-Male;75.11111111111111;0.16534620020410706
2441;13-15-years old first drink before age 14, (%);75.11111111111111;-26825.948401749978
2442;Alcohol-related road traffic crashes with fatalities, per 100,000  population;82.22222222222223;-23358.210280976284
2443;Alcohol-related road traffic crashes with fatalities, per 100,000  population;82.22222222222223;-23358.210280976284
2444;Alcohol-related crimes (% of all crimes);90.22222222222223;-26824.275347998926
2445;Alcohol-related crimes (% of all crimes);90.22222222222223;-26824.275347998926
2446;National drinking guidelines;0.0;
2447;Graduated licensing;0.0;
2448;National legislation to prevent illegal alcohol sales;0.0;
2449;Penalties for drink driving, repeated offense;0.0;
2450;Licensing required for exports of alcoholic beverages;0.0;
2451;Licensing required for imports of alcoholic beverages;0.0;
2452;Licensing required for wholesale/distribution of alcoholic beverages;0.0;
2453;Licenses issued for production, change since 2010;0.0;
2454;Licenses issued for retail sale, change since 2010;0.0;
2455;Licenses issued for wholesale/distribution, change since 2010;0.0;
2456;Monopoly on exports of alcoholic beverages;0.0;
2457;Monopoly on imports of alcoholic beverages;0.0;
2458;Monopoly on wholesale /distribution of alcoholic beverages;0.0;
2459;Health warning labels on pregnancy;0.0;
2460;Health warning labels on under-age drinking;0.0;
2461;Health warning labels on drink-driving;0.0;
2462;Legal requirement for size of health warning labels;0.0;
2463;Cancer, age-standardized death rates (15+), per 100,000 population;0.0;
2464;Alcohol-attributable fractions (15+), cancer deaths;0.0;
2465;National system of epidemiological data collection for alcohol use;0.0;
2466;National system of data collection based on health service delivery;0.0;
2467;Report with epidemiological data on lcohol use and AUDs;0.0;
2468;Report with data from health services on alcohol use and AUDs;0.0;
2469;National organization for monitoring alcohol;0.0;
2470;Taxation of ethanol production;0.0;
2471;Ethanol tax deducted from excise tax;0.0;
2472;Tax incentives for production low/no alcohol content beer;0.0;
2473;Tax incentives for production of other alcoholic beverages;0.0;
2474;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2020 and 2025;16.0;-27807.40911192029
2475;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Both sexes;16.0;0.3353287230854747
2476;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Female;16.0;0.31030454296554577
2477;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Male;16.0;0.3417195678196858
2478;Heavy episodic drinking (youth 15 -19 years) past 30 days (%);16.0;-25134.522349201023
2479;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Female;16.0;0.3437502974595521
2480;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Both sexes;16.0;0.3431958836020925
2481;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Male;16.0;0.3471707321947939
2482;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%);16.0;-25134.515167774665
2483;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-20164.194013759527
2484;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-20164.194013759527
2485;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;16.0;0.8469336536308107
2486;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;16.0;0.7404154773590061
2487;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;16.0;0.9044754268730948
2488;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI;16.0;-20194.77965923539
2489;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;16.0;0.8469336536308107
2490;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;16.0;0.7404154773590061
2491;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;16.0;0.9044754268730948
2492;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI;16.0;-20194.779347967888
2493;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-24760.27435562595
2494;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-24760.27435562595
2495;Alcohol, regional alcohol per capita (15+) consumption (in litres of pure alcohol);0.0;
2496;Regional prevalence, AAFs (15+), liver cirrhosis deaths (%);0.0;
2497;Regional prevalence, AAFs (15+), road traffic crash deaths (%);0.0;
2498;Regional prevalence, AAFs (15+), cancer;0.0;
2499;Regional prevalence, AAFs ,all-cause deaths (%);0.0;
2500;Average price 500 mls Beer in US$;25.77777777777777;-25438.362530669587
2501;Average price 750 mls Wine in US$;41.333333333333336;-25936.916632541866
2502;Average price 500 mls Spirits in US$;70.22222222222223;-26860.155173053237
2503;Births attended by skilled health personnel (in the two or three years preceding the survey) (%)-15-19 years-nan;49.33333333333333;0
2504;Births attended by skilled health personnel (in the two or three years preceding the survey) (%)-20-49 years-nan;49.33333333333333;0
2505;Births attended by skilled health personnel (in the two or three years preceding the survey) (%);49.33333333333333;-23013.29960163598
2506;Births attended by skilled health personnel (in the five years preceding the survey) (%)-15-19 years-nan;66.22222222222223;0
2507;Births attended by skilled health personnel (in the five years preceding the survey) (%)-20-49 years-nan;66.22222222222223;0
2508;Births attended by skilled health personnel (in the five years preceding the survey) (%);66.22222222222223;-25024.045219839547
2509;Number of deaths attributed to non-communicable diseases, by type of disease and sex;18.66666666666667;-70.5442531229003
2510;Ambient and household air pollution attributable death rate (per 100 000 population)-Male;18.66666666666667;1.69057175828714
2511;Ambient and household air pollution attributable death rate (per 100 000 population)-Both sexes;18.66666666666667;1.69057175828714
2512;Ambient and household air pollution attributable death rate (per 100 000 population)-Female;18.66666666666667;1.690294388466988
2513;Ambient and household air pollution attributable death rate (per 100 000 population);18.66666666666667;-25222.59910103469
2514;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Female;18.66666666666667;1.690294388466988
2515;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;18.66666666666667;1.690294388466988
2516;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Male;18.66666666666667;1.69057175828714
2517;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized);18.66666666666667;-25222.59910103469
2518;Completeness of cause-of-death data (%);47.55555555555555;-26155.0339283135
2519;Estimated direct deaths from major conflicts (per 100 000 population);18.66666666666667;-25222.662688398024
2520;Average death rate due to natural disasters (per 100 000 population)-Male;18.66666666666667;0.2939241192454807
2521;Average death rate due to natural disasters (per 100 000 population)-Female;18.66666666666667;0.2878958389759658
2522;Average death rate due to natural disasters (per 100 000 population)-Both sexes;18.66666666666667;0.2939241192454807
2523;Average death rate due to natural disasters (per 100 000 population);18.66666666666667;-25222.649450835765
2524;Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%);20.444444444444443;-25249.57718254409
2525;New HIV infections (per 1000 uninfected population);41.333333333333336;-2682.7948953568334
2526;Average of 13 International Health Regulations core capacity scores;13.777777777777771;-13633.706882303175
2527;Reported number of people requiring interventions against NTDs;13.777777777777771;-6742.393228309309
2528;Total net official development assistance to medical research and basic health sectors per capita (constant 2014 US$), by recipient;39.11111111111111;-25830.859398813725
2529;Total net official development assistance to medical research and basic health sectors per capita (US$), by recipient country;37.33333333333333;-20341.61844863204
2530;Concentrations of fine particulate matter (PM2.5);13.777777777777771;-11555.938573829017
2531;Mortality rate attributed to unintentional poisoning (per 100 000 population);18.66666666666667;-70.54758642992435
2532;Skilled health professionals density (per 10 000 population);20.888888888888886;-24221.410360125712
2533;Crude suicide rates (per 100 000 population)-15-24 years of age-Both sexes;18.66666666666667;0.34705284646707124
2534;Crude suicide rates (per 100 000 population)-15-24 years of age-Female;18.66666666666667;0.3409452373187998
2535;Crude suicide rates (per 100 000 population)-15-24 years of age-Male;18.66666666666667;0.34691868027636286
2536;Crude suicide rates (per 100 000 population)-25-34 years of age-Both sexes;18.66666666666667;0.34785089436343863
2537;Crude suicide rates (per 100 000 population)-25-34 years of age-Female;18.66666666666667;0.3396976523707753
2538;Crude suicide rates (per 100 000 population)-25-34 years of age-Male;18.66666666666667;0.34834052064674204
2539;Crude suicide rates (per 100 000 population)-35-44 years of age-Both sexes;18.66666666666667;0.34705284646707035
2540;Crude suicide rates (per 100 000 population)-35-44 years of age-Female;18.66666666666667;0.34416212724678097
2541;Crude suicide rates (per 100 000 population)-35-44 years of age-Male;18.66666666666667;0.3502519873004255
2542;Crude suicide rates (per 100 000 population)-45-54 years-Both sexes;18.66666666666667;0.34905144083193207
2543;Crude suicide rates (per 100 000 population)-45-54 years-Female;18.66666666666667;0.3481192267448563
2544;Crude suicide rates (per 100 000 population)-45-54 years-Male;18.66666666666667;0.35082874129490715
2545;Crude suicide rates (per 100 000 population)-55-64 years-Both sexes;18.66666666666667;0.34954106711523636
2546;Crude suicide rates (per 100 000 population)-55-64 years-Female;18.66666666666667;0.3483405206467429
2547;Crude suicide rates (per 100 000 population)-55-64 years-Male;18.66666666666667;0.34925498563919266
2548;Crude suicide rates (per 100 000 population)-65-74 years-Both sexes;18.66666666666667;0.34954106711523636
2549;Crude suicide rates (per 100 000 population)-65-74 years-Female;18.66666666666667;0.34449983824474906
2550;Crude suicide rates (per 100 000 population)-65-74 years-Male;18.66666666666667;0.3498965272078314
2551;Crude suicide rates (per 100 000 population)-75-84 years-Both sexes;18.66666666666667;0.3489172746412237
2552;Crude suicide rates (per 100 000 population)-75-84 years-Female;18.66666666666667;0.34640386796593603
2553;Crude suicide rates (per 100 000 population)-75-84 years-Male;18.66666666666667;0.3502519873004264
2554;Crude suicide rates (per 100 000 population)-85+ years of age-Both sexes;18.66666666666667;0.3503213659169777
2555;Crude suicide rates (per 100 000 population)-85+ years of age-Female;18.66666666666667;0.34505884314460555
2556;Crude suicide rates (per 100 000 population)-85+ years of age-Male;18.66666666666667;0.3503213659169777
2557;Crude suicide rates (per 100 000 population)-15-29  years-Both sexes;18.66666666666667;0.34869598073933705
2558;Crude suicide rates (per 100 000 population)-15-29  years-Female;18.66666666666667;0.34201161759658394
2559;Crude suicide rates (per 100 000 population)-15-29  years-Male;18.66666666666667;0.3489172746412237
2560;Crude suicide rates (per 100 000 population)-15-19 years-Both sexes;18.66666666666667;0.3447211321466366
2561;Crude suicide rates (per 100 000 population)-15-19 years-Female;18.66666666666667;0.3414055742171982
2562;Crude suicide rates (per 100 000 population)-15-19 years-Male;18.66666666666667;0.34663259880031916
2563;Crude suicide rates (per 100 000 population)-30-49 years of age-Both sexes;18.66666666666667;0.3502519873004255
2564;Crude suicide rates (per 100 000 population)-30-49 years of age-Female;18.66666666666667;0.3439230842502683
2565;Crude suicide rates (per 100 000 population)-30-49 years of age-Male;18.66666666666667;0.3494069009245271
2566;Crude suicide rates (per 100 000 population);18.66666666666667;-70.64974309954405
2567;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Male;18.66666666666667;0.34427392031870685
2568;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Female;18.66666666666667;0.34427392031870685
2569;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Both sexes;18.66666666666667;0.34427392031870685
2570;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2);18.66666666666667;-25222.59910103469
2571;Children aged 36-59 months who are developmentally on track in at least three of the following domains: literacy-numeracy, physical development, social-emotional development and learning (%);73.33333333333333;-26934.884480614535
2572;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Both sexes;59.55555555555556;0.3681405593134146
2573;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Female;59.55555555555556;0.31837293372156505
2574;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Male;59.55555555555556;0.31872839381416007
2575;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%);59.55555555555556;-24992.040974157528
2576;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Both sexes;76.88888888888889;0.1740338941975157
2577;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Male;76.88888888888889;0.1297713886717391
2578;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Female;76.88888888888889;0.12821538211065064
2579;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%);76.88888888888889;-26456.34716663081
2580;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Both sexes;53.77777777777778;0.8057729050320654
2581;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Male;53.77777777777778;0.7424002752219341
2582;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Female;53.77777777777778;0.7424002752219341
2583;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%);53.77777777777778;-21816.627021422395
2584;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Both sexes;62.666666666666664;0.28834223235490075
2585;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Female;62.666666666666664;0.24095720968725232
2586;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Male;62.666666666666664;0.24131266977984733
2587;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%);62.666666666666664;-25553.38489270927
2588;Participation rate in organized learning (one year before the official primary entry age) (%);29.777777777777786;-10659.913898685125
2589;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Male;64.88888888888889;0.28371099620135
2590;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Both sexes;64.88888888888889;0.36453411092670684
2591;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Female;64.88888888888889;0.28371099620135
2592;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%);64.88888888888889;-25082.431594521797
2593;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Both sexes;78.22222222222223;0.1525775170143202
2594;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Female;78.22222222222223;0.09125527297519831
2595;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Male;78.22222222222223;0.09161073306779333
2596;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%);78.22222222222223;-26626.286995612736
2597;Proportion of countries that have conducted at least one population and housing census in the last 10 years (%);0.0;
2598;Proportion of girls and women aged 15-49 years who have undergone female genital mutilation/cutting (FMG/C) (%);87.11111111111111;-27361.215680693782
2599;Percentage of children under 15 years exposed to second-hand smoke;0.0;
2600;Second-hand smoke attributable DALYs ('000) in children under 5 years;0.0;
2601;Second-hand smoke  attributable DALYs per 100'000 children under 5 years;0.0;
2602;Percentage of women (15+ years) exposed to second-hand smoke;0.0;
2603;Percentage of men (15+ years) exposed to second-hand smoke;0.0;
2604;Second-hand smoke attributable deaths;0.0;
2605;Second-hand smoke attributable DALYs ('000);0.0;
2606;Second-hand smoke attributable deaths per 100'000 capita;0.0;
2607;Second-hand smoke attributable DALYs per 100'000 capita;0.0;
2608;Second-hand smoke attributable deaths ('000) in children under 5 years;0.0;
2609;Second-hand smoke  attributable deaths per 100'000 children under 5 years;0.0;
2610;Proportion of population below the international poverty line of US$1.90 per day (%);30.222222222222214;-13846.447675263658
2611;Proportion of women aged 20-24 years who were married or in a union by age 15 (%);44.888888888888886;-26017.119100117747
2612;Proportion of women aged 20-24 years who were married or in a union by age 18 (%);44.888888888888886;-26017.088462636006
2613;Stunting prevalence in children aged < 5 years (%);54.22222222222222;-23798.859513520685
2614;Existence of national regulation;0.0;
2615;Existence of subnational regulation;0.0;
2616;Year of national implementation of regulation;0.0;
2617;Access restrictions;0.0;
2618;Restriction and inspection of facilities;0.0;
2619;Information requirements;0.0;
2620;Safety requirements;0.0;
2621;Training requirements;0.0;
2622;Tuberculosis treatment coverage;13.777777777777771;-37.942229424510906
2623;New cases tested for RR-/MDR-TB (%);14.666666666666657;-5009.567152375767
2624;Previously treated cases tested for RR-/MDR-TB (%);16.0;-6114.177600068856
2625;Laboratories providing tuberculosis diagnostic services using culture (per 5 million population);15.111111111111114;-9971.582581203946
2626;Laboratories providing drug susceptibility testing (DST) (per 5 million population);16.0;-10231.319890679177
2627;Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population);18.66666666666667;-10009.12396892732
2628;Treatment success rate for patients treated for MDR-TB (%);22.222222222222214;-8910.450755078387
2629;Cases started on MDR-TB treatment;13.777777777777771;-6156.744332651926
2630;Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases;21.333333333333343;-13783.94739461698
2631;Treatment success rate: new TB cases;13.777777777777771;-201.64547744816198
2632;Tuberculosis - new and relapse cases;13.777777777777771;-14.232780572872512
2633;Total number of notified TB cases;13.777777777777771;-4690.75062162223
2634;Treatment success rate: previously treated TB cases;16.0;-1724.6268024541105
2635;Treatment success rate: HIV-positive TB cases;24.444444444444443;-10004.352525713362
2636;Treatment success rate: XDR-TB cases;48.88888888888889;-20789.274609494878
2637;Confirmed cases of MDR-TB started treatment for MDR-TB (%);28.0;-20082.60954879616
2638;Number of incident tuberculosis cases in children aged 0 - 14;13.777777777777771;-27807.40911192029
2639;Incidence of tuberculosis (per 100 000 population) (HIV-positive cases);16.444444444444443;-185.4187027553023
2640;Number of incident tuberculosis cases,  (HIV-positive cases);16.444444444444443;-185.6019468107527
2641;Estimated MDR-TB cases among notified pulmonary TB cases;16.0;-25115.755399291513
2642;Number of deaths due to tuberculosis, excluding HIV;14.222222222222229;0.27630953502046207
2643;Number of prevalent tuberculosis cases;13.777777777777771;-1689.8575372477503
2644;Tuberculosis effective treatment coverage (%);14.666666666666657;-882.3679812729632
2645;HIV-positive TB patients on ART (antiretroviral therapy) (%);28.0;-8681.22215239253
2646;HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%);32.0;-15351.654579514998
2647;TB patients with known HIV status (%);17.777777777777786;-3533.627331524213
2648;Tested TB patients HIV-positive (%);22.222222222222214;-5345.9263509913235
2649;Confirmed cases of MDR-TB;15.555555555555557;-13382.815269477152
2650;New or unknown treatment history cases: Pulmonary, clinically diagnosed;13.777777777777771;-11734.437695707938
2651;New cases: extrapulmonary;13.777777777777771;-29.67272937453135
2652;New or unknown treatment history cases: Pulmonary, bacteriologically confirmed;13.777777777777771;-7231.965892690056
2653;New cases: other;15.555555555555557;-13077.40188039241
2654;New cases: pulmonary smear-negative;13.777777777777771;-3905.399325629982
2655;New cases: Pulmonary, smear-negative/unknown/not done and other new cases;13.777777777777771;-3832.0507758435765
2656;New cases: Pulmonary, smear-positive;13.777777777777771;-3747.3341544759583
2657;New cases: pulmonary smear unknown/not done;13.777777777777771;-6135.11605346582
2658;Treatment history unknown;14.222222222222229;-11352.359903242326
2659;Previously treated  cases, excluding relapse;13.777777777777771;-453.1005565808381
2660;Retreatment cases: other;13.777777777777771;-8152.748573934732
2661;Relapse cases (pre-2013 definition);14.222222222222229;-4395.862300797173
2662;Relapse cases: Pulmonary, clinically diagnosed;16.888888888888886;-13275.551010031919
2663;Relapse cases: extrapulmonary;16.888888888888886;-13355.804103971741
2664;Relapse cases: Pulmonary, bacteriologically confirmed;16.0;-12176.337526576765
2665;Retreatment cases: treatment after default (pulmonary smear and/or culture positive);14.222222222222229;-8132.234141258199
2666;Retreatment cases: treatment after failure (pulmonary smear and/or culture positive);14.222222222222229;-8145.637190617234
2667;Confirmed cases of RR-/MDR-TB;13.777777777777771;-3561.6466901182625
2668;Second-line drug susceptibility testing (DST) available;0.0;
2669;Tuberculosis - new and relapse cases;13.777777777777771;-14.232780572872512
2670;Total fertility rate (per woman)-nan;59.11111111111111;0
2671;Total fertility rate (per woman)-None;59.11111111111111;0.48026139184595174
2672;Total fertility rate (per woman)-Primary;59.11111111111111;0.4902457392684427
2673;Total fertility rate (per woman)-Secondary or higher;59.11111111111111;0.5032425184838321
2674;Total fertility rate (per woman);59.11111111111111;-24181.319437904236
2675;Deaths attributable to the environment;13.777777777777771;-25063.86596413923
2676;Total environment  attributable DALYs per 100'000 children under 5 years;0.0;
2677;Deaths attributable to the environment in children under 5 years (%);0.0;
2678;DALYs attributable to the environment in children under 5 years (%);0.0;
2679;Age-standardized deaths attributable to the environment (per 100 000 population);13.777777777777771;-25063.86596413923
2680;Disability-adjusted life years (DALYs) attributable to the environment;13.777777777777771;-25063.86596413923
2681;Age-standardized DALYs attributable to the environment (per 100 000 population);13.777777777777771;-25063.86596413923
2682;Deaths attributable to the environment (%);13.777777777777771;-25063.977869493858
2683;Disability-adjusted life years (DALYs) attributable to the environment (%);13.777777777777771;-25063.988932862438
2684;Total environment attributable deaths ('000) in children under 5 years;0.0;
2685;Total environment  attributable deaths per 100'000 children under 5 years;0.0;
2686;Total environment attributable DALYs ('000) in children under 5 years;0.0;
2687;Under-five mortality rate (deaths per 1000 live births);59.11111111111111;-24195.263693651563
2688;Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%);13.777777777777771;-25041.075334894664
2689;Compliance with international health regulations;14.222222222222229;-15324.907731390273
2690;UHC Service Coverage Index (SDG 3.8.1);13.777777777777771;-13410.717769536144
2691;UHC Service Coverage sub-index on service capacity and access;13.777777777777771;-13410.99832096289
2692;UHC Service Coverage sub-index on infectious diseases;13.777777777777771;-13410.723772268484
2693;UHC Service Coverage sub-index on noncommunicable diseases;13.777777777777771;-13410.718124996238
2694;UHC Service Coverage sub-index on reproductive, maternal, newborn and child health;13.777777777777771;-13410.717769536144
2695;Children aged <5 years with diarrhoea receiving ORS (%);45.77777777777777;-22742.626320217754
2696;Women age 15-49 years who received a health check within 2 days after delivery of their most recent live birth in the last 2 years (%);62.22222222222222;-25919.8939650439
2697;Proportion of newborns who have postnatal contact with a health provider within 2 days of delivery (%);64.88888888888889;-26212.535647107354
2698;UV radiation;15.111111111111114;-25081.804974569757
2699;UV radiation attributable deaths;15.555555555555557;-25092.921661149212
2700;UV radiation attributable DALYs ('000);0.0;
2701;UV radiation attributable deaths per 100'000 capita;0.0;
2702;UV radiation attributable DALYs per 100'000 capita;0.0;
2703;Lifetime prevalence of child emotional abuse (%);0.0;
2704;Lifetime prevalence of child physical neglect (%);0.0;
2705;Lifetime prevalence of child physical abuse (%);0.0;
2706;Lifetime prevalence of child sexual abuse (%);0.0;
2707;Extent of implementation of  mental health services for victims of all types of violence;0.0;
2708;Child maltreatment: Extent of implementation of home-visiting programmes;0.0;
2709;Extent of implementation of child protection services;0.0;
2710;Elder abuse: Extent of implementation  of caregiver-support programmes;0.0;
2711;Intimate partner violence: Extent of implementation  of dating violence prevention programmes;0.0;
2712;Extent of implementation of medico-legal services for victims of sexual violence;0.0;
2713;Youth violence: Extent of implementation of life-skills and social development programmes;0.0;
2714;Estimates of number of homicides;18.66666666666667;-70.5442531229003
2715;Estimates of rates of homicides per 100 000 population;18.66666666666667;-70.5446085829929
2716;Children aged 6-59 months who received vitamin A supplementation (%);61.333333333333336;-23870.136154778524
2717;Warning about the dangers of tobacco;13.333333333333329;-11526.710623731426
2718;Law mandates that health warnings appear on tobacco packages;0.0;
2719;Law mandates that health warnings appear on other smoked tobacco packages;0.0;
2720;Law mandates that health warnings appear on smokeless tobacco packages;0.0;
2721;Do the health warnings on cigarette packaging include a photograph or graphic?;0.0;
2722;Do the health warnings on other smoked tobacco packaging include a photograph or graphic?;0.0;
2723;Do the health warnings on smokeless tobacco packaging include a photograph or graphic?;0.0;
2724;Do health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale?;0.0;
2725;Do health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale?;0.0;
2726;Do health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale?;0.0;
2727;Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2728;Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2729;Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2730;Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry;0.0;
2731;Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry;0.0;
2732;Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry;0.0;
2733;Do health warnings on cigarette packaging describe the harmful effects of tobacco use on health?;0.0;
2734;Do health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health?;0.0;
2735;Do health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health?;0.0;
2736;Does the law mandate specific health warnings on cigarette packaging?;0.0;
2737;Does the law mandate specific health warnings on other smoked tobacco packaging?;0.0;
2738;Does the law mandate specific health warnings on smokeless tobacco packaging?;0.0;
2739;How many health warnings are approved by the law for cigarette packaging?;30.666666666666657;-15512.716761576547
2740;How many health warnings are approved by the law for other smoked tobacco packaging?;28.0;-16865.19082586026
2741;How many health warnings are approved by the law for smokeless tobacco packaging?;46.22222222222222;-19020.56090732079
2742;Health warnings on cigarette packaging law requires or establishes fines for violations;0.0;
2743;Health warnings on other smoked tobacco packaging law requires or establishes fines for violations;0.0;
2744;Health warnings on smokeless tobacco packaging law requires or establishes fines for violations;0.0;
2745;Ban on deceitful terms on cigarette packaging;0.0;
2746;Ban on deceitful terms on other smoked tobacco packaging;0.0;
2747;Ban on deceitful terms on smokeless tobacco packaging;0.0;
2748;Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2749;Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2750;Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2751;Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging;27.555555555555557;-16029.747757757625
2752;Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging;31.111111111111114;-17222.899996256685
2753;Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging;42.22222222222223;-19097.028831219028
2754;Cigarette packaging and labelling must not use descriptors depicting flavours;0.0;
2755;Other smoked tobacco packaging and labelling must not use descriptors depicting flavours;0.0;
2756;Smokeless tobacco packaging and labelling must not use descriptors depicting flavours;0.0;
2757;Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2758;Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2759;Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2760;Cigarette packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2761;Other smoked tobacco packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2762;Smokeless tobacco packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2763;Cigarette packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-27792.396890169126
2764;Other smoked tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-27792.396890169126
2765;Smokeless tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-27792.396890169126
2766;Cigarette packaging and labelling must not display expiry dates;0.0;
2767;Other smoked tobacco packaging and labelling must not display expiry dates;0.0;
2768;Smokeless tobacco packaging and labelling must not display expiry dates;0.0;
2769;The quit line number must appear on cigarette packaging or labelling;0.0;
2770;The quit line number must appear on other smoked tobacco packaging or labelling;0.0;
2771;The quit line number must appear on smokeless tobacco packaging or labelling;0.0;
2772;Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2773;Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2774;Congenital Rubella Syndrome - number of reported cases;15.111111111111114;-4313.704206510214
2775;Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2776;The sale of all smokeless tobacco products is completely banned;0.0;
2777;Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging;29.777777777777786;-16368.294629961447
2778;Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging;32.888888888888886;-17515.46257935255
2779;Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging;44.44444444444444;-19528.015126017413
2780;Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging;29.777777777777786;-16368.24306680191
2781;Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging;32.888888888888886;-17515.41446665637
2782;Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging;44.44444444444444;-19528.000322937736
2783;Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package;0.0;
2784;Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package;0.0;
2785;Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package;0.0;
2786;Does the law mandate font style, font size and colour of health warnings on cigarette packaging?;0.0;
2787;Does the law mandate font style, font size and colour of health warnings on other smoked tobacco packaging?;0.0;
2788;Does the law mandate font style, font size and colour of health warnings on smokeless tobacco packaging?;0.0;
2789;Are the health warnings on cigarette packaging rotating?;0.0;
2790;Are the health warnings on other smoked tobacco packaging rotating?;0.0;
2791;Are the health warnings on smokeless tobacco packaging rotating?;0.0;
2792;Are the health warnings on cigarette packaging written in the principal language(s) of the country?;0.0;
2793;Are the health warnings on other smoked tobacco packaging written in the principal language(s) of the country?;0.0;
2794;Are the health warnings on smokeless tobacco packaging written in the principal language(s) of the country?;0.0;
2795;Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2796;Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2797;Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2798;Wasting prevalence in children aged < 5 years (%);54.22222222222222;-23826.766535990773
2799;Life expectancy at birth (years)-Female;18.66666666666667;1.4060101500642919
2800;Life expectancy at birth (years)-Male;18.66666666666667;1.4063656101568869
2801;Life expectancy at birth (years)-Both sexes;18.66666666666667;1.4063656101568869
2802;Life expectancy at birth (years);18.66666666666667;-18131.46746270506
2803;Healthy life expectancy (HALE) at birth (years)-Female;18.66666666666667;1.4063656101568869
2804;Healthy life expectancy (HALE) at birth (years)-Both sexes;18.66666666666667;1.4063656101568869
2805;Healthy life expectancy (HALE) at birth (years)-Male;18.66666666666667;1.4063656101568869
2806;Healthy life expectancy (HALE) at birth (years);18.66666666666667;-18131.467818165154
2807;Adult mortality rate (probability of dying between 15 and 60 years per 1000 population);18.66666666666667;-997.0320471726674
2808;Infants exclusively breastfed for the first six months of life (%);40.0;-21114.81769057201
2809;Healthy life expectancy (HALE) at age 60 (years)-Both sexes;18.66666666666667;1.4056546899716968
2810;Healthy life expectancy (HALE) at age 60 (years)-Female;18.66666666666667;1.4056546899716968
2811;Healthy life expectancy (HALE) at age 60 (years)-Male;18.66666666666667;1.4063656101568869
2812;Healthy life expectancy (HALE) at age 60 (years);18.66666666666667;-18131.46746270506
2813;Life expectancy at age 60 (years)-Male;18.66666666666667;1.4063656101568869
2814;Life expectancy at age 60 (years)-Female;18.66666666666667;1.4063656101568869
2815;Life expectancy at age 60 (years)-Both sexes;18.66666666666667;1.4063656101568869
2816;Life expectancy at age 60 (years);18.66666666666667;-18131.46746270506
2817;Preterm birth rate (per 100 live births);18.66666666666667;-25213.441409488045
2818;Civil registration coverage of cause-of-death (%);47.111111111111114;-23856.72307778257
2819;Ill-defined causes in cause-of-death registration (%);49.33333333333333;-26213.64917830518
2820;Distribution of years of life lost by major cause group;23.555555555555557;-22989.78997527377
2821;Age-standardized NCD mortality rate  (per 100 000 population);18.66666666666667;-70.5442531229003
2822;Deaths due to HIV/AIDS (per 100 000 population);57.33333333333333;-25209.57949491094
2823;Deaths due to malaria (per 100 000 population);0.0;
2824;Age-standardized mortality rate by cause (per 100 000 population) - Cancer;0.0;
2825;Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular;0.0;
2826;Distribution of years of life lost by broader causes (%) - Injuries;0.0;
2827;Diphtheria - number of reported cases;13.333333333333329;-835.2591058760856
2828;Japanese encephalitis - number of reported cases;24.8888888888889;-13172.356418735228
2829;Pertussis - number of reported cases;13.333333333333329;-702.4738243886196
2830;Number of new leprosy cases;13.777777777777771;-6943.754788319631
2831;Total tetanus - number of reported cases;13.333333333333329;-771.1430448925678
2832;Poliomyelitis - number of reported cases;13.777777777777771;-361.5514340143724
2833;Yellow fever - number of reported cases;14.222222222222229;-2531.430976674807
2834;Number of reported cases of tuberculosis;0.0;
2835;Mumps - number of reported cases;19.111111111111114;-3822.7315879457697
2836;Neonatal tetanus - number of reported cases;13.333333333333329;-492.88389587564603
2837;Rubella - number of reported cases;13.333333333333329;-874.6398950451759
2838;Measles - number of reported cases;13.333333333333329;-81.44340203585814
2839;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-Primary-nan;45.333333333333336;0
2840;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-Secondary or higher-nan;45.333333333333336;0
2841;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-None-nan;45.333333333333336;0
2842;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%);45.333333333333336;-22453.367047982185
2843;Children aged <5 years with diarrhoea receiving ORT (%);54.22222222222222;-25031.152540861338
2844;Children aged <5 years with ARI symptoms who took antibiotic treatment (%);61.333333333333336;-25945.31397147918
2845;Antenatal care coverage - at least one visit (%);29.33333333333333;-25531.385924732087
2846;Antenatal care coverage - at least one visit, among girls aged 15-19 (%);62.666666666666664;-26551.81466549931
2847;Births by caesarean section (%);23.555555555555557;-25357.683388305457
2848;Hepatitis B (HepB3) immunization coverage among 1-year-olds (%);15.555555555555557;-546.1008471070022
2849;Children aged 6-59 months who received vitamin A supplementation (%);61.333333333333336;-23870.136154778524
2850;Neonates protected at birth against neonatal tetanus (PAB) (%);52.88888888888889;-5300.434483845158
2851;Hib (Hib3) immunization coverage among 1-year-olds (%);14.666666666666657;-1845.3606643654332
2852;Antenatal care coverage - at least four visits (%);29.33333333333333;-18437.197832189388
2853;BCG immunization coverage among 1-year-olds (%);27.111111111111114;-742.7355282510587
2854;Population using solid fuels (%);50.22222222222222;-26188.563725043645
2855;Radiotherapy units (per 1 000 000 population);0.0;
2856;Median availability of selected generic medicines (%) - Private;83.11111111111111;-27247.814438419893
2857;Hospital beds (per 10 000 population);20.888888888888886;-8114.51229839559
2858;Median consumer price ratio of selected generic medicines - Private;85.77777777777777;-27338.556965415682
2859;Anti-tobacco mass media campaigns;13.333333333333329;-15447.24980324637
2860;SDG 3.9.2 WASH deaths;18.66666666666667;-25222.59910103469
2861;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-All age groups (total)-Both sexes;18.66666666666667;0.34427392031870685
2862;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-All age groups (total)-Male;18.66666666666667;0.34427392031870685
2863;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-All age groups (total)-Female;18.66666666666667;0.34427392031870685
2864;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-<5 years-Both sexes;18.66666666666667;0.27134813419886417
2865;Number of diarrhoea deaths from inadequate water, sanitation and hygiene;18.66666666666667;-25222.59910103469
2866;Number of diarrhoea deaths from inadequate hygiene-All age groups (total)-Both sexes;18.66666666666667;0.34427392031870685
2867;Number of diarrhoea deaths from inadequate hygiene-All age groups (total)-Male;18.66666666666667;0.34427392031870685
2868;Number of diarrhoea deaths from inadequate hygiene-All age groups (total)-Female;18.66666666666667;0.34427392031870685
2869;Number of diarrhoea deaths from inadequate hygiene-<5 years-Both sexes;18.66666666666667;0.2567097253664343
2870;Number of diarrhoea deaths from inadequate hygiene;18.66666666666667;-25222.59910103469
2871;Number of diarrhoea deaths from inadequate sanitation-All age groups (total)-Both sexes;41.333333333333336;0.2519893341312436
2872;Number of diarrhoea deaths from inadequate sanitation-All age groups (total)-Male;41.333333333333336;0.2519893341312436
2873;Number of diarrhoea deaths from inadequate sanitation-All age groups (total)-Female;41.333333333333336;0.2519893341312436
2874;Number of diarrhoea deaths from inadequate sanitation-<5 years-Both sexes;41.333333333333336;0.22135560533506649
2875;Number of diarrhoea deaths from inadequate sanitation;41.333333333333336;-25916.498065523527
2876;Number of diarrhoea deaths from inadequate water-All age groups (total)-Both sexes;41.333333333333336;0.2519893341312436
2877;Number of diarrhoea deaths from inadequate water-All age groups (total)-Female;41.333333333333336;0.2519893341312436
2878;Number of diarrhoea deaths from inadequate water-All age groups (total)-Male;41.333333333333336;0.2519893341312436
2879;Number of diarrhoea deaths from inadequate water-<5 years-Both sexes;41.333333333333336;0.23053179457834183
2880;Number of diarrhoea deaths from inadequate water;41.333333333333336;-25916.498065523527
2881;Water, sanitation and hygiene attributable deaths ('000) in children under 5 years;0.0;
2882;Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene-All age groups (total);18.66666666666667;0.25060777628948205
2883;Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene;18.66666666666667;-25222.69276717872
2884;Attributable fraction of diarrhoea to inadequate hygiene-All age groups (total);18.66666666666667;0.17594264476729116
2885;Attributable fraction of diarrhoea to inadequate hygiene;18.66666666666667;-25222.767432310244
2886;Attributable fraction of diarrhoea to inadequate sanitation-All age groups (total);41.333333333333336;0.20643250792376922
2887;Attributable fraction of diarrhoea to inadequate sanitation;41.333333333333336;-25916.543622349727
2888;Attributable fraction of diarrhoea to inadequate water-All age groups (total);41.333333333333336;0.1997584276036175
2889;Attributable fraction of diarrhoea to inadequate water;41.333333333333336;-25916.550296430047
2890;Water, sanitation and hygiene attributable deaths per 100'000 capita;0.0;
2891;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-All age groups (total)-Both sexes;18.66666666666667;0.34427392031870685
2892;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-All age groups (total)-Female;18.66666666666667;0.34427392031870685
2893;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-All age groups (total)-Male;18.66666666666667;0.34427392031870685
2894;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-<5 years-Both sexes;18.66666666666667;0.34427392031870685
2895;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene;18.66666666666667;-25222.59910103469
2896;Number of diarrhoea DALYs from inadequate hygiene-All age groups (total)-Female;18.66666666666667;0.34427392031870685
2897;Number of diarrhoea DALYs from inadequate hygiene-All age groups (total)-Male;18.66666666666667;0.34427392031870685
2898;Number of diarrhoea DALYs from inadequate hygiene-All age groups (total)-Both sexes;18.66666666666667;0.34427392031870685
2899;Number of diarrhoea DALYs from inadequate hygiene-<5 years-Both sexes;18.66666666666667;0.34427392031870685
2900;Number of diarrhoea DALYs from inadequate hygiene;18.66666666666667;-25222.59910103469
2901;Number of diarrhoea DALYs from inadequate sanitation-All age groups (total)-Male;41.333333333333336;0.2519893341312436
2902;Number of diarrhoea DALYs from inadequate sanitation-All age groups (total)-Female;41.333333333333336;0.2519893341312436
2903;Number of diarrhoea DALYs from inadequate sanitation-All age groups (total)-Both sexes;41.333333333333336;0.2519893341312436
2904;Number of diarrhoea DALYs from inadequate sanitation-<5 years-Both sexes;41.333333333333336;0.2519893341312436
2905;Number of diarrhoea DALYs from inadequate sanitation;41.333333333333336;-25916.498065523527
2906;Number of diarrhoea DALYs from inadequate water-All age groups (total)-Both sexes;41.333333333333336;0.2519893341312436
2907;Number of diarrhoea DALYs from inadequate water-All age groups (total)-Male;41.333333333333336;0.2519893341312436
2908;Number of diarrhoea DALYs from inadequate water-All age groups (total)-Female;41.333333333333336;0.2519893341312436
2909;Number of diarrhoea DALYs from inadequate water-<5 years-Both sexes;41.333333333333336;0.2519893341312436
2910;Number of diarrhoea DALYs from inadequate water;41.333333333333336;-25916.498065523527
2911;Water, sanitation and hygiene  attributable deaths per 100'000 children under 5 years;0.0;
2912;Water, sanitation and hygiene attributable DALYs ('000);0.0;
2913;Water, sanitation and hygiene attributable DALYs ('000) in children under 5 years;0.0;
2914;Water, sanitation and hygiene attributable DALYs per 100'000 capita;0.0;
2915;Water, sanitation and hygiene  attributable DALYs per 100'000 children under 5 years;0.0;
2916;Population with basic handwashing facilities at home (%);53.77777777777778;-13128.191219808974
2917;Population practising open defecation (%);12.8888888888889;-3.1348323221515333
2918;Population using safely managed sanitation services (%);41.77777777777778;-2855.866645937206
2919;Population using safely managed drinking-water services (%);41.77777777777778;-2860.0234829481305
2920;General availability of Angiotensin II receptor blockers (ARBs) in the public health sector;0.0;
2921;Legislation and Financing;14.222222222222229;-22855.767212622093
2922;Early initiation of breastfeeding (in the two years preceding the survey) (%);48.88888888888889;-22965.11498159118
2923;Cheapest brand of cigarettes - price in PPP$;26.66666666666667;-27807.40911192029
2924;Sources of assistive products (%);90.22222222222223;-27792.92000414784
2925;Number of indigenous P. falciparum malaria cases;58.666666666666664;-17604.419674757268
2926;Cytisine - legally sold;13.333333333333329;-25030.246882514955
2927;Households further impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%);85.77777777777777;-24700.691306733803
2928;Radiation Emergencies;14.222222222222229;-22855.844880194203
2929;Population with primary reliance on fuels and technologies)for cooking, by fuel type (in millions);42.22222222222223;-2602.815427712082
2930;Prevalence of current cigarette smoking among adolescents (%)-Both sexes;20.0;0.0
2931;Prevalence of current cigarette smoking among adolescents (%)-Female;20.0;0.0
2932;Prevalence of current cigarette smoking among adolescents (%)-Male;20.0;0.0
2933;Prevalence of current cigarette smoking among adolescents (%);20.0;-27807.40911192029
2934;Number of imported malaria cases;74.22222222222223;-22477.327706093303
2935;Reported use of earmarked tobacco taxes;0.0;
2936;Zoonotic Events and the Human-animal Interface;14.222222222222229;-22855.863942630647
2937;Human Resources (SPAR);14.222222222222229;-22855.86157813545
2938;Population with primary reliance on polluting fuels and technologies for cooking (in millions);15.555555555555557;-6.025745786054827
2939;Surveillance (SPAR);14.222222222222229;-22855.826100144284
2940;Population with access to an insecticide-treated bed net (ITN) for malaria protection (%), modelled;82.22222222222223;-26594.632890627472
2941;Prevalence of current smokeless tobacco use among adults (%)-Male;43.111111111111114;0.19224176215307498
2942;Prevalence of current smokeless tobacco use among adults (%)-Female;43.111111111111114;0.17747238287907585
2943;Prevalence of current smokeless tobacco use among adults (%)-Both sexes;43.111111111111114;0.18985468800634742
2944;Prevalence of current smokeless tobacco use among adults (%);43.111111111111114;-25978.16771791228
2945;Name of latest youth prevalence survey (nonsmoked);0.0;
2946;Reference level for dwellings (Bq/m3);99.55555555555556;-27792.92000414784
2947;Care-seeking by type of patient and source of care (%);0.0;
2948;Compliance with ban on promotional discounts (score);56.888888888888886;-26416.74838278085
2949;Representation of latest adult prevalence survey (nonsmoked);0.0;
2950;Year of latest youth prevalence survey (nonsmoked);0.0;
2951;Compliance with ban on appearance of tobacco products in TV and/or films (score);82.22222222222223;-27237.733229835154
2952;Total population pushed  further below the $3.20 a day poverty line by household health expenditures (millions);0.0;
2953;Compliance with smoke-free health-care facilities law (score);49.33333333333333;-26182.9165544304
2954;Existence of national reference level for workplaces;0.0;
2955;Estimated number of malaria deaths;52.44444444444444;-5032.82450477708
2956;Population pushed further below the $3.20 a day poverty line by household health expenditures (%);36.44444444444444;-19239.474087135175
2957;Most sold brand of cigarettes - price in PPP$;16.0;-14348.056561806628
2958;Compliance with smoke-free government facilities law (score);57.33333333333333;-26434.50019489005
2959;Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2960;Estimated malaria incidence (per 1000 population at risk);52.44444444444444;-5194.920988571125
2961;Risk Communication (SPAR);14.222222222222229;-22855.856819773686
2962;Ban on tobacco vending machines;0.0;
2963;Subnational bans on tobacco advertising, promotion and sponsorship authority exists;0.0;
2964;Workforce availability for assistive technology;0.0;
2965;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-15-19  years-Female;52.44444444444444;0.10833425120432327
2966;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-35-39 years-Female;52.44444444444444;0.12019894189735503
2967;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-20-24 years-Female;52.44444444444444;0.1151663375505052
2968;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-25-29 years-Female;52.44444444444444;0.12316635190857372
2969;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-45-49 years-Female;52.44444444444444;0.119488021712165
2970;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-15-49 years-Female;52.44444444444444;0.14191875861791647
2971;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-30-34 years-Female;52.44444444444444;0.11674235704056901
2972;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-40-44 years-Female;52.44444444444444;0.11828747524367156
2973;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-18-49 years-Female;52.44444444444444;0.0440575515781072
2974;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-15-24 years-Female;52.44444444444444;0.00779050669409731
2975;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-15-44 years-Female;52.44444444444444;0.0016833939391887043
2976;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-18-24 years-Female;52.44444444444444;0.0035383741856600537
2977;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-30-39 years-Female;52.44444444444444;0.006774037690540524
2978;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-40-49 years-Female;52.44444444444444;0.006774037690540524
2979;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-30-35 years-Female;52.44444444444444;0.001683393939186928
2980;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-18-19 years-Female;52.44444444444444;0.002376565029750921
2981;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-18-50-Female;52.44444444444444;0.0020211049371559042
2982;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-35-44 years-Female;52.44444444444444;0.002376565029750921
2983;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-45-59 years-Female;52.44444444444444;0.002376565029750921
2984;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-25-34 years-Female;52.44444444444444;0.002376565029750921
2985;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-20-29 years-Female;52.44444444444444;0.002376565029750921
2986;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months;52.44444444444444;-26279.200227739486
2987;Proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis;88.88888888888889;-27254.388073068483
2988;General availability of bone marrow transplantation in the public health system;0.0;
2989;Reference level for buildings with high public occupancy (Bq/m3);99.55555555555556;-27792.92000414784
2990;Points of Entry (SPAR);14.222222222222229;-22855.79547899629
2991;Age range of latest adult prevalence survey (nonsmoked);0.0;
2992;Reporting countries;0.0;
2993;Cheapest brand of cigarettes - price in currency reported;24.0;-27807.40911192029
2994;Prevalence of daily smokeless tobacco use among adolescents (%)-Male;99.55555555555556;0.0
2995;Prevalence of daily smokeless tobacco use among adolescents (%)-Female;99.55555555555556;0.0
2996;Prevalence of daily smokeless tobacco use among adolescents (%);99.55555555555556;-27807.40911192029
2997;Availability of education/training for assistive technology;0.0;
2998;Overall compliance with bans on promotion and sponsorship (score);40.0;-25889.19579200252
2999;Existence of financial mechanisms for assistive technology;0.0;
3000;Existence of any subnational radon activity;0.0;
3001;Contraceptive prevalence - use of modern methods (%)-15-19 years-nan;50.666666666666664;0
3002;Contraceptive prevalence - use of modern methods (%)-20-49 years-nan;50.666666666666664;0
3003;Contraceptive prevalence - use of modern methods (%);50.666666666666664;-23143.99295931348
3004;Mean HDL cholesterol, age-standardized-Male;15.111111111111114;1.0848324167801104
3005;Mean HDL cholesterol, age-standardized-Female;15.111111111111114;1.2988416965739136
3006;Mean HDL cholesterol, age-standardized-Both sexes;15.111111111111114;1.185403090807191
3007;Mean HDL cholesterol, age-standardized;15.111111111111114;-99.98516313279873
3008;Overall compliance with bans on direct advertising (score);37.33333333333333;-25811.803012946533
3009;Representativeness of most recent survey of adults;0.0;
3010;IHR Coordination and National IHR Focal Point Functions;14.222222222222229;-22855.808069963234
3011;Number of malaria suspects examined by microscopy;55.55555555555556;-16163.053524818451
3012;Estimated number of malaria cases;52.44444444444444;-5031.976375285617
3013;Compliance with smoke-free indoor offices law (score);67.55555555555556;-26763.079219297804
3014;Chemical Events;14.222222222222229;-22855.8461766478
3015;Prevalence of current e-cigarette use among adults (%)-Both sexes;82.66666666666666;0.0683144119738941
3016;Prevalence of current e-cigarette use among adults (%)-Male;82.66666666666666;0.05230387968189287
3017;Prevalence of current e-cigarette use among adults (%)-Female;82.66666666666666;0.051458793305994455
3018;Prevalence of current e-cigarette use among adults (%);82.66666666666666;-27249.888551585285
3019;Population pushed further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);36.0;-18767.373763303898
3020;Laboratory (SPAR);14.222222222222229;-22855.784684924314
3021;Number of suspected malaria cases;55.55555555555556;-15653.964039979674
3022;Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in their lifetime;32.888888888888886;-25647.816872140564
3023;National Health Emergency Framework;14.222222222222229;-22855.765370410623
3024;Cytisine - place available;13.333333333333329;-25030.246882514955
3025;BCG immunization coverage among one-year-olds (%);52.44444444444444;-23241.373091410762
3026;Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months;30.666666666666657;-25575.40577189563
3027;Status of indigenous malaria cases;0.0;
3028;Publication year of the policy or plan (latest revision);0.0;
3029;Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population;56.44444444444445;-26402.61868037172
3030;Number of indigenous P. vivax malaria cases;69.77777777777777;-20513.741528513914
3031;Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA), median (%);62.22222222222222;-25466.926829712902
3032;Proportion of vaccination cards seen (%);45.77777777777777;-26031.478247617375
3033;Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefixime reported to WHO-GASP;70.66666666666667;-23409.36726315783
3034;Number of indigenous malaria cases;55.55555555555556;-15153.77501346359
3035;Inclusion of radon education for building professionals;0.0;
3036;Existence of initiatives/collaborations on assistive technology;0.0;
3037;Number of confirmed malaria cases;56.0;-15284.322783374517
3038;Compliance with ban on indentifying non-tobacco products with tobacco brand names (score);71.55555555555556;-26895.958205791852
3039;Prevalence of anaemia in non-pregnant women (aged 15-49) (%)-nan;13.333333333333329;0
3040;Satisfaction with assistive products for different environments and activities (%);90.22222222222223;-27792.92000414784
3041;Compliance with ban on advertising at point of sale (score);63.111111111111114;-26613.001802670096
3042;Number of malaria suspects examined by rapid diagnostic test (RDT);60.44444444444444;-18632.099717715093
3043;Underweight prevalence in children aged < 5 years (%);54.22222222222222;-23826.766535990773
3044;Care-seeking by type of patient and source of care (%) (see CARE_SOURCE);0.0;
3045;Status of endemicity of buruli ulcder;0.0;
3046;Compliance with smoke-free restaurants law (score);69.33333333333334;-26810.4678112264
3047;Estimate of current tobacco smoking prevalence (%)-Both sexes;27.111111111111114;1.5955046986236052
3048;Estimate of current tobacco smoking prevalence (%)-Male;27.111111111111114;1.6460471755299722
3049;Estimate of current tobacco smoking prevalence (%)-Female;27.111111111111114;1.4927356528012474
3050;Estimate of current tobacco smoking prevalence (%);27.111111111111114;-15296.014932474267
3051;Mean total cholesterol,  crude;15.111111111111114;-98.95380734125061
3052;Households impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%);85.77777777777777;-24700.7037254969
3053;Authorization/accreditation required for official radon measurement providers;0.0;
3054;Prevalence of daily smokeless tobacco use among adults (%)-Male;64.88888888888889;0.1267609872054054
3055;Prevalence of daily smokeless tobacco use among adults (%)-Both sexes;64.88888888888889;0.1339224588863157
3056;Prevalence of daily smokeless tobacco use among adults (%)-Female;64.88888888888889;0.11809348215480231
3057;Prevalence of daily smokeless tobacco use among adults (%);64.88888888888889;-26665.123946945554
3058;Ban on Corporate Social Responsibility activities (CSR);0.0;
3059;One-year-old children who have not received any doses of the DTP vaccine (%);51.55555555555556;-23121.580857260382
3060;Satisfaction with assistive products and related services (%);90.22222222222223;-27792.92000414784
3061;Barriers to accessing assistive products (%);90.22222222222223;-27792.92000414784
3062;Compliance with ban on billboard and outdoor advertising (score);40.888888888888886;-25923.709621386464
3063;Prevalence of anaemia in women of reproductive age (aged 15-49) (%)-nan;13.333333333333329;0
3064;Reported number of tests performed where results were received by a person (testing volume);56.0;-26388.524954265973
3065;Compliance with ban on advertising in local magazines and newspapers (score);41.77777777777778;-25940.463919768496
3066;Age range of most recent adolescent survey;0.0;
3067;Mean HDL cholesterol, crude-Male;15.111111111111114;1.0998707324039145
3068;Mean HDL cholesterol, crude-Female;15.111111111111114;1.3009289529886763
3069;Mean HDL cholesterol, crude-Both sexes;15.111111111111114;1.1919214858617941
3070;Mean HDL cholesterol, crude;15.111111111111114;-99.9792470520504
3071;Compliance with smoke-free education facilities except universities law (score);47.111111111111114;-26115.548430612504
3072;Title of most recent survey of adults;0.0;
3073;Existence of national radon map;0.0;
3074;Total population pushed   further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions);0.0;
3075;Travel distance to obtain assistive products (%);90.22222222222223;-27792.92000414784
3076;Institutional Births (birth taken place in a facility) (%);22.66666666666667;-11741.668594331932
3077;Population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);35.55555555555556;-18696.264948808403
3078;Women of reproductive age (15−49 years) who are married or in-union who have their need for family planning satisfied with modern methods (%), UNPD;18.222222222222214;-53.8054273537513
3079;Number of women of reproductive age (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
3080;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Both sexes;26.66666666666667;0.0
3081;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Male;26.66666666666667;0.0
3082;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Female;26.66666666666667;0.0
3083;Estimate of current cigarette smoking prevalence (%) (age-standardized rate);26.66666666666667;-27807.40911192029
3084;Proportion of bloodstream infection due Escherichia coli resistant to 3rd-generation cephalosporin, median (%);61.77777777777778;-25338.582102282035
3085;Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%)-15-49 years-Female;40.888888888888886;0.774588006549366
3086;Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%);40.888888888888886;-22032.90835070001
3087;Compliance with ban on free distribution in mail or through other means (score);50.22222222222222;-26215.60791075092
3088;Prevalence of daily tobacco smoking among adolescents (%)-Male;96.44444444444444;0.0
3089;Prevalence of daily tobacco smoking among adolescents (%)-Both sexes;96.44444444444444;0.0
3090;Prevalence of daily tobacco smoking among adolescents (%)-Female;96.44444444444444;0.0
3091;Prevalence of daily tobacco smoking among adolescents (%);96.44444444444444;-27807.40911192029
3092;Low birth weight (in thousands);35.111111111111114;-4249.780034616093
3093;Low birth weight, prevalence (%);35.111111111111114;-4250.442302221321
3094;Prevalence of need of assistive products (%)-70-79 years-nan;90.22222222222223;0
3095;Prevalence of need of assistive products (%)-80+ years-nan;90.22222222222223;0
3096;Prevalence of need of assistive products (%)-0-4 years-nan;90.22222222222223;0
3097;Prevalence of need of assistive products (%)-5-17 years-nan;90.22222222222223;0
3098;Prevalence of need of assistive products (%)-18-29 years-nan;90.22222222222223;0
3099;Prevalence of need of assistive products (%)-30-39  years-nan;90.22222222222223;0
3100;Prevalence of need of assistive products (%)-40-49  years-nan;90.22222222222223;0
3101;Prevalence of need of assistive products (%)-50-59  years-nan;90.22222222222223;0
3102;Prevalence of need of assistive products (%)-60-69  years-nan;90.22222222222223;0
3103;Prevalence of need of assistive products (%)-All age groups (total)-nan;90.22222222222223;0
3104;Prevalence of need of assistive products (%);90.22222222222223;-27792.92000414784
3105;Existence of national policy instruments for occupational health and safety for health workers;0.0;
3106;Total population pushed further below the $1.90 a day poverty line by household health expenditures (%);0.0;
3107;Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions);0.0;
3108;Number of surveillance sites reporting to GLASS: In- and outpatient facilities;0.0;
3109;Total population pushed  further  below the $3.20 a day poverty line by household health expenditures (%);0.0;
3110;Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month-1-14 years;62.22222222222222;0.10709501358097562
3111;Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month-2-14 years;62.22222222222222;0.05484451435931259
3112;Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month-nan;62.22222222222222;0
3113;Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month;62.22222222222222;-26572.610496373076
3114;Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP;60.888888888888886;-20772.828286416137
3115;Process evaluation was employed to assess implementation of the campaign;0.0;
3116;Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP;61.77777777777778;-20576.11986187396
3117;Number of malaria cases treated with artemisinin-based combination therapies (ACTs);62.666666666666664;-25640.314539279105
3118;Number of children aged 6–59 months with anaemia (thousands)-nan;13.333333333333329;0
3119;Number of reported cases of poliomyelitis by wild poliovirus (WPV);18.66666666666667;-18170.215393704697
3120;Prevalence of current tobacco smoking among adults (%)-Male;36.44444444444444;0.25622859804702536
3121;Prevalence of current tobacco smoking among adults (%)-Female;36.44444444444444;0.24502813050634487
3122;Prevalence of current tobacco smoking among adults (%)-Both sexes;36.44444444444444;0.22913197414093922
3123;Prevalence of current tobacco smoking among adults (%);36.44444444444444;-25782.18814823012
3124;Number of malaria positive cases by microscopy;56.0;-15838.947048710928
3125;Prevalence of current smokeless tobacco use among adolescents (%)-Male;44.888888888888886;0.0
3126;Prevalence of current smokeless tobacco use among adolescents (%)-Both sexes;44.888888888888886;0.0
3127;Prevalence of current smokeless tobacco use among adolescents (%)-Female;44.888888888888886;0.0
3128;Prevalence of current smokeless tobacco use among adolescents (%);44.888888888888886;-27807.40911192029
3129;Compliance with smoke-free pubs and bars law (score);71.55555555555556;-26883.99451931205
3130;Prevalence of current cigarette smoking among adults (%)-Male;58.22222222222222;0.17095041073054595
3131;Prevalence of current cigarette smoking among adults (%)-Female;58.22222222222222;0.15910381057883072
3132;Prevalence of current cigarette smoking among adults (%)-Both sexes;58.22222222222222;0.11858775193408189
3133;Prevalence of current cigarette smoking among adults (%);58.22222222222222;-26440.69642748113
3134;Girls aged 15 years old that received the recommended doses of HPV vaccine (%);57.33333333333333;-20949.33082773753
3135;Prevalence of daily cigarette smoking among adolescents (%)-Male;92.88888888888889;0.0
3136;Prevalence of daily cigarette smoking among adolescents (%)-Female;92.88888888888889;0.0
3137;Prevalence of daily cigarette smoking among adolescents (%)-Both sexes;92.88888888888889;0.0
3138;Prevalence of daily cigarette smoking among adolescents (%);92.88888888888889;-27807.40911192029
3139;Existence of responsible ministry/authority on assistive technology;0.0;
3140;Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP;61.333333333333336;-21249.247385105253
3141;Representation of latest youth prevalence survey (nonsmoked);0.0;
3142;Number of pregnant women (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
3143;Amount of water- and sanitation-related official development assistance that is part of a government-coordinated spending plan (current US$ millions);39.55555555555556;-27807.40911192029
3144;Year of most recent adolescent survey;0.0;
3145;Health Service Provision;14.222222222222229;-22855.771458032563
3146;Prevalence of current tobacco use among adults (%)-Male;58.666666666666664;0.1669824219352405
3147;Prevalence of current tobacco use among adults (%)-Female;58.666666666666664;0.16564661805435588
3148;Prevalence of current tobacco use among adults (%)-Both sexes;58.666666666666664;0.12071613266717574
3149;Prevalence of current tobacco use among adults (%);58.666666666666664;-26459.822478863567
3150;Existence of legislation on access to assistive technology;0.0;
3151;Proportion of isolates with resistance to azithromycin reported to WHO-GASP;69.33333333333334;-22064.86820383853
3152;Prevalence of daily e-cigarette use among adolescents (%)-Male;96.88888888888889;0.0
3153;Prevalence of daily e-cigarette use among adolescents (%)-Female;96.88888888888889;0.0
3154;Prevalence of daily e-cigarette use among adolescents (%)-Both sexes;96.88888888888889;0.0
3155;Prevalence of daily e-cigarette use among adolescents (%);96.88888888888889;-27807.40911192029
3156;Total number of surveillance sites reporting to GLASS;0.0;
3157;Ban on tobacco companies/the tobacco industry publicizing their CSR activities;0.0;
3158;Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place;0.0;
3159;Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line (60% of median daily per capita consumption or income) (%);36.0;-18754.828532230382
3160;Existence of national policies on trans-fatty acid elimination;0.0;
3161;Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry;0.0;
3162;Cheapest brand of cigarettes - price in US$ at official exchange rates;24.0;-27807.40911192029
3163;Mean Non-HDL cholesterol, crude-Female;15.111111111111114;1.8943108323469051
3164;Mean Non-HDL cholesterol, crude-Both sexes;15.111111111111114;1.964655499903122
3165;Mean Non-HDL cholesterol, crude;15.111111111111114;-99.19628239028837
3166;Coverage of people in need of assistive technology by legislation;0.0;
3167;Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score);63.111111111111114;-26631.519616765956
3168;Compliance with ban on advertising on national television and radio (score);37.33333333333333;-25809.05548495155
3169;Cytisine - cost covered;13.333333333333329;-25030.246882514955
3170;ICD-11 implementation progress level;56.44444444444445;-26400.707407910406
3171;Reference level for workplaces (Bq/m3);99.55555555555556;-27792.92000414784
3172;Compliance with smoke-free public transport law (score);55.55555555555556;-26378.771346901063
3173;Nursing personnel (%)-Female;35.111111111111114;0.8799209281144478
3174;Nursing personnel (%)-Male;35.111111111111114;0.8814769346755362
3175;Nursing personnel (%);35.111111111111114;-21368.570168826012
3176;Mean total cholesterol,  age-standardized-Female;15.111111111111114;1.9033815023875187
3177;Mean total cholesterol,  age-standardized-Both sexes;15.111111111111114;1.9719112547773712
3178;Mean total cholesterol,  age-standardized;15.111111111111114;-99.08969135838608
3179;Subnational bans on advertising, promotion and sponsorship - at least one jurisdiction has a comprehensive ban in place;0.0;
3180;Year the law was enacted (latest revision);0.0;
3181;Number of malaria positive cases by rapid diagnostic test (RDT);60.0;-18817.029400723954
3182;Most sold brand of cigarettes - price in US$ at official exchange rates;13.333333333333329;-14000.763132460599
3183;Total population pushed  further below the $1.90 a day poverty line by household health expenditures (millions);0.0;
3184;Proportion of population with primary reliance on polluting fuels and technologies for cooking (%);15.555555555555557;-6.219995266918627
3185;Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes;0.0;
3186;Households pushed below or further below a relative poverty line (reflecting basic needs: food, housing, utilities) by out-of-pocket payments (%);85.77777777777777;-24700.680531104976
3187;Compliance with ban on appearance of tobacco brands in TV and/or films (score);53.77777777777778;-26320.850467613018
3188;Number of malaria cases treated with any first  line tx courses (including artemisinin-based combination therapies (ACTs));61.333333333333336;-25596.685160347304
3189;Name of latest adult prevalence survey (nonsmoked);0.0;
3190;SDG 6.3.1 Proportion of safely treated domestic wastewater flows (%);48.88888888888889;-27807.40911192029
3191;Availability of government/registered services for assistive technology;0.0;
3192;Number of confirmed yaws cases reported;90.22222222222223;-27274.068779167064
3193;Full immunization coverage among one-year-olds (%);52.44444444444444;-23309.110402228704
3194;Population pushed further below the $1.90 a day poverty line by household health expenditures (%);36.44444444444444;-19239.613226533125
3195;Population with primary reliance on clean fuels and technologies for cooking (in millions);15.555555555555557;-4.341313603784327
3196;Medical doctors (%)-Male;43.111111111111114;1.6651955927655875
3197;Medical doctors (%)-Female;43.111111111111114;1.6661278068526642
3198;Medical doctors (%);43.111111111111114;-16285.053892127527
3199;Estimated malaria mortality rate (per 100 000 population);52.44444444444444;-5457.861914816199
3200;Prevalence of current tobacco use among adolescents (%)-Male;40.0;0.0
3201;Prevalence of current tobacco use among adolescents (%)-Both sexes;40.0;0.0
3202;Prevalence of current tobacco use among adolescents (%)-Female;40.0;0.0
3203;Prevalence of current tobacco use among adolescents (%);40.0;-27807.40911192029
3204;Affordability – category of change 2010-2020 (Yes (less affordable), No (more affordable), No change).;0.0;
3205;Age range of latest youth prevalence survey (nonsmoked);0.0;
3206;Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%)-15-19 years-nan;70.22222222222223;0
3207;Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%)-20-49 years-nan;70.22222222222223;0
3208;Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%);70.22222222222223;-25492.29214448252
3209;Severe wasting prevalence in children aged < 5 years (%);54.22222222222222;-23826.766535990773
3210;Availability of public funding for assistive technology;0.0;
3211;Funding for assistive products (%);90.22222222222223;-27792.92000414784
3212;Year of most recent survey of adults;0.0;
3213;Number of isolates tested for ciprofloxacin;61.77777777777778;-20576.197593561945
3214;Prevalence of current tobacco smoking among adolescents (%)-Both sexes;56.44444444444445;0.0
3215;Prevalence of current tobacco smoking among adolescents (%)-Female;56.44444444444445;0.0
3216;Prevalence of current tobacco smoking among adolescents (%)-Male;56.44444444444445;0.0
3217;Prevalence of current tobacco smoking among adolescents (%);56.44444444444445;-27807.40911192029
3218;Proportion of population with primary reliance on clean fuels and technologies for cooking (%);15.111111111111114;-1.8758911789600425
3219;Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products;0.0;
3220;Pregnant women attending antenatal care  at least once and receiving at least 3 doses of Intermittent Preventive Treatment of Malaria for Pregnant Women (IPTp3) (%);85.33333333333333;-22947.047670902684
3221;Measles immunization coverage among one-year-olds (%);51.55555555555556;-23175.400930521217
3222;Reported number of tests performed where results were received by a person (testing volume), reporting period;0.0;
3223;Number of presumed malaria cases;56.0;-15669.223783037924
3224;Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);0.0;
3225;Title of most recent adolescent survey;0.0;
3226;Mean Non-HDL cholesterol, age-standardized-Female;15.111111111111114;1.8155150305726
3227;Mean Non-HDL cholesterol, age-standardized-Both sexes;15.111111111111114;1.9091662039048174
3228;Mean Non-HDL cholesterol, age-standardized;15.111111111111114;-99.27790594180026
3229;Number of suspected yaws cases reported;87.55555555555556;-25858.590144561033
3230;Demand for family planning satisfied - use of modern methods (%)-15-19 years-nan;52.88888888888889;0
3231;Demand for family planning satisfied - use of modern methods (%)-20-49 years-nan;52.88888888888889;0
3232;Demand for family planning satisfied - use of modern methods (%);52.88888888888889;-23403.32267069561
3233;Number of isolates tested for azithromycin;69.33333333333334;-22064.842815482774
3234;Prevalence of daily cigarette smoking among adults (%)-Male;70.66666666666667;0.11389492268047796
3235;Prevalence of daily cigarette smoking among adults (%)-Female;70.66666666666667;0.0995765268838289
3236;Prevalence of daily cigarette smoking among adults (%)-Both sexes;70.66666666666667;0.10419185389903696
3237;Prevalence of daily cigarette smoking among adults (%);70.66666666666667;-26857.440270747098
3238;Existence of regulations/standards/guidelines/protocols on assistive technology;0.0;
3239;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Both sexes;27.111111111111114;1.5842843078304503
3240;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Male;27.111111111111114;1.6548018698596252
3241;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Female;27.111111111111114;1.5450550954461306
3242;Estimate of current tobacco use prevalence (%) (age-standardized rate);27.111111111111114;-15296.04649803918
3243;Number of non-pregnant women (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
3244;Total population pushed  further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);0.0;
3245;Ban on advertising at point of sale;0.0;
3246;Households with out-of-pocket payments greater than 40% of capacity to pay for health care (food, housing and utilities approach - developed by WHO/Europe) (%);85.77777777777777;-24700.676708171668
3247;Prevalence of current e-cigarette use among adolescents (%)-Male;60.888888888888886;0.0
3248;Prevalence of current e-cigarette use among adolescents (%)-Female;60.888888888888886;0.0
3249;Prevalence of current e-cigarette use among adolescents (%)-Both sexes;60.888888888888886;0.0
3250;Prevalence of current e-cigarette use among adolescents (%);60.888888888888886;-27807.40911192029
3251;Prevalence of daily tobacco smoking among adults (%)-Male;43.111111111111114;0.21176414506895647
3252;Prevalence of daily tobacco smoking among adults (%)-Female;43.111111111111114;0.18720608731205157
3253;Prevalence of daily tobacco smoking among adults (%)-Both sexes;43.111111111111114;0.208765703152757
3254;Prevalence of daily tobacco smoking among adults (%);43.111111111111114;-25994.564957058967
3255;Number of people protected from malaria by indoor residual spraying (IRS);69.33333333333334;-26142.767116121224
3256;Ban on sale of duty-free or excise-free cigarettes;0.0;
3257;Representativeness of most recent adolescent survey;0.0;
3258;Prevalence of anaemia in pregnant women (aged 15-49) (%)-nan;13.333333333333329;0
3259;A minimum price policy is implemented;0.0;
3260;Average of 13 International Health Regulations core capacity scores, SPAR version, 1st edition;14.666666666666657;-22855.622023615473
3261;Compliance with smoke-free universities law (score);52.88888888888889;-26297.479155125344
3262;Polio immunization coverage among one-year-olds (%);51.55555555555556;-23204.66986303012
3263;Law requires fines for violations of advertising bans;0.0;
3264;Proportion of population with primary reliance on fuels and technologies for cooking, by fuel type (%);42.22222222222223;-2604.456087911951
3265;Compliance with ban on use of brand name of non-tobacco product for tobacco product (score);58.22222222222222;-26463.241901344245
3266;Law requires fines for violations of promotion and sponsorship bans;0.0;
3267;Food Safety (SPAR);14.222222222222229;-22855.857386197866
3268;DTP3 immunization coverage among one-year-olds (%);51.55555555555556;-23214.469371501225
3269;New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population;16.0;-15669.812967856247
3270;Number of isolates tested for extended-spectrum cephalosporins;60.888888888888886;-20772.58950777588
3271;Number of isolates tested for ceftriaxone;61.333333333333336;-21248.87634488026
3272;Prevalence of use of assistive products (%)-70-79 years-nan;90.22222222222223;0
3273;Prevalence of use of assistive products (%)-80+ years-nan;90.22222222222223;0
3274;Prevalence of use of assistive products (%)-0-4 years-nan;90.22222222222223;0
3275;Prevalence of use of assistive products (%)-5-17 years-nan;90.22222222222223;0
3276;Prevalence of use of assistive products (%)-18-29 years-nan;90.22222222222223;0
3277;Prevalence of use of assistive products (%)-30-39  years-nan;90.22222222222223;0
3278;Prevalence of use of assistive products (%)-40-49  years-nan;90.22222222222223;0
3279;Prevalence of use of assistive products (%)-50-59  years-nan;90.22222222222223;0
3280;Prevalence of use of assistive products (%)-60-69  years-nan;90.22222222222223;0
3281;Prevalence of use of assistive products (%)-All age groups (total)-nan;90.22222222222223;0
3282;Prevalence of use of assistive products (%);90.22222222222223;-27792.92000414784
3283;Prevalence of daily tobacco use among adults (%)-Female;77.33333333333334;0.07391490770321418
3284;Prevalence of daily tobacco use among adults (%)-Male;77.33333333333334;0.07498128798099923
3285;Prevalence of daily tobacco use among adults (%)-Both sexes;77.33333333333334;0.08569381645150287
3286;Prevalence of daily tobacco use among adults (%);77.33333333333334;-27078.633271693216
3287;Age range of most recent survey of adults;0.0;
3288;Total number of  malaria cases (presumed + confirmed cases);55.55555555555556;-14993.748113470647
3289;Persistence to last grade of primary (% of cohort)-Male;28.0;1.4824255692149384
3290;Persistence to last grade of primary (% of cohort)-Female;28.0;1.4787768913299262
3291;Persistence to last grade of primary (% of cohort)-Both sexes;28.0;1.6007145685866977
3292;Persistence to last grade of primary (% of cohort);28.0;-16890.74221169156
3293;Existence of national radon action plan - Years covered;0.0;
3294;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Both sexes;27.111111111111114;1.5922702143091145
3295;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Male;27.111111111111114;1.6439619411385396
3296;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Female;27.111111111111114;1.4968909754553055
3297;Estimate of current tobacco smoking prevalence (%) (age-standardized rate);27.111111111111114;-15296.05634481684
3298;Year of latest adult prevalence survey (nonsmoked);0.0;
3299;Prevalence of daily e-cigarette use among adults (%)-Male;95.55555555555556;0.016272223126755136
3300;Prevalence of daily e-cigarette use among adults (%)-Female;95.55555555555556;0.01591676303416012
3301;Prevalence of daily e-cigarette use among adults (%)-Both sexes;95.55555555555556;0.018292735588086195
3302;Prevalence of daily e-cigarette use among adults (%);95.55555555555556;-27663.548650168315
3303;Overall compliance with regulations on smoke-free environments (score);40.888888888888886;-25918.020168279305
3304;Number of isolates tested for cefixime;70.66666666666667;-23409.247147747097
3305;Best-practice policy implemented for industrially produced trans-fatty acids (TFA) (Y/N);42.22222222222223;-5869.306979073191
